Compound for treating and preventing respiratory syncytial virus infection diseases

MYPI2026000166A0Undetermined Publication Date: 2025-01-10CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2026000166
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-03-08
Filing Date
2024-07-10
Publication Date
2025-01-10

AI Technical Summary

Technical Problem

The existing RSV virus treatment drugs lack high efficiency and specificity, and have toxicity problems, which fail to effectively solve the clinical treatment needs of RSV infection.

Method used

A new class of anti-RSV virus compounds and their derivatives have been developed to prevent and treat diseases caused by RSV viruses, and to inhibit viral replication through specific compound structures.

Benefits of technology

It provides a potentially efficient antiviral treatment plan that can effectively inhibit RSV virus, make up for the shortcomings of existing drugs, and has high safety and specificity.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided are a compound represented by formula (I) or a tautomer, a stereoisomer, an isotope derivative or a pharmaceutically acceptable salt thereof. The compound has a good inhibitory effect on RSV viruses. [No Available Figure]
Need to check novelty before this filing date? Find Prior Art

Description

Compounds for treating and preventing respiratory syncytial virus infection diseases

[0001] This application claims priority to two prior applications, patent application number 202310837957.0, filed with the State Intellectual Property Office of China on July 10, 2023, and patent application number 202410267846.5, filed with the State Intellectual Property Office of China on March 8, 2024, both entitled “Compounds for Treating and Preventing Respiratory Syncytial Virus Infections.” The entire texts of both applications are incorporated herein by reference. Technical Field

[0002] The present invention relates to the field of medical technology, and in particular to an RSV inhibitor derivative, a preparation method and use thereof. Background Art

[0003] Respiratory syncytial virus (RSV) is a negative-stranded single-stranded RNA virus of the genus Pneumovirus in the family Paramyxoviridae. RSV can cause respiratory tract infections, from the upper respiratory tract to the lower respiratory tract, leading to airway infection and symptoms such as bronchiolitis, pneumonia, and in some cases, respiratory failure. It is estimated that RSV is the most important viral source of acute lower respiratory tract infection (ALRT1) in children under 5 years old. Globally, almost all children are infected with RSV before the age of 2 years, of which ~40% develop LRTI, and more severe cases can be seen under 6 months of age (possibly related to the imperfect immune system of infants and young children). In addition to infants, the elderly with underlying cardiopulmonary diseases such as chronic obstructive pulmonary disease are also increasingly considered to be at high risk of severe infection.

[0004] RSV severely impacts human health, yet there is currently no effective treatment. To date, the FDA has only approved the small molecule nucleoside drug ribavirin for the treatment of severe RSV infection in hospitalized children. However, its poor antiviral efficacy and lack of specificity lead to high drug toxicity, and it is currently not recommended for clinical use as a therapeutic drug. Other approved drugs, such as palivizumab and nirsevimab, are highly effective monoclonal antibodies that target the fusion protein involved in viral replication and can provide relatively long-term protection for infants. However, these drugs are complex to administer and expensive, making their widespread use unfavorable.

[0005] To date, a variety of anti-RSV small molecule inhibitors acting on different targets have been reported. Targeting the F protein conserved during viral replication, Johnson & Johnson reported a class of inhibitors with benzimidazole as the parent core, with representative molecules such as JNJ-53718678, and Gilead reported a class of pyrrolopyridine inhibitors GS-5806, but they all failed in Phase II clinical trials. Roche reported a class of small molecule inhibitors with quinazoline as the parent core in 2013, which achieved good therapeutic effects in clinical trials in 2022. Several small molecule inhibitors have also been reported for other conserved proteins in the viral replication process, such as L protein and N protein. However, no small molecule inhibitors have yet been approved for marketing.

[0006] Therefore, developing highly effective small molecule inhibitors targeting the specific conformation of the conserved F protein of the RSV virus to exert good antiviral effects can provide new treatment options for RSV infection and related diseases.

[0007] Currently, there are no proven effective antiviral drugs for the treatment of RSV. RSV inhibitors in preclinical development generally suffer from low in vivo exposure and high clearance rates. Therefore, the development of RSV inhibitors holds great promise and could address a significant clinical treatment gap for this disease.

[0008] Summary of the Invention

[0009] The present invention provides a novel class of anti-RSV virus compounds or their tautomers, stereoisomers, isotopic derivatives or pharmaceutically acceptable salts, and also provides the use of such compounds or their tautomers, stereoisomers, isotopic derivatives or pharmaceutically acceptable salts in drugs for preventing and / or treating diseases caused by RSV virus infection.

[0010] Specifically, the present invention provides a compound represented by formula (I), or a tautomer, stereoisomer, isotopic derivative, or pharmaceutically acceptable salt thereof, which has the following structure:

[0011] in,

[0012] Cy1 is independently selected from the group consisting of absence, C 4-12 Carbocyclic group, 4-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; when Cy1 is absent, R 1 Connected to the heteroaromatic ring, that is

[0013] R 1 Independently selected from: hydrogen, deuterium, halogen, oxo, hydroxy, amino, nitro, cyano, -R a1 、-OR a1 、-SRa1 、-N(R a1 )2, -S(O)2R a1 、-S(O)2N(R a1 )2、-S(O)R a1 、-S(O)(NR a1 )R a1 、-S(O)N(R a1 )2、-P(O)(OR a1 )2、-P(O)(N(R a1 )2)2、-SC(R a1 )3、-C(R a1 )2OR a1 、-C(R a1 )2N(R a1 )2、-C(O)R a1 、-C(O)OR a1 、-C(O)N(R a1 )2、-C(O)OR a1 -OC(O)R a1 、-C(O)N(R a1 )OR a1 、-OC(O)R a1 、-OC(O)N(R a1 )2、-N(R a1 )C(O)OR a1 、-N(R a1 )C(O)R a1 、-N(R a1 )C(O)N(R a1 )2、-N(R a1 )S(O)2R a1 、-C(S)R a1 、-C(S)OR a1 、-C(S)N(R a1 )2、-C(S)N(R a1 )OR a1 、-OC(S)R a1 、-OC(S)N(R a1 )2;

[0014] R a1 Independently selected from: hydrogen, deuterium, C 1-6 Alkyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1- 6 alkyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, optionally substituted with one or more Ra2 replace;

[0015] or two R's attached to the same atom a1 Together with the atoms to which they are attached, they form deuterium, halogen, oxo, hydroxyl, amino, nitro, cyano, thiol, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-14 Aryl, 5-12 membered heteroaryl, one or more optionally substituted C 3-12 Carbocyclyl, 3-12 membered heterocyclyl or 5-12 membered heteroaryl;

[0016] R a2 Independently selected from: deuterium, halogen, oxo, hydroxy, amino, nitro, cyano, mercapto, C 1-6 Alkyl, C 1-6 alkoxy;

[0017] X 1 Independently selected from CR 2 or N;

[0018] X is independently selected from CR 2 or N;

[0019] R 2 are independently selected from hydrogen, deuterium, halogen, hydroxy, amino, nitro, cyano, -OR b1 、-SR b1 、-N(R b1 )2、-S(O)2R b1 、-S(O)2N(R b1 )2、-S(O)R b1 、-S(O)(NR b1 )R b1 、-S(O)N(R b1 )2、-P(O)(OR b1 )2、-P(O)(N(R b1 )2)2、-C(R b1 )2(OR b1 )、-C(R b1 )2N(R b1 )2、-C(O)R b1 、-C(O)OR b1 、-C(O)N(R b1 )2、-C(O)N(R b1 )OR b1 、-OC(O)R b1 、-OC(O)N(R b1 )2、-N(R b1 )C(O)ORb1 、-N(R b1 )C(O)R b1 、-N(R b1 )C(O)N(R b1 )2、-N(R b1 )S(O)2R b1 、C 1-6 Alkyl, C 3-7 Carbocyclic group, 3-7 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1-6 Alkyl, C 3-7 Cycloalkyl, 3-7 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl is optionally substituted with one or more R b2 replace;

[0020] R b1 Independently selected from: hydrogen, deuterium, C 1-6 Alkyl, C 3-7 Carbocyclic group, 4-7 membered heterocyclic group, phenyl group, 5-6 membered heteroaryl group; the C 1-6 Alkyl, C 3-7 Carbocyclic group, 4-7 membered heterocyclic group, phenyl group or 5-6 membered heteroaryl group are optionally substituted by one or more selected from deuterium, halogen, oxo group, hydroxyl, amino group, nitro group, cyano group, mercapto group, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocycloalkyl, C 6-14 substituted by a substituent of an aryl group or a 5-12 membered heteroaryl group;

[0021] or two R's attached to the same atom b1 Together with the atoms to which they are attached, they form deuterium, halogen, oxo, hydroxyl, amino, nitro, cyano, thiol, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocycloalkyl, C 6-14 Aryl, 5-12 membered heteroaryl, one or more optionally substituted C 3-12 Carbocyclyl, 3-12 membered heterocyclyl or 5-12 membered heteroaryl;

[0022] R b2 Independently selected from: deuterium, halogen, oxo, hydroxy, amino, nitro, cyano, mercapto, C 1-6 Alkyl, C 1-6 alkoxy;

[0023] m is independently selected from: 0, 1, 2, 3, 4;

[0024] Q is independently selected from: deuterium, halogen, -R3 、-OR 3 、-SR 3 、-N(R 3 )-C 0-6 Alkylene-R 3 、-N(R 3 )-C 0-6 Alkylene-N(R 3 )2、-S(O)2R 3 、-S(O)2N(R 3 )2、-S(O)R 3 、-S(O)(NR 3 )R 3 、-S(O)N(R 3 )2、-P(O)(OR 3 )2、-P(O)(N(R 3 )2)2、-C(R 3 )2(OR 3 )、-C(R 3 )2N(R 3 )2、-C(O)R 3 、-C(O)OR 3 、-C(O)N(R 3 )2、-C(O)N(R 3 )OR 3 、-OC(O)R 3 、-OC(O)N(R 3 )2、-N(R 3 )C(O)OR 3 、-N(R 3 )C(O)R 3 、-N(R 3 )C(O)N(R 3 )2、-N(R 3 )S(O)2R 3 ; The alkylene group is optionally replaced by one or more R c1 replace;

[0025] R 3 Each independently selected from: hydrogen, deuterium, C 1-6 Alkyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1-6 Alkyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, optionally substituted with one or more R c2 replace;

[0026] or two R attached to the same nitrogen atom3 Together with the nitrogen atom to which they are attached, they form halogen, hydroxyl, amino, -C(O)NH2, -(CH2) 1-6 NH2, oxo, C 1-6 Alkyl, C 1-6 Alkoxy, oxetanylamino, C 1-6 one or more optionally substituted 3-12 membered heterocyclic groups or 5-12 membered heteroaryl groups in the alkylpiperazinyl group;

[0027] R c1 Independently selected from: deuterium, halogen, hydroxyl, amino, nitro, cyano, thiol, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, phenyl, 5-6 membered heteroaryl;

[0028] R c2 Independently selected from: deuterium, oxo, halogen, hydroxyl, amino, cyano, -OR c3 、-SR c3 、-N(R c3 )2、-S(O)2R c3 、-S(O)2N(R c3 )2、-S(O)R c3 、-S(O)(NR c3 )R c3 、-P(O)(OR c3 )2、-P(O)(N(R c3 )2)2、-C(R c3 )2(OR c3 )、-C(R c3 )2N(R c3 )2、-C(O)R c3 、-C(O)OR c3 、-C(O)N(R c3 )2、-C(O)N(R c3 )OR c3 、-OC(O)R c3 、-OC(O)N(R c3 )2、-N(R c3 )C(O)OR c3 、-N(R c3 )C(O)R c3 、-N(R c3 )C(O)N(R c3 )2、-N(R c3 )C(O)R c3 N(R c3 )OC(O)R c3 、-N(R c3)S(O)2R c3 、C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl; said C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl is optionally substituted by one or more R c4 replace;

[0029] R c3 、R c4 are independently selected from: hydrogen, deuterium, oxo, halogen, hydroxyl, amino, C 1-18 Alkyl, C 1-6 Alkoxy, C 1-6 haloalkyl, C 1-6 Alkyl, optionally substituted with one or more amino groups 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-6 membered heteroaryl;

[0030] Het has the following structure:

[0031] in,

[0032] When A or B and When connected, A and B are independently selected from -C(R d1 )-、-N-、 The "#" is a link one end;

[0033] When A or B does not When connected, A and B are independently selected from a bond, -C(R d1 )2-、-NR d1 -、-C(R d1 )2N(R d1 )-、-NR d1 C(R d1 )2-;

[0034] R d1 Independently selected from: absence, bond, hydrogen, deuterium, hydroxyl, amino, nitro, cyano, C 1-6 Alkyl; or two R attached to the same carbon atom d1 Together they form an oxo group;

[0035] When R d1 When it does not exist, That is

[0036] Y is independently selected from -O-, -N(R d2 )-、-C(R d2 )2-, -S-, -C(O)-, -C(=N-OC 0-6 alkyl)-、-S(O)-、-S(O)2-、-S(O)(=NR d2 )-;

[0037] R d2 Independently selected from: hydrogen, deuterium, halogen, hydroxyl, amino, nitro, cyano, -OR d3 、-SR d3 、-N(R d3 )2、-C(O)R d3 、-(C 1- 6-alkylene)-C(O)R d3 、-(C 1-6 Alkylene)-S(O)2R d3 、-C(O)OR d3 、-(C 1-6 alkylene)-C(O)OR d3 、-C(O)N(R d3 )2、-(C 1-6 Alkylene)-C(O)N(R d3 )2、-C(O)-(C 1-6 Alkylene)-N(R d3 )2、-S(O)2R d3 、-S(O)2N(R d3 )2、-S(O)R d3 、-C(O)N(R d3 )OR d3 、-OC(O)R d3 、-OC(O)N(R d3 )2、-N(R d3 )C(O)OR d3 、-N(R d3 )C(O)R d3 、-N(R d3 )C(O)N(R d3 )2、-N(R d3 )S(O)2R d3 、C 1- 6 alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1-6 Alkyl, C 1- 6 alkylene, C2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, optionally substituted with one or more selected from deuterium, halogen, oxo, hydroxy, amino, nitro, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 substituted by a substituent of an aryl group or a 5-12 membered heteroaryl group;

[0038] R d3 Independently selected from: hydrogen, deuterium, halogen, hydroxyl, amino, nitro, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, optionally substituted with one or more selected from deuterium, halogen, oxo, hydroxy, amino, nitro, cyano, C 1-6 Alkyl, C 1-6 substituted by an alkoxy substituent;

[0039] R 13 、R 14 、R 15 、R 16 are independently selected from: hydrogen, deuterium, oxo, halogen, hydroxyl, amino, imino, sulfinamide, nitro, cyano, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, optionally substituted with one or more R d4 Replace; when R 13 、R 14When one of them is selected from oxo group and imino group, the other one does not exist; when R 15 、R 16 When one of them is selected from an oxo group and an imino group, the other one does not exist;

[0040] or R 13 and R 14 Together with the carbon atoms to which they are attached, they form groups that are substituted by halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 One or more optionally substituted C 3-12 Carbocyclic group or 3-12 membered heterocyclic group;

[0041] or R 15 and R 16 Together with the carbon atoms to which they are attached, they form groups that are substituted by halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 One or more optionally substituted C 3-12 Carbocyclic group or 3-12 membered heterocyclic group;

[0042] R d4 Independently selected from: deuterium, halogen, oxo, hydroxy, amino, cyano, sulfonyl, urea, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl; the C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl is optionally substituted with one or more halogens;

[0043] Cy2 is independently selected from: phenyl, 5-6 membered heterocyclyl, 5-6 membered heteroaryl;

[0044] Cy3 is independently selected from: phenyl, 5-6 membered heterocyclyl, 5-6 membered heteroaryl;

[0045] R 17 and R 18 are independently selected from: deuterium, halogen, hydroxyl, amino, cyano, nitro, carboxyl, oxo, -OR d5 、-SR d5 、-N(R d5 )2、-S(O)2R d5 、-S(O)2N(R d5 )2、-S(O)R d5 、-S(O)(NR d5 )R d5 、-S(O)N(R d5 )2、-P(O)(ORd5 )2、-P(O)(N(R d5 )2)2、-C(R d5 )2(OR d5 )、-C(R d5 )2N(R d5 )2、-C(O)R d5 、-C(O)OR d5 、-C(O)N(R d5 )2、-C(O)N(R d5 )OR d5 、-OC(O)R d5 、-OC(O)N(R d5 )2、-N(R d5 )C(O)OR d5 、-N(R d5 )C(O)R d5 、-N(R d5 )C(O)N(R d5 )2、-N(R d5 )S(O)2R d5 、-N(R d5 )S(O)2N(R d5 )2、-N(R d5 )S(O)2O(R d5 ), C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, optionally substituted with one or more selected from deuterium, halogen, oxo, hydroxy, amino, cyano, carboxyl, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 substituted by a cycloalkyl substituent;

[0046] R d5 Independently selected from: hydrogen, deuterium, halogen, hydroxyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl are optionally substituted with one or more substituents selected from deuterium, halogen, hydroxy, amino, cyano, and carboxyl;

[0047] Z is independently selected from C, N;

[0048] E is independently selected from: -C(R d6 )2-、-N(R d6 )-;

[0049] R d6 Independently selected from: hydrogen, deuterium, halogen, hydroxyl, amino, cyano, nitro, sulfenamide, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl may be substituted with one or more substituents selected from deuterium, halogen, oxo, hydroxyl, amino, carboxyl, cyano; or two R groups attached to the same carbon atom ... d6 Together form an oxo group, a thio group, an imino group; or two R groups connected to the same carbon atom d6 Together with the carbon atoms to which they are attached, they form a C 3-15 Carbocyclyl, 3-15 membered heterocyclyl;

[0050] n and q are independently selected from 0, 1, 2, 3, and 4;

[0051] When multiple R a1 、R a2 、R b1 、R b2 、R c1 、R c2 、R c3 、R c4 、R d1 、R d2 、R d3 、Rd4 、R d5 、R d6 、R 1 、R 3 、R 17 、R 18 When they appear simultaneously, each R a1 , each R a2 , each R b1 , each R b2 , each R c1 , each R c2 , each R c3 , each R d1 , each R d2 , each R d3 , each R d4 , each R d5 , each R d6 , each R 1 , each R 3 , each R 17 , each R 18 Can be the same or different.

[0052] In some embodiments, a compound represented by the following formula (I), or a tautomer, stereoisomer, or pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of the compound is provided:

[0053] in,

[0054] Cy1 is independently selected from the group consisting of absence, C 4-12 Carbocyclic group, 4-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; when Cy1 is absent, R 1 Connected to the heteroaromatic ring, that is

[0055] R 1 Independently selected from: hydrogen, deuterium, halogen, oxo, hydroxy, amino, nitro, cyano, -R a1 、-OR a1 、-SR a1 、-N(R a1 )2、-S(O)2R a1 、-S(O)2N(R a1 )2、-S(O)R a1 、-S(O)(NR a1 )R a1 、-S(O)N(R a1 )2、-P(O)(OR a1 )2、-P(O)(N(R a1 )2)2、-SC(Ra1 )3、-C(R a1 )2OR a1 、-C(R a1 )2N(R a1 )2、-C(O)R a1 、-C(O)OR a1 、-C(O)N(R a1 )2、-C(O)OR a1 -OC(O)R a1 、-C(O)N(R a1 )OR a1 、-OC(O)R a1 、-OC(O)N(R a1 )2、-N(R a1 )C(O)OR a1 、-N(R a1 )C(O)R a1 、-N(R a1 )C(O)N(R a1 )2、-N(R a1 )S(O)2R a1 、-C(S)R a1 、-C(S)OR a1 、-C(S)N(R a1 )2、-C(S)N(R a1 )OR a1 、-OC(S)R a1 、-OC(S)N(R a1 )2;

[0056] R a1 Independently selected from: hydrogen, deuterium, C 1-6 Alkyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1- 6 alkyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, optionally substituted with one or more R a2 replace;

[0057] or two R's attached to the same atom a1 Together with the atoms to which they are attached, they form deuterium, halogen, oxo, hydroxyl, amino, nitro, cyano, thiol, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-14 Aryl, 5-12 membered heteroaryl, one or more optionally substituted C 3-12Carbocyclyl, 3-12 membered heterocyclyl or 5-12 membered heteroaryl;

[0058] R a2 Independently selected from: deuterium, halogen, oxo, hydroxy, amino, nitro, cyano, mercapto, C 1-6 Alkyl, C 1-6 alkoxy;

[0059] X is independently selected from CR 2 or N;

[0060] R 2 are independently selected from hydrogen, deuterium, halogen, hydroxy, amino, nitro, cyano, -OR b1 、-SR b1 、-N(R b1 )2、-S(O)2R b1 、-S(O)2N(R b1 )2、-S(O)R b1 、-S(O)(NR b1 )R b1 、-S(O)N(R b1 )2、-P(O)(OR b1 )2、-P(O)(N(R b1 )2)2、-C(R b1 )2(OR b1 )、-C(R b1 )2N(R b1 )2、-C(O)R b1 、-C(O)OR b1 、-C(O)N(R b1 )2、-C(O)N(R b1 )OR b1 、-OC(O)R b1 、-OC(O)N(R b1 )2、-N(R b1 )C(O)OR b1 、 -N(R b1 )C(O)R b1 、-N(R b1 )C(O)N(R b1 )2、-N(R b1 )S(O)2R b1 、C 1-6 Alkyl, C 3-7 Carbocyclic group, 3-7 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1-6 Alkyl, C 3-7 Cycloalkyl, 3-7 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl is optionally substituted with one or more Rb2 replace;

[0061] R b1 Independently selected from: hydrogen, deuterium, C 1-6 Alkyl, C 3-7 Carbocyclic group, 4-7 membered heterocyclic group, phenyl group, 5-6 membered heteroaryl group; the C 1-6 Alkyl, C 3-7 Carbocyclic group, 4-7 membered heterocyclic group, phenyl group or 5-6 membered heteroaryl group are optionally substituted by one or more selected from deuterium, halogen, oxo group, hydroxyl, amino group, nitro group, cyano group, mercapto group, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocycloalkyl, C 6-14 substituted by a substituent of an aryl group or a 5-12 membered heteroaryl group;

[0062] or two R's attached to the same atom b1 Together with the atoms to which they are attached, they form deuterium, halogen, oxo, hydroxyl, amino, nitro, cyano, thiol, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocycloalkyl, C 6-14 Aryl, 5-12 membered heteroaryl, one or more optionally substituted C 3-12 Carbocyclyl, 3-12 membered heterocyclyl or 5-12 membered heteroaryl;

[0063] R b2 Independently selected from: deuterium, halogen, oxo, hydroxy, amino, nitro, cyano, mercapto, C 1-6 Alkyl, C 1-6 alkoxy;

[0064] m is independently selected from: 0, 1, 2, 3, 4;

[0065] Q is independently selected from: deuterium, halogen, -R 3 、-OR 3 、-SR 3 、-N(R 3 )-C 0-6 Alkylene-R 3 、-N(R 3 )-C 0-6 Alkylene-N(R 3 )2、-S(O)2R 3 、-S(O)2N(R 3 )2、-S(O)R 3 、-S(O)(NR 3 )R 3 、-S(O)N(R 3)2、-P(O)(OR 3 )2、-P(O)(N(R 3 )2)2、-C(R 3 )2(OR 3 )、-C(R 3 )2N(R 3 )2、-C(O)R 3 、-C(O)OR 3 、-C(O)N(R 3 )2、-C(O)N(R 3 )OR 3 、-OC(O)R 3 、-OC(O)N(R 3 )2、-N(R 3 )C(O)OR 3 、-N(R 3 )C(O)R 3 、-N(R 3 )C(O)N(R 3 )2、-N(R 3 )S(O)2R 3 ; The alkylene group is optionally replaced by one or more R c1 replace;

[0066] R 3 Each independently selected from: hydrogen, deuterium, C 1-6 Alkyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1-6 Alkyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, optionally substituted with one or more R c2 replace;

[0067] or two R attached to the same nitrogen atom 3 Together with the nitrogen atom to which they are attached, they form halogen, hydroxyl, amino, -C(O)NH2, -(CH2) 1-6 NH2, oxo, C 1-6 Alkyl, C 1-6 Alkoxy, oxetanylamino, C 1-6 one or more optionally substituted 3-12 membered heterocyclic groups or 5-12 membered heteroaryl groups in the alkylpiperazinyl group;

[0068] R c1 Independently selected from: deuterium, halogen, hydroxyl, amino, nitro, cyano, thiol, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6Cycloalkyl, 3-6 membered heterocyclyl, phenyl, 5-6 membered heteroaryl;

[0069] R c2 Independently selected from: deuterium, oxo, halogen, hydroxyl, amino, -OR c3 、-SR c3 、-N(R c3 )2、-S(O)2R c3 、-S(O)2N(R c3 )2、-S(O)R c3 、-S(O)(NR c3 )R c3 、-P(O)(OR c3 )2、-P(O)(N(R c3 )2)2、-C(R c3 )2(OR c3 )、-C(R c3 )2N(R c3 )2、-C(O)R c3 、-C(O)OR c3 、-C(O)N(R c3 )2、-C(O)N(R c3 )OR c3 、-OC(O)R c3 、-OC(O)N(R c3 )2、-N(R c3 )C(O)OR c3 、-N(R c3 )C(O)R c3 、-N(R c3 )C(O)N(R c3 )2、-N(R c3 )C(O)R c3 N(R c3 )OC(O)R c3 、-N(R c3 )S(O)2R c3 、C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl; said C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl is optionally substituted by one or more R c4 replace;

[0070] R c3 、R c4 are independently selected from: hydrogen, deuterium, oxo, halogen, hydroxyl, amino, C 1-18Alkyl, C 1-6 Alkoxy, C 1-6 haloalkyl, C 1-6 Alkyl, optionally substituted with one or more amino groups 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-6 membered heteroaryl;

[0071] Het has the following structure:

[0072] in,

[0073] When A or B and When connected, A and B are independently selected from -C(R d1 )-、-N-、 The "#" is a link one end;

[0074] When A or B does not When connected, A and B are independently selected from a bond, -C(R d1 )2-、-NR d1 -、-C(R d1 )2N(R d1 )-、-NR d1 C(R d1 )2-;

[0075] R d1 Independently selected from: absence, bond, hydrogen, deuterium, hydroxyl, amino, nitro, cyano, C 1-6 Alkyl; or two R attached to the same carbon atom d1 Together they form an oxo group;

[0076] Y is independently selected from -O-, -N(R d2 )-、-C(R d2 )2-, -S-, -C(O)-, -C(=N-OC 0-6 alkyl)-、-S(O)-、-S(O)2-、-S(O)(=NR d2 )-;

[0077] R d2 Independently selected from: hydrogen, deuterium, halogen, hydroxyl, amino, nitro, cyano, -OR d3 、-SR d3 、-N(R d3 )2、-C(O)R d3 、-(C 1- 6-alkylene)-C(O)R d3 、-C(O)OR d3、-(C 1-6 alkylene)-C(O)OR d3 、-C(O)N(R d3 )2、-(C 1-6 Alkylene)-C(O)N(R d3 )2、-C(O)-(C 1-6 Alkylene)-N(R d3 )2、-S(O)2R d3 、-S(O)2N(R d3 )2、-S(O)R d3 、-C(O)N(R d3 )OR d3 、-OC(O)R d3 、-OC(O)N(R d3 )2、-N(R d3 )C(O)OR d3 、-N(R d3 )C(O)R d3 、-N(R d3 )C(O)N(R d3 )2、-N(R d3 )S(O)2R d3 、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1-6 Alkyl, C 1-6 Alkylene, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, optionally substituted with one or more selected from deuterium, halogen, oxo, hydroxy, amino, nitro, cyano, C 1-6 Alkyl, C 1-6 substituted by an alkoxy substituent;

[0078] R d3 Independently selected from: hydrogen, deuterium, halogen, hydroxyl, amino, nitro, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, optionally substituted with one or more selected from deuterium, halogen, oxo, hydroxy, amino, nitro, cyano, C 1-6 Alkyl, C 1-6 substituted by an alkoxy substituent;

[0079] R 13 、R 14 、R 15 、R 16 are independently selected from: hydrogen, deuterium, oxo, halogen, hydroxyl, amino, imino, sulfinamide, nitro, cyano, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, optionally substituted with one or more R d4 Replace; when R 13 、R 14 When one of them is selected from oxo group and imino group, the other one does not exist; when R 15 、R 16 When one of them is selected from an oxo group and an imino group, the other one does not exist;

[0080] or R 13 and R 14 Together with the carbon atoms to which they are attached, they form groups that are substituted by halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 One or more optionally substituted C 3-12 Carbocyclic group or 3-12 membered heterocyclic group;

[0081] or R 15 and R 16 Together with the carbon atoms to which they are attached, they form groups that are substituted by halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 One or more optionally substituted C 3-12 Carbocyclic group or 3-12 membered heterocyclic group;

[0082] R d4 Independently selected from: deuterium, halogen, oxo, hydroxy, amino, cyano, sulfonyl, urea, C2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl; the C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl is optionally substituted with one or more halogens;

[0083] Cy2 is independently selected from: phenyl, 5-6 membered heterocyclyl, 5-6 membered heteroaryl;

[0084] Cy3 is independently selected from: phenyl, 5-6 membered heterocyclyl, 5-6 membered heteroaryl;

[0085] R 17 and R 18 are independently selected from: deuterium, halogen, hydroxyl, amino, cyano, nitro, carboxyl, oxo, -OR d5 、-SR d5 、-N(R d5 )2、-S(O)2R d5 、-S(O)2N(R d5 )2、-S(O)R d5 、-S(O)(NR d5 )R d5 、-S(O)N(R d5 )2、-P(O)(OR d5 )2、-P(O)(N(R d5 )2)2、-C(R d5 )2(OR d5 )、-C(R d5 )2N(R d5 )2、-C(O)R d5 、-C(O)OR d5 、-C(O)N(R d5 )2、-C(O)N(R d5 )OR d5 、-OC(O)R d5 、-OC(O)N(R d5 )2、-N(R d5 )C(O)OR d5 、-N(R d5 )C(O)R d5 、-N(R d5 )C(O)N(R d5 )2、-N(R d5 )S(O)2R d5 、-N(R d5 )S(O)2N(R d5)2、-N(R d5 )S(O)2O(R d5 ), C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, optionally substituted with one or more selected from deuterium, halogen, oxo, hydroxy, amino, cyano, carboxyl, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 substituted by a cycloalkyl substituent;

[0086] R d5 Independently selected from: hydrogen, deuterium, halogen, hydroxyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl are optionally substituted with one or more substituents selected from deuterium, halogen, hydroxy, amino, cyano, and carboxyl;

[0087] Z is independently selected from C, N;

[0088] E is independently selected from: -C(R d6 )2-、-N(R d6 )-;

[0089] R d6 Independently selected from: hydrogen, deuterium, halogen, hydroxyl, amino, cyano, nitro, sulfenamide, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12Aryl, 5-12 membered heteroaryl; said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl may be substituted with one or more substituents selected from deuterium, halogen, oxo, hydroxyl, amino, carboxyl, cyano; or two R groups attached to the same carbon atom ... d6 Together form an oxo group, a thio group, an imino group; or two R groups connected to the same carbon atom d6 Together with the carbon atoms to which they are attached, they form a C 3-15 Carbocyclyl, 3-15 membered heterocyclyl;

[0090] n and q are independently selected from 0, 1, 2, 3, and 4;

[0091] When multiple R a1 、R a2 、R b1 、R b2 、R c1 、R c2 、R c3 、R c4 、R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R 1 、R 3 、R 17 、R 18 When they appear simultaneously, each R a1 , each R a2 , each R b1 , each R b2 , each R c1 , each R c2 , each R c3 , each R d1 , each R d2 , each R d3 , each R d4 , each R d5 , each R d6 , each R 1 , each R 3 , each R 17 , each R 18 Can be the same or different.

[0092] In a preferred embodiment of the present invention, Cy1 is independently selected from 4-6 membered heterocyclic group, phenyl group, and 5-6 membered heteroaryl group.

[0093] In a preferred embodiment of the present invention, wherein Cy1 is independently selected from 4-12 membered heterocyclic groups, C 5-12 Aryl.

[0094] In a further preferred embodiment, wherein Cy1 is independently selected from 5-6 membered heterocyclic group and phenyl.

[0095] In a further preferred embodiment, Cy1 is independently selected from a 5-6 membered heterocyclic group and a phenyl group; the heteroatom in the heterocyclic group is selected from N, and the number of the heteroatom is 1.

[0096] In a further preferred embodiment, wherein Cy1 is independently selected from phenyl.

[0097] In a preferred embodiment of the present invention, Cy1 is independently selected from a 5-6 membered heterocyclic group; the heteroatom in the heterocyclic group is selected from N or S.

[0098] In a preferred embodiment of the present invention, wherein Cy1 is independently selected from the following groups:

[0099] In a preferred embodiment of the present invention, Independently selected from the following groups:

[0100] In a further preferred embodiment, wherein, Selected from the following groups:

[0101] In a further preferred embodiment, wherein, Selected from the following groups:

[0102] In a preferred embodiment of the present invention, wherein R 1 are independently selected from: hydrogen, halogen, oxo, hydroxy, amino, nitro, cyano, -R a1 、-OR a1 、-SR a1 、-N(R a1 )2、-S(O)2R a1 、-S(O)2N(R a1 )2、-C(O)R a1 、-C(O)OR a1 、-C(O)N(R a1 )2、-C(O)OR a1 -OC(O)Ra1 、-N(R a1 )C(O)R a1 .

[0103] In a further preferred embodiment, wherein R 1 Independently selected from: hydrogen, halogen, oxo, hydroxy, amino, cyano, -R a1 、-C(O)R a1 、-C(O)OR a1 .

[0104] In a preferred embodiment of the present invention, wherein R a1 Independently selected from: hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl; the C 1-6 Alkyl, C 3-6 The cycloalkyl group is optionally substituted with one or more R a2 replace.

[0105] In a further preferred embodiment, wherein R a1 Independently selected from: C 1-3 Alkyl; the C 1-3 The alkyl group is optionally substituted with one or more R a2 replace.

[0106] In a further preferred embodiment, wherein R a1 Independently selected from: C 1-6 Alkyl, C 1-6 Halogenated alkyl.

[0107] In a further preferred embodiment, wherein R a1 Independently selected from: methyl, ethyl, n-propyl, isopropyl.

[0108] In a preferred embodiment of the present invention, wherein R a2 Independently selected from: deuterium, halogen, oxo, hydroxy, amino, nitro, cyano, mercapto, C 1-4 Alkyl, C 1-4 Alkoxy.

[0109] In a further preferred embodiment, wherein R a2 Independently selected from halogen (eg, fluorine, chlorine, bromine), hydroxyl.

[0110] In a further preferred embodiment, wherein R a2 are independently selected from halogen (eg, fluorine, chlorine, bromine).

[0111] In a further preferred embodiment, wherein R a2 Independently selected from fluorine and hydroxy.

[0112] In a further preferred embodiment, wherein R a2 are independently selected from fluorine.

[0113] In a preferred embodiment of the present invention, wherein R 1 are independently selected from: hydrogen, fluorine, chlorine, bromine, oxo, hydroxy, amino, -R a1 、-OR a1 、-S(O)2R a1 、-C(O)R a1 、-C(O)OR a1 、-C(O)N(R a1 )2、-C(O)OR a1 -OC(O)R a1 ;

[0114] R a1 Independently selected from: hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl; the C 1-6 Alkyl, C 3-6 The cycloalkyl group is optionally substituted with one or more R a2 replace;

[0115] R a2 Independently selected from: fluorine, chlorine, bromine, oxo, hydroxy, amino.

[0116] In a preferred embodiment of the present invention, wherein R 1 Independently selected from: hydrogen, halogen, oxo, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 1-4 Halogenated alkyl, C 1-4 Alkyl, -S(O)2C 1-4 Alkyl, -C(O)C 1-4 Alkyl, -C(O)C 1-4 Haloalkyl, -C(O)OC 1-4 Alkyl, -C(O)NHC 1-4 Alkyl, -C(O)O-(C 1-4 alkyl)-OC(O)C 1-4 alkyl.

[0117] In a further preferred embodiment, wherein R 1 Independently selected from: hydrogen, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, -C(O)C 1-6 Alkyl, -C(O)C 1-6 Haloalkyl, -C(O)OC1-6 alkyl.

[0118] In a further preferred embodiment, wherein R 1 Independently selected from: hydrogen, fluorine, chlorine, bromine, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, -C(O)C 1-3 Alkyl, -C(O)C 1-3 Haloalkyl, -C(O)OC 1-3 alkyl.

[0119] In a further preferred embodiment, wherein R 1 Independently selected from: hydrogen, C 1-2 Alkyl, C 1-2 Haloalkyl, -C(O)C 1-2 Halogenated alkyl.

[0120] In a further preferred embodiment, wherein R 1 Independently selected from: C 1-2 Alkyl, C 1-2 Halogenated alkyl.

[0121] In a further preferred embodiment, wherein R 1 Independently selected from: hydrogen, fluorine, chlorine, bromine, oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -CH2F, -CF2H, -CF3, -CH2CF3, -C(O)CH3, -C(O)CH2CH3, -S(O)2CH3, -CH2OH, -C(O)CF3, -C(O)CF2H, -C(O)OCH3, -C(O)OCH2CH3, -C(O)NHCH3, -C(O)O-CH(CH3)-OC(O)CH(CH3)2.

[0122] In a further preferred embodiment, wherein R 1 Independently selected from methyl, -CF2H.

[0123] In a preferred embodiment of the present invention, wherein R 1 Independently selected from C 1-4 alkyl.

[0124] In a further preferred embodiment, wherein R 1 are independently selected from methyl.

[0125] In a preferred embodiment of the present invention, wherein X 1 Selected from N.

[0126] In a preferred embodiment of the present invention, wherein X is selected from N.

[0127] In a preferred embodiment of the present invention, wherein X is selected from CR 2 .

[0128] In a preferred embodiment of the present invention, wherein X 1 is selected from N; and X is selected from N.

[0129] In a preferred embodiment of the present invention, wherein R 2 Independently selected from halogen (eg fluorine, chlorine, bromine, preferably fluorine), cyano.

[0130] In a preferred embodiment of the present invention, wherein X is selected from CR 2 or N; R 2 independently selected from hydrogen, fluorine, chlorine, bromine, hydroxy, amino, cyano, C 1-4 Alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl).

[0131] In a further preferred embodiment, wherein X is selected from CR 2 ; R 2 Independently selected from fluoro, cyano, and methyl.

[0132] In a preferred embodiment of the present invention, m is independently selected from the group consisting of: 0, 1, 2, and 3.

[0133] In a further preferred embodiment, wherein m is independently selected from: 0, 1, 2.

[0134] In a further preferred embodiment, wherein m is independently selected from: 1, 2.

[0135] In a further preferred embodiment, wherein m is independently selected from 1.

[0136] In a preferred embodiment of the present invention, wherein Q is independently selected from: -R 3 、-N(R 3 )-C 0-6 Alkylene-R 3 、-N(R 3 )-C 0-6 Alkylene-N(R 3 )2、-N(R 3 )C(O)OR 3 、-N(R 3 )C(O)R 3 、-N(R 3 )C(O)N(R 3 )2、-N(R 3 )S(O)2R3 ; The alkylene group is optionally replaced by one or more R c1 replace.

[0137] In a further preferred embodiment, wherein Q is independently selected from: -R 3 、-N(R 3 )-C 0-6 Alkylene-R 3 、-N(R 3 )-C 0-6 Alkylene-N(R 3 )2; the alkylene group is optionally replaced by one or more R c1 replace.

[0138] In a further preferred embodiment, wherein Q is independently selected from: -R 3 、-NH-C 0-4 Alkylene-R 3 、-NH-C 0-4 Alkylene-NHR 3 ; The alkylene group is optionally replaced by one or more R c1 replace.

[0139] In a further preferred embodiment, wherein Q is independently selected from: -R 3 、-NH-C 1-4 Alkylene-R 3 、-NH-C 1-4 Alkylene-NHR 3 ; The alkylene group is optionally replaced by one or more R c1 replace.

[0140] In a further preferred embodiment, wherein Q is independently selected from: -R 3 、-NH-C 1-2 Alkylene-R 3 、-NH-C 1-4 Alkylene-NHR 3 ; The alkylene group is optionally replaced by one or more R c1 replace.

[0141] In a preferred embodiment of the present invention, wherein R 3 Independently selected from: hydrogen, C 1-6 Alkyl, C 3-7 Carbocyclic group, 3-7 membered heterocyclic group, phenyl group, 5-6 membered heteroaryl group; the C 1-6 Alkyl, C 3-7 Carbocyclic group, 3-7 membered heterocyclic group, phenyl group, 5-6 membered heteroaryl group are optionally substituted with one or more R c2 replace;

[0142] or two R attached to the same nitrogen atom3 Together with the nitrogen atom to which they are attached, they form halogen, hydroxyl, amino, -C(O)NH2, -(CH2) 1-4 NH2, oxo, C 1-4 Alkyl, C 1-4 Alkoxy, oxetanylamino, C 1-4 The alkylpiperazinyl group may be one or more optionally substituted 3-7 membered heterocyclic groups or 5-6 membered heteroaryl groups.

[0143] In a preferred embodiment of the present invention, wherein R 3 Independently selected from: hydrogen, C 1-6 Alkyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group; the C 1-6 Alkyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group is replaced by one or more R c2 replace.

[0144] In a further preferred embodiment, wherein R 3 Independently selected from: hydrogen, C 1-6 Alkyl, C 3-10 Carbocyclic group, 3-10 membered heterocyclic group; the C 1-6 Alkyl, C 3-10 Carbocyclic group, 3-10 membered heterocyclic group is replaced by one or more R c2 replace.

[0145] In a further preferred embodiment, wherein R 3 Independently selected from: hydrogen, C 1-6 Alkyl, C 3-6 Carbocyclic group, 4-10 membered heterocyclic group; the C 1-6 Alkyl, C 3-6 Carbocyclic group, 4-10 membered heterocyclic group is replaced by one or more R c2 replace.

[0146] In a further preferred embodiment, wherein R 3 Independently selected from: hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 5-6 bridged cyclic group, 3-6 membered heterocycloalkyl group, 6-10 membered heterospirocyclic group, 5-10 membered bridged heterocyclic group, 6-10 membered heterocyclic group; the C 1-6 Alkyl, C 3-6 Cycloalkyl, C 5-6 Bridged ring group, 3-6 membered heterocycloalkyl group, 6-10 membered heterospirocyclic group, 5-10 membered bridged ring heterocyclic group, 6-10 membered heterocyclic group are optionally substituted by one or more R c2 replace.

[0147] In a further preferred embodiment, wherein R 3 Independently selected from: hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 5-6 bridged ring group, 3-6 membered heterocycloalkyl, 3-membered / 5-membered heterospirocyclyl, 5-membered / 3-membered heterospirocyclyl, 4-membered / 4-membered heterospirocyclyl, 4-membered / 5-membered heterospirocyclyl, 5-membered / 5-membered heterospirocyclyl, 4-membered / 6-membered heterospirocyclyl, 6-membered / 4-membered heterospirocyclyl, 7-8 membered bridged ring heterocyclyl, 3-membered / 5-membered heterocyclyl, 5-membered / 3-membered heterocyclyl, 4-membered / 4-membered heterocyclyl, 4-membered / 5-membered heterocyclyl, 5-membered / 4-membered heterocyclyl, 5-membered / 5-membered heterocyclyl, 4-membered / 6-membered heterocyclyl, 6-membered / 4-membered heterospirocyclyl, 5-membered / 6-membered heterocyclyl, 6-membered / 5-membered heterocyclyl; the above groups are optionally replaced by one or more R c2 replace.

[0148] In a further preferred embodiment, wherein R 3 Independently selected from: hydrogen, C 1-4 Alkyl, C 3-6 Cycloalkyl, C 5-6 bridged ring group, 4-6 membered heterocycloalkyl group, 4-membered / 4-membered heterospirocyclic group, 7-8 membered bridged ring heterocyclic group, 3-membered / 5-membered heterocyclic group, 5-membered / 3-membered heterocyclic group, 5-membered / 5-membered heterocyclic group; the above groups are optionally replaced by one or more R c2 replace.

[0149] In a further preferred embodiment, wherein R 3 Independently selected from: hydrogen, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, 6-9 membered heterospirocyclic group; the C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, 6-9 membered heterospirocyclic group are optionally substituted by one or more R c2 replace.

[0150] In a further preferred embodiment, wherein R 3 Independently selected from: hydrogen, C 1-4 Alkyl, C 4-6 Cycloalkyl, 4-6 membered heterocycloalkyl, 7 membered heterospirocyclic group; the heteroatom in the 4-6 membered heterocycloalkyl, 7 membered heterospirocyclic group is selected from N or O, and the number of heteroatoms is 1 or 2; the C 1-4 Alkyl, C 4-6 Cycloalkyl, 4-6 membered heterocycloalkyl, 7 membered heterospirocycloalkyl are optionally substituted with one or more R c2 replace.

[0151] In a further preferred embodiment, wherein R3 Independently selected from: hydrogen, C 1-4 alkyl, 4-6 membered heterocycloalkyl, 7 membered heterospirocycloalkyl; the heteroatom in the 4-6 membered heterocycloalkyl and 7 membered heterospirocycloalkyl is selected from N or O, and the number of heteroatoms is 1; the C 1-4 Alkyl, 4-6 membered heterocycloalkyl, 7 membered heterospirocyclic group are optionally substituted by one or more R c2 replace.

[0152] In a further preferred embodiment, wherein R 3 Independently selected from: hydrogen, methyl, ethyl, n-propyl, isopropyl, The above groups are optionally replaced by one or more R c2 replace.

[0153] In a further preferred embodiment, wherein R 3 Independently selected from: hydrogen, methyl, ethyl, n-propyl, isopropyl, The above groups are optionally replaced by one or more R c2 replace.

[0154] In a further preferred embodiment, wherein R 3 Independently selected from: hydrogen, methyl, ethyl, n-propyl, isopropyl,

[0155] In a preferred embodiment of the present invention, wherein R 3 Independently selected from: hydrogen, C 1-6 Alkyl, C 3-6 Carbocyclic group, 4-10 membered heterocyclic group; the C 1-6 Alkyl, C 3-6 Carbocyclic group, 4-10 membered heterocyclic group is replaced by one or more R c2 replace;

[0156] R c2 Independently selected from: halogen, hydroxy, amino, cyano, -OC 1-6 Alkyl, -C(O)OH, -C(O)OC 1-6 Alkyl, C 1-6 Alkyl; the C 1-6 The alkyl group is optionally substituted with one or more substituents selected from halogen, hydroxy, and amino.

[0157] In a further preferred embodiment, wherein R 3 Independently selected from: hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 5-6 bridged ring group, 4-10 membered heterocyclic group; said C 1-6 Alkyl, C 3-6 Cycloalkyl, C5-6 Bridged ring group, 4-10 membered heterocyclic group is one or more R c2 replace;

[0158] R c2 Independently selected from: halogen, hydroxy, amino, cyano, -OC 1-6 Alkyl, -C(O)OH, -C(O)OC 1-6 Alkyl, C 1-6 Alkyl; the C 1-6 The alkyl group is optionally substituted with one or more substituents selected from halogen, hydroxy, and amino.

[0159] In a further preferred embodiment, wherein R 3 Independently selected from: hydrogen, C 1-4 Alkyl, C 3-6 Cycloalkyl, C 5-6 bridged ring group, 4-6 membered heterocycloalkyl group, 4-membered / 4-membered heterospirocyclic group, 7-8 membered bridged ring heterocyclic group, 3-membered / 5-membered heterocyclic group, 5-membered / 3-membered heterocyclic group, 5-membered / 5-membered heterocyclic group; the above groups are optionally replaced by one or more R c2 replace;

[0160] R c2 Independently selected from: halogen, hydroxy, amino, cyano, -OC 1-3 Alkyl, -C(O)OH, -C(O)OC 1-3 Alkyl, C 1-3 Alkyl, C 1-3 Haloalkyl, hydroxy substituted C 1-3 Alkyl, amino substituted C 1-3 alkyl.

[0161] In a preferred embodiment of the present invention, wherein R c1 Independently selected from: deuterium, halogen, hydroxyl, amino, nitro, cyano, thiol, C 1-4 Alkyl, C 1-4 Alkoxy.

[0162] In a further preferred embodiment, wherein R c1 Independently selected from the group consisting of fluorine, chlorine, bromine, hydroxy, amino, methyl, ethyl, n-propyl, isopropyl.

[0163] In a further preferred embodiment, wherein R c1 Independently selected from: fluorine.

[0164] In a preferred embodiment of the present invention, wherein R c2 Independently selected from: deuterium, oxo, halogen, hydroxyl, amino, -OR c3 、-N(R c3 )2、-C(Rc3 )2(OR c3 )、-C(R c3 )2N(R c3 )2、-C(O)R c3 、-C(O)OR c3 、-C(O)N(R c3 )2、-C(O)N(R c3 )OR c3 、-OC(O)R c3 、-OC(O)N(R c3 )2、-N(R c3 )C(O)OR c3 、-N(R c3 )C(O)R c3 、-N(R c3 )C(O)N(R c3 )2、-N(R c3 )S(O)2R c3 、C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, phenyl, 5-6 membered heteroaryl; the C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, phenyl, 5-6 membered heteroaryl, optionally substituted with one or more R c4 replace.

[0165] In a further preferred embodiment, wherein R c2 Independently selected from: halogen, hydroxy, amino, cyano, -OR c3 、-C(O)OR c3 、C 1- 6 alkyl; the C 1-6 The alkyl group is optionally substituted with one or more R c4 replace.

[0166] In a further preferred embodiment, wherein R c2 Independently selected from: halogen, hydroxy, amino, C 1-4 Alkyl; the C 1-4 The alkyl group is optionally substituted with one or more R c4 replace.

[0167] In a further preferred embodiment, wherein R c2 Independently selected from: halogen (such as fluorine, chlorine, bromine), hydroxyl, amino, methyl, ethyl, n-propyl, isopropyl; the above groups are optionally substituted by one or more substituents selected from halogen (such as fluorine, chlorine, bromine), hydroxyl, amino.

[0168] In a preferred embodiment of the present invention, wherein R c2Independently selected from: halogen, hydroxy, amino, cyano, -OC 1-6 Alkyl, -C(O)OH, -C(O)OC 1-6 Alkyl, C 1-6 Alkyl; the C 1-6 The alkyl group is optionally substituted with one or more substituents selected from halogen, hydroxy, and amino.

[0169] In a further preferred embodiment, wherein R c2 Independently selected from: halogen, hydroxy, amino, cyano, -OC 1-3 Alkyl, -C(O)OH, -C(O)OC 1-3 Alkyl, C 1-3 Alkyl; the C 1-3 The alkyl group is optionally substituted with one or more substituents selected from halogen (eg, fluorine, chlorine, bromine), hydroxyl, and amino.

[0170] In a further preferred embodiment, wherein R c2 Independently selected from: fluorine, chlorine, bromine, hydroxyl, amino, cyano, methoxy, ethoxy, -C(O)OH, -C(O)OCH3, -C(O)OCH2CH3, -CH2OH, -CH2CH2OH, trifluoromethyl, difluoromethyl, monofluoromethyl, -CH2NH2, -CH2CH2NH2, -C(CH3)2NH2.

[0171] In a preferred embodiment of the present invention, wherein R c3 、R c4 are independently selected from: hydrogen, halogen, hydroxyl, amino, C 1-6 Alkyl, C 1-6 haloalkyl, C 1-6 alkyl.

[0172] In a preferred embodiment of the present invention, wherein R c3 Independently selected from: hydrogen, methyl, ethyl, n-propyl, isopropyl.

[0173] In a preferred embodiment of the present invention, wherein R c4 Independently selected from: halogen, hydroxy, amino.

[0174] In a further preferred embodiment, wherein R c4 Independently selected from: fluorine, chlorine, bromine, hydroxyl, amino.

[0175] In a further preferred embodiment, wherein R c4 Independently selected from: hydroxyl, amino.

[0176] In a preferred embodiment of the present invention, wherein Q is independently selected from: -R 3 、-N(R 3 )-C 0-6 Alkylene-R 3 、-N(R 3 )-C 0-6 Alkylene-N(R 3 ) 2; The alkylene group is optionally substituted by one or more selected from halogen, hydroxy, amino, C 1-6 substituted by an alkyl substituent;

[0177] R 3 are independently selected from: hydrogen, C 1-6 Alkyl, C 3-6 Carbocyclic group, 3-10 membered heterocyclic group; the C 1-6 Alkyl, C 3-6 Carbocyclic group, 3-10 membered heterocyclic group are optionally substituted by one or more R c2 replace;

[0178] R c2 Independently selected from: halogen, hydroxy, amino, cyano, -OC 1-6 Alkyl, -C(O)OH, -C(O)OC 1-6 Alkyl, C 1-6 Alkyl; the C 1-6 The alkyl group is optionally substituted with one or more substituents selected from halogen, hydroxy, and amino.

[0179] In a further preferred embodiment, wherein Q is independently selected from: 3-10 membered heterocyclyl, -NH-C 0-4 Alkylene-C 3-6 Carbocyclic group, -NH-C 0-4 Alkylene-3-10 membered heterocyclic group, -NH-C 0-4 Alkylene-NH2, -NH-C 0-4 Alkylene-NH(C 1-6 Alkyl), -NH-C 0-4 Alkylene-N(C 1-6 alkyl) 2; the alkylene group is optionally substituted by one or more substituents selected from halogen (eg, fluorine, chlorine, bromine); the C 1-6 Alkyl, C 3- 6-membered carbonyl, 3-10-membered heterocyclic group optionally with one or more R c2 replace;

[0180] R c2 Independently selected from: halogen, hydroxy, amino, cyano, -OC 1-6 Alkyl, -C(O)OH, -C(O)OC 1-6 Alkyl, C 1-6 Alkyl, C1- 6 haloalkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 alkyl.

[0181] In a further preferred embodiment, wherein Q is independently selected from: 3-6 membered heterocycloalkyl, 7-8 membered heterospirocyclyl, 7-8 membered bridged heterocyclyl, 6-10 membered heterocyclyl, -NH-C 0-4 Alkylene-C 3-6 Cycloalkyl, -NH-C 0-4 Alkylene-C 5-6 Bridged ring group, -NH-C 0-4 Alkylene-3-6 membered heterocyclic group, -NH-C 0-4 Alkylene-7-8 membered heterospirocyclic group, -NH-C 0-4 Alkylene-NH2, -NH-C 0-4 Alkylene-NH(C 1-6 Alkyl), -NH-C 0- 4-alkylene-N(C 1-4 alkyl) 2; the alkylene group is optionally substituted by one or more substituents selected from halogen (eg, fluorine, chlorine, bromine); the C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, 7-8 membered heterospirocyclic group, 7-8 membered bridged heterocyclic group, 6-10 membered heterocyclic group, C 5-6 The bridged ring group is optionally substituted by one or more R c2 replace;

[0182] R c2 Independently selected from: halogen, hydroxy, amino, cyano, -OC 1-3 Alkyl, -C(O)OH, -C(O)OC 1-3 Alkyl, C 1-3 Alkyl, C 1- 3 haloalkyl, hydroxy substituted C 1-3 Alkyl, amino substituted C 1-3 alkyl.

[0183] In a further preferred embodiment, wherein Q is independently selected from: 3-6 membered heterocycloalkyl, 7-8 membered heterospirocyclyl, 7-8 membered bridged heterocyclyl, 6-10 membered heterocyclyl, -NH-C 0-2 Alkylene-C 3-6 Cycloalkyl, -NH-C 0-2 Alkylene-C 5-6 Bridged ring group, -NH-C 0-2 Alkylene-3-6 membered heterocyclic group, -NH-C 0-2Alkylene-7-8 membered heterospirocyclic group; the cycloalkyl, heterocycloalkyl, heterospirocyclic group, bridged heterocyclic group, heterocyclic group, bridged heterocyclic group are optionally substituted by one or more R c2 Substitution; the heteroatoms in the 3-6 membered heterocycloalkyl, 7-8 membered heterospirocyclic group, 7-8 membered bridged heterocyclic group, and 6-10 membered heterocyclic group are N, O, and the number of heteroatoms is 1 or 2, and Connected to the N atom in Q;

[0184] R c2 Independently selected from: halogen, hydroxy, amino, cyano, -OC 1-3 Alkyl, -C(O)OH, -C(O)OC 1-3 Alkyl, C 1-3 Alkyl, C 1- 3 haloalkyl, hydroxy substituted C 1-3 Alkyl, amino substituted C 1-3 alkyl.

[0185] In a preferred embodiment of the present invention, wherein Q is independently selected from: -R 3 、-N(R 3 )-C 0-6 Alkylene-R 3 、-N(R 3 )-C 0-6 Alkylene-N(R 3 ) 2; The alkylene group is optionally substituted by one or more selected from halogen, hydroxy, amino, C 1-6 substituted by an alkyl substituent;

[0186] R 3 are independently selected from: hydrogen, C 1-6 Alkyl, C 3-10 Carbocyclic group, 3-10 membered heterocyclic group; the C 1-6 Alkyl, C 3-10 Carbocyclic group, 3-10 membered heterocyclic group are optionally substituted by one or more R c2 replace;

[0187] R c2 Independently selected from: halogen, hydroxy, amino, C 1-6 Alkyl; the C 1-6 The alkyl group is optionally substituted with one or more substituents selected from halogen, hydroxy, and amino.

[0188] In a further preferred embodiment, wherein Q is independently selected from: C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -NH-C 0-6 Alkylene-R 3 、-NH-C 0-6 Alkylene-N(R 3) 2; the alkylene group is optionally substituted by one or more substituents selected from halogen, hydroxy, amino, methyl, and ethyl;

[0189] R 3 are independently selected from: hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, 6-9 membered heterospirocyclic group; the C 1-6 Alkyl, C 3- 6-membered cycloalkyl, 3-6-membered heterocyclic group, 6-9-membered heterospirocyclic group are optionally substituted by one or more R c2 replace;

[0190] R c2 Independently selected from: halogen, hydroxy, amino, C 1-6 Alkyl, amino substituted C 1-6 Alkyl, hydroxy substituted C 1-6 alkyl.

[0191] In a further preferred embodiment, wherein Q is independently selected from: C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -NH-C 0-4 Alkylene-C 3-6 Cycloalkyl, -NH-C 0-4 Alkylene-3-6 membered heterocyclic group, -NH-C 0-4 Alkylene-7-membered heterospirocyclic group, -NH-C 0-4 Alkylene-NH2, -NH-C 0-4 Alkylene-NH(C 1-4 Alkyl), -NH-C 0-4 Alkylene-N(C 1-4 alkyl) 2; the alkylene group is optionally substituted by one or more substituents selected from halogen (eg, fluorine, chlorine, bromine); the C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, 7 membered heterospirocyclic group are optionally substituted by one or more halogen (such as fluorine, chlorine, bromine), hydroxyl, amino, C 1-4 Alkyl, amino substituted C 1-4 Alkyl, hydroxy substituted C 1-4 substituted by an alkyl substituent.

[0192] In a preferred embodiment of the present invention, wherein Q is independently selected from: 3-10 membered nitrogen-containing heterocyclic group (preferably 3-8 membered nitrogen-containing heterocyclic group), -NH-C 0-2 Alkylene-C 3-6 Cycloalkyl-NH2, -NH-C 0-2 Alkylene-3-6 membered heterocyclic group; Connected to the nitrogen atom in a 3-10 membered nitrogen-containing heterocyclic group, The heteroatom in the 3-6 membered heterocyclic group is selected from N or O, and the number of heteroatoms is 1 or 2; the 3-10 membered nitrogen-containing heterocyclic group, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group are optionally substituted by one or more halogen (eg fluorine, chlorine, bromine), hydroxyl, amino, -C 1-2 Alkyl-NH2, -C 1-2 Alkyl-OH, -C(O)OC 1-2 substituted by an alkyl substituent.

[0193] In a preferred embodiment of the present invention, wherein Q is independently selected from: 3-7 membered nitrogen-containing heterocyclic group (more preferably 4-5 membered nitrogen-containing heterocyclic group), -NH-C 0-2 Alkylene-C 3-6 Cycloalkyl-NH2 (more preferably -NH-C 0-1 Alkylene-C 4-5 Cycloalkyl-NH2), -NH-C 0-2 Alkylene-3-6 membered heterocyclic group (more preferably -NH-C 0-1 Alkylene-4-5 membered heterocyclic group); Connected to the nitrogen atom in a 3-7 membered nitrogen-containing heterocyclic group, The heteroatom in the 3-6 membered heterocyclic group is selected from N or O, and the number of heteroatoms is 1 or 2; the 3-7 membered nitrogen-containing heterocyclic group, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group are optionally substituted by one or more halogen (eg fluorine, chlorine, bromine), hydroxyl, amino, -C 1-2 Alkyl-NH2, -C 1-2 Alkyl-OH, -C(O)OC 1-2 substituted by an alkyl substituent.

[0194] In a further preferred embodiment, wherein Q is independently selected from: 4-6 membered nitrogen-containing heterocyclic group (more preferably 4-5 membered nitrogen-containing heterocyclic group), -NH-C 4-5 Cycloalkyl-NH2 (more preferably -NH-cyclobutane-NH2), -NH-C 0-2 Alkylene-4-6 membered heterocyclic group (more preferably -NH-C 0-1 Alkylene-4-5 membered heterocyclic group); Connected to the nitrogen atom in a 4-6 membered nitrogen-containing heterocyclic group, The heteroatoms in the 4-6 membered heterocyclic group are selected from N or O, and the number of heteroatoms is 1 or 2; the 4-6 membered nitrogen-containing heterocyclic group and the 4-6 membered heterocyclic group are optionally substituted by one or more halogens (such as fluorine, chlorine, bromine), hydroxyl, amino, -C 1-2 Alkyl-NH2, -C 1-2 Alkyl-OH, -C(O)OC1-2 substituted by an alkyl substituent.

[0195] In a further preferred embodiment, wherein Q is independently selected from: 4-6 membered nitrogen-containing heterocyclic group (more preferably 4-5 membered nitrogen-containing heterocyclic group), -NH-C 4-5 Cycloalkyl-NH2 (more preferably -NH-cyclobutane-NH2), -NH-C 0-2 Alkylene-4-6 membered heterocyclic group (more preferably -NH-C 0-1 Alkylene-4-5 membered heterocyclic group); Connected to the nitrogen atom in a 4-6 membered nitrogen-containing heterocyclic group, is a connection site; the heteroatom in the 4-6 membered heterocyclic group is selected from N or O, and the number of heteroatoms is 1; the 4-6 membered nitrogen-containing heterocyclic group and the 4-6 membered heterocyclic group are optionally substituted by one or more substituents selected from fluorine, chlorine, hydroxyl, amino, -CH2NH2, -CH2OH, -C(O)OCH3.

[0196] In a preferred embodiment of the present invention, wherein Q is independently selected from: 4-5 membered nitrogen-containing heterocyclic group, -NH-C 4-5 Cycloalkyl-NH2, -NH-C 0-1 Alkylene-4-5 membered heterocyclic group; Connected to the nitrogen atom in a 4-5 membered nitrogen-containing heterocyclic group, is a connection site; the heteroatom in the 4-5 membered heterocyclic group is selected from N or O, and the number of heteroatoms is 1; the 4-5 membered nitrogen-containing heterocyclic group and the 4-6 membered heterocyclic group are optionally substituted by one or more substituents selected from fluorine, hydroxyl, amino, -CH2NH2, -CH2OH, -C(O)OCH3.

[0197] In a preferred embodiment of the present invention, wherein Q is independently selected from: 4-6 membered nitrogen-containing heterocyclic group, -NH-C 0-1 Alkylene-4-5 membered heterocyclic group; Connected to the nitrogen atom in a 4-6 membered nitrogen-containing heterocyclic group, is a connection site; the heteroatom in the 4-5 membered heterocyclic group is selected from N or O, and the number of heteroatoms is 1; the 4-6 membered nitrogen-containing heterocyclic group and the 4-5 membered heterocyclic group are optionally substituted by one or two substituents selected from fluorine, amino, and -CH2NH2.

[0198] In a further preferred embodiment, wherein Q is independently selected from:

[0199] In a further preferred embodiment, wherein Q is selected from:

[0200] In a preferred embodiment of the present invention, wherein Het is selected from the following structures:

[0201] In a further preferred embodiment, wherein Het is selected from B is -N-; A is -CH2-.

[0202] In a further preferred embodiment, wherein Het is selected from the following structures: Cy2 is selected from phenyl or pyridyl.

[0203] In a preferred embodiment of the present invention, when A or B and When connected, A and B are independently selected from -N-; when A or B is not connected When connected, A and B are independently selected from -C(R d1 )2-.

[0204] In a further preferred embodiment, wherein, when A or B and When connected, A and B are independently selected from -N-; when A or B is not connected When connected, A and B are each independently selected from -CH2-.

[0205] In a preferred embodiment of the present invention, wherein R d1 Independently selected from: hydrogen, hydroxy, amino, cyano, methyl, ethyl.

[0206] In a further preferred embodiment, wherein R d1 Independently selected from: hydrogen.

[0207] In a preferred embodiment of the present invention, wherein Y is independently selected from -O-, -N(R d2 )-, -S(O)-, -S(O)2-, -S(O)(=NR d2 )-.

[0208] In a further preferred embodiment, wherein Y is independently selected from -S(O)-, -S(O)2-, -S(O)(=NR d2 )-.

[0209] In a further preferred embodiment, wherein Y is independently selected from -S(O)2-, -S(O)(=NR d2 )-.

[0210] In a further preferred embodiment, wherein Y is independently selected from -S(O)2-.

[0211] In a further preferred embodiment, wherein Y is independently selected from -S(O)(=NRd2 )-.

[0212] In a preferred embodiment of the present invention, wherein R d2 Independently selected from: hydrogen, deuterium, halogen, hydroxyl, amino, nitro, cyano, -SR d3 、-N(R d3 )2、-C(O)R d3 、-(C 1-6 Alkylene)-C(O)R d3 、-C(O)OR d3 、-(C 1-6 alkylene)-C(O)OR d3 、-C(O)N(R d3 )2、-(C 1-6 Alkylene)-C(O)N(R d3 )2、-C(O)-(C 1-6 Alkylene)-N(R d3 )2、-S(O)2R d3 、-C(O)N(R d3 )OR d3 、-OC(O)R d3 、-OC(O)N(R d3 )2、C 1-6 Alkyl, C 3-10 Carbocyclic group, 3-10 membered heterocyclic group, C 6-8 Aryl, 5-10 membered heteroaryl; said C 1-6 Alkyl, C 1-6 Alkylene, C 3-10 Carbocyclic group, 3-10 membered heterocyclic group, C 6-8 Aryl, 5-10 membered heteroaryl, optionally substituted with one or more selected from deuterium, halogen, oxo, hydroxy, amino, nitro, cyano, C 1-6 Alkyl, C 1-6 substituted by an alkoxy substituent.

[0213] In a further preferred embodiment, wherein R d2 Independently selected from: hydrogen, deuterium, halogen, hydroxyl, amino, nitro, cyano, -SR d3 、-N(R d3 )2、-C(O)R d3 、-(C 1-4 Alkylene)-C(O)R d3 、-C(O)OR d3 、-(C 1-4 alkylene)-C(O)OR d3 、-C(O)N(R d3 )2、-(C 1-4 Alkylene)-C(O)N(Rd3 )2、-C(O)-(C 1-4 Alkylene)-N(R d3 )2、-S(O)2R d3 、C 1-4 Alkyl, C 3-6 Carbocyclic group, 3-6 membered heterocyclic group, phenyl group, 5-6 membered heteroaryl group; the C 1-4 Alkyl, C 1-4 Alkylene, C 3-6 Carbocyclic group, 3-6 membered heterocyclic group, phenyl group, 5-6 membered heteroaryl group are optionally substituted with one or more selected from deuterium, halogen, oxo group, hydroxyl, amino group, nitro group, cyano group, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent.

[0214] In a further preferred embodiment, wherein R d2 Independently selected from: hydrogen, -SR d3 、-C(O)R d3 、-(C 1-4 Alkylene)-C(O)R d3 、-(C 1- 4-alkylene)-S(O)2R d3 、-(C 1-4 alkylene)-C(O)OR d3 、-C(O)N(R d3 )2、-(C 1-4 Alkylene)-C(O)N(R d3 )2、-C(O)-(C 1-4 Alkylene)-N(R d3 )2、-S(O)2R d3 、C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered monocyclic heterocyclic group, 7-8 membered spirocyclic heterocyclic group, phenyl, 5-6 membered heteroaryl; the heteroatom in the 3-6 membered monocyclic heterocyclic group, 7-8 membered spirocyclic heterocyclic group, 5-6 membered heteroaryl is selected from N or O, and the number of heteroatoms is 1 or 2; the C 1-6 Alkyl, C 1-4 Alkylene, C 3-6 Cycloalkyl, 3-6 membered monocyclic heterocyclic group, 7-8 membered spirocyclic heterocyclic group, phenyl, 5-6 membered heteroaryl, optionally substituted by one or more selected from deuterium, halogen (such as fluorine, chlorine, bromine, preferably fluorine), oxo, hydroxyl, amino, cyano, C 1-3 Alkyl, C 1- 3 alkoxy, C 3-6 The alkyl group is substituted by a cycloalkyl group or a 3- to 6-membered heterocyclic group.

[0215] In a further preferred embodiment, wherein Rd2 Independently selected from: hydrogen, -SR d3 、-C(O)R d3 、-(C 1-4 Alkylene)-C(O)R d3 、-(C 1- 4-alkylene)-C(O)OR d3 、-C(O)N(R d3 )2、-(C 1-4 Alkylene)-C(O)N(R d3 )2、-C(O)-(C 1-4 Alkylene)-N(R d3 )2、-S(O)2R d3 、C 1- 4 alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, phenyl, 5-6 membered heteroaryl; the heteroatom in the 3-6 membered heterocyclic group and 5-6 membered heteroaryl is selected from N or O, and the number of heteroatoms is 1 or 2; the C 1-4 Alkyl, C 1-4 Alkylene, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, phenyl, 5-6 membered heteroaryl are optionally substituted by one or more substituents selected from deuterium, halogen (e.g., fluorine, chlorine, bromine, preferably fluorine), oxo, hydroxy, amino, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, methoxy, ethoxy, n-propoxy, isopropoxy.

[0216] In a preferred embodiment of the present invention, wherein R d3 Independently selected from: hydrogen, deuterium, halogen, hydroxyl, amino, nitro, cyano, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, phenyl, 5-6 membered heteroaryl; the C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, phenyl, 5-6 membered heteroaryl, optionally substituted with one or more selected from deuterium, halogen, oxo, hydroxy, amino, nitro, cyano, C 1-6 Alkyl, C 1-6 substituted by an alkoxy substituent.

[0217] In a further preferred embodiment, wherein R d3 Independently selected from: hydrogen, halogen, hydroxy, amino, nitro, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group; the C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group may be substituted by one or more selected from halogen, oxo, hydroxy, amino, nitro, cyano, C 1-4 Alkyl, C1-4 substituted by an alkoxy substituent.

[0218] In a further preferred embodiment, wherein R d3 Independently selected from: hydrogen, amino, C 1-6 Alkyl, C 3-6 Cycloalkyl; the C 1-6 Alkyl, C 3-6 The cycloalkyl group is optionally substituted by one or more substituents selected from halogen and hydroxy.

[0219] In a further preferred embodiment, wherein R d3 Independently selected from: hydrogen, fluorine, chlorine, bromine, hydroxyl, amino, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclobutyl; the above groups are optionally substituted by one or more substituents selected from fluorine, chlorine, bromine, hydroxyl, amino.

[0220] In a preferred embodiment of the present invention, wherein R d2 Independently selected from: hydrogen, -SR d3 、-C(O)R d3 、-(C 1-6 Alkylene)-C(O)R d3 、-C(O)OR d3 、-(C 1-6 alkylene)-C(O)OR d3 、-C(O)N(R d3 )2、-(C 1-6 Alkylene)-C(O)N(R d3 )2、-C(O)-(C 1-6 Alkylene)-N(R d3 )2、-S(O)2R d3 、C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, phenyl, 5-6 membered heteroaryl; the C 1-6 Alkyl, C 1-6 Alkylene, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, phenyl, 5-6 membered heteroaryl, optionally substituted with one or more selected from deuterium, halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 substituted by an alkoxy substituent;

[0221] R d3 Independently selected from: hydrogen, halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, phenyl, 5-6 membered heteroaryl; the C 1-6 Alkyl, C3-6 Cycloalkyl, 3-6 membered heterocyclic group, phenyl, 5-6 membered heteroaryl, optionally substituted with one or more selected from deuterium, halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 substituted by an alkoxy substituent.

[0222] In a preferred embodiment of the present invention, wherein R d2 For hydrogen.

[0223] In a preferred embodiment of the present invention, wherein R d2 Independently selected from: -SC 1-6 Alkyl, -C(O)NH2, -C(O)NH(C 1-6 alkyl), -C(O)N(C 1-6 Alkyl)2, -C(O)C 1-6 Alkyl, -C(O)C 3-6 Cycloalkyl, -C(O)3-6 membered heterocyclic group, -C(O)-(C 1-4 Alkylene)-NH(C 1-6 alkyl), -C(O)-(C 1-4 Alkylene)-N(C 1-6 Alkyl)2, -(C 1-4 Alkylene)-C(O)OC 1-6 Alkyl, -(C 1-4 Alkylene)-C(O)C 1-6 Alkyl, -(C 1-4 Alkylene)-S(O)2(C 1-6 Alkyl), -(C 1-4 Alkylene)-C(O)NH2, -(C 1-4 Alkylene)-C(O)NH(C 1-6 Alkyl), -(C 1-4 Alkylene)-C(O)N(C 1- 6alkyl)2, -S(O)2C 1-6 Alkyl, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group, phenyl, 5-6 membered heteroaryl; the C 1-6 Alkyl, C 1- 4 alkylene, C 3-6 Cycloalkyl, 3-8 membered heterocyclyl, phenyl, 5-6 membered heteroaryl, optionally substituted with one or more selected from deuterium, halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 The alkyl group is substituted by a cycloalkyl group or a 3- to 6-membered heterocyclic group.

[0224] In a preferred embodiment of the present invention, wherein Rd2 Independently selected from: -SC 1-3 Alkyl, -C(O)NH2, -C(O)NH(C 1-3 alkyl), -C(O)N(C 1-3 Alkyl)2, -C(O)C 1-3 Alkyl, -C(O)C 3-6 Cycloalkyl, -C(O)3-6 membered heterocyclic group, -C(O)-(C 1-2 Alkylene)-NH(C 1-6 alkyl), -C(O)-(C 1-2 Alkylene)-N(C 1-3 Alkyl)2, -(C 1-2 Alkylene)-C(O)OC 1-3 Alkyl, -(C 1-2 Alkylene)-C(O)C 1-3 Alkyl, -(C 1-2 Alkylene)-S(O)2(C 1-3 Alkyl), -(C 1-2 Alkylene)-C(O)NH2, -(C 1-2 Alkylene)-C(O)NH(C 1-3 Alkyl), -(C 1-2 Alkylene)-C(O)N(C 1- 3alkyl)2, -S(O)2C 1-3 Alkyl, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered monocyclic heterocyclic group, 7 membered spirocyclic heterocyclic group, 8 membered spirocyclic heterocyclic group, phenyl, 5-6 membered heteroaryl; the alkyl, alkylene, C 3-6 Cycloalkyl, 3-6 membered monocyclic heterocyclic group, 7 membered spirocyclic heterocyclic group, 8 membered spirocyclic heterocyclic group, phenyl, 5-6 membered heteroaryl, optionally substituted with one or more selected from deuterium, halogen, hydroxyl, amino, cyano, C 1-3 Alkyl, C 1-3 substituted by an alkoxy group or a 3- to 6-membered heterocyclic group.

[0225] In a further preferred embodiment, wherein R d2 Independently selected from: -SC 1-3 Alkyl, -C(O)NH2, -C(O)NH(C 1-3 alkyl), -C(O)N(C 1- 3 alkyl) 2, -C(O)C 1-3 Alkyl, -C(O)C 3-6 Cycloalkyl, -C(O)-(C 1-2 Alkylene)-NH(C 1-3 alkyl), -C(O)-(C 1-2 Alkylene)-N(C1-3 Alkyl)2, -(C 1-2 Alkylene)-C(O)OC 1-3 Alkyl, -(C 1-2 Alkylene)-C(O)C 1-3 Alkyl, -(C 1-2 Alkylene)-S(O)2(C 1-3 Alkyl), -(C 1-2 Alkylene)-C(O)NH2, -(C 1-2 Alkylene)-C(O)NH(C 1-3 Alkyl), -(C 1-2 Alkylene)-C(O)N(C 1-3 Alkyl)2, -S(O)2C 1-3 Alkyl, C 1- 6 alkyl, C 3-6 Cycloalkyl, 3-6 membered monocyclic heterocyclic group, 7 membered spirocyclic heterocyclic group (such as 4 membered / 4 membered spirocyclic heterocyclic group), phenyl, 5-6 membered heteroaryl; the heteroatoms of the monocyclic heterocyclic group, spirocyclic heterocyclic group and heteroaryl are independently selected from O or N, and the number of heteroatoms is 1 or 2; the alkyl, alkylene, cycloalkyl, monocyclic heterocyclic group, spirocyclic heterocyclic group, phenyl and heteroaryl are optionally substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, hydroxyl, amino, cyano, methyl, ethyl, methoxy, ethoxy, cyclopropane, cyclobutane, oxirane and oxetane.

[0226] In a further preferred embodiment, wherein R d2 Independently selected from: hydrogen, -SC 1-4 Alkyl, -C(O)NH2, -C(O)NH(C 1-4 alkyl), -C(O)N(C 1-4 Alkyl)2, -C(O)C 1-4 Alkyl, -C(O)C 3-6 Cycloalkyl, -C(O)3-6 membered heterocyclic group, -C(O)-(C 1-4 Alkylene)-NH(C 1-4 alkyl), -C(O)-(C 1-4 Alkylene)-N(C 1-4 Alkyl)2, -(C 1-4 Alkylene)-C(O)OC 1-4 Alkyl, -(C 1-4 Alkylene)-C(O)C 1-4 Alkyl, -(C 1-4 Alkylene)-C(O)NH2, -(C 1-4 Alkylene)-C(O)NH(C 1-4 Alkyl), -(C 1-4 Alkylene)-C(O)N(C1-4 Alkyl)2, -S(O)2C 1-4 Alkyl, C 1- 4 alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, phenyl, 5-6 membered heteroaryl; the C 1-4 Alkyl, C 1-4 Alkylene, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, phenyl, 5-6 membered heteroaryl are optionally substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, hydroxyl, amino, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl. In a further preferred embodiment, wherein R d2 Independently selected from C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, hydroxy, amino, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, and 3-6 membered heterocyclic groups.

[0227] In a further preferred embodiment, wherein R d2 Independently selected from C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted by one or more substituents selected from a 3-6 membered heterocyclic group; preferably, the 3-6 membered heterocyclic group contains 1, 2 or more ring atoms selected from N, O or S; preferably, the 3-6 membered heterocyclic group is selected from oxetanyl, thietanyl, tetrahydrofuranyl.

[0228] In a preferred embodiment of the present invention, wherein R d2 independently selected from: hydrogen, -C(O)NH2, -C(O)NH(C 1-3 alkyl), -C(O)C 1- 3 alkyl, -C(O)C 3-6 Cycloalkyl, -(C 1-3 Alkylene)-S(O)2(C 1-3 Alkyl), C 1-6 Alkyl (more preferably C 1-5 Alkyl, more preferably C 1-3 Alkyl), C 3-6 Cycloalkyl (more preferably C 3-4 cycloalkyl), 3-7 membered heterocyclyl (more preferably 4-5 membered heterocyclyl), 5-6 membered heteroaryl (more preferably 5 membered heteroaryl containing 2 nitrogen atoms); the alkyl, cycloalkyl, heterocyclyl, heteroaryl are optionally substituted by one or more selected from deuterium, halogen (more preferably fluorine, chlorine, bromine, more preferably fluorine), hydroxyl, amino, cyano, C 1-3 Alkyl (more preferably methyl), C 1-3The substituents are substituted by alkoxy (more preferably methoxy) or 3-6 membered heterocyclic group (more preferably 4-5 membered oxygen-containing heterocyclic group); the heteroatoms in the heterocyclic group and heteroaryl group are independently selected from O or N, and the number of heteroatoms is 1 or 2.

[0229] In a preferred embodiment of the present invention, wherein R d2 independently selected from: hydrogen, -C(O)NH2, -C(O)NH(C 1-2 alkyl), -C(O)C 1- 2-alkyl, -C(O)C 3-4 Cycloalkyl, -(C 1-2 Alkylene)-S(O)2(C 1-2 Alkyl), C 1-6 Alkyl (more preferably C 1-5 Alkyl, more preferably C 1-3 Alkyl), -C 1-3 Alkylene-C 1-2 Alkoxy, -C 1-2 Alkylene-(3-6 membered heterocyclic group) (more preferably -C 1-2 Alkylene-(4-5 membered heterocyclic group)), C 3-6 Cycloalkyl (more preferably C 3-4 cycloalkyl), 4-6 membered heterocyclyl (more preferably 4-5 membered heterocyclyl), 5-6 membered heteroaryl (more preferably 5 membered heteroaryl containing 2 nitrogen atoms); the alkyl group is optionally substituted with one or more substituents selected from deuterium, halogen (more preferably fluorine, chlorine, bromine, more preferably fluorine), hydroxyl, and cyano; the cycloalkyl group is optionally substituted with one or more substituents selected from halogen (more preferably fluorine, chlorine, bromine, more preferably fluorine); the heteroaryl group is optionally substituted with one or more substituents selected from C 1-2 The heterocyclic group and the heteroaryl group are substituted by a substituent of an alkyl group (preferably a methyl group); the heteroatoms in the heterocyclic group and the heteroaryl group are independently selected from O or N, and the number of heteroatoms is 1 or 2.

[0230] In a preferred embodiment of the present invention, wherein R d2 Independently selected from: -(C 1-3 Alkylene)-S(O)2(C 1-3 Alkyl), C 1-6 Alkyl (more preferably C 1-5 Alkyl, more preferably C 1-3 Alkyl), C 3-6 Cycloalkyl (more preferably C 3-4 cycloalkyl), 3-6 membered heterocyclic group (more preferably 4-5 membered heterocyclic group); the alkyl, cycloalkyl, heterocyclic group are optionally substituted by one or more selected from deuterium, halogen (more preferably fluorine, chlorine, bromine, more preferably fluorine), hydroxyl, cyano, C 1-3 Alkyl (more preferably methyl), C 1-3The substituent is substituted by an alkoxy group (more preferably a methoxy group) or a 3-6 membered heterocyclic group (more preferably a 4-5 membered heterocyclic group); the heteroatom in the heterocyclic group is O, and the number of heteroatoms is 1.

[0231] In a preferred embodiment of the present invention, wherein R d2 Independently selected from: -(C 1-2 Alkylene)-S(O)2(C 1-2 Alkyl), C 1-6 Alkyl (more preferably C 1-5 Alkyl, more preferably C 1-3 Alkyl), -C 1-3 Alkylene-C 1-2 Alkoxy, -C 1-2 Alkylene-(3-6 membered heterocyclic group) (more preferably -C 1-2 Alkylene-(4-5 membered heterocyclic group)), C 3-6 Cycloalkyl (more preferably C 3-4 cycloalkyl), 4-6 membered heterocyclic group (more preferably 4-5 membered heterocyclic group); the alkyl group is optionally substituted by one or more substituents selected from deuterium, halogen (more preferably fluorine, chlorine, bromine, more preferably fluorine), hydroxyl, and cyano; the heteroatom in the heterocyclic group is O, and the number of heteroatoms is 1.

[0232] In a preferred embodiment of the present invention, wherein R d2 Independently selected from: -C 1-2 Alkylene-(3-6 membered heterocyclic group) (more preferably -C 1-2 Alkylene-(4-5 membered heterocyclic group)), C 3-6 Cycloalkyl (more preferably C 3-4 cycloalkyl), 3-6 membered heterocyclic group (more preferably 4-5 membered heterocyclic group); the heteroatom in the heterocyclic group is O, and the number of heteroatoms is 1.

[0233] In a preferred embodiment of the present invention, wherein R d2 Independently selected from: -(C 1-2 Alkylene)-S(O)2(C 1-2 Alkyl), C 1-3 Alkyl (more preferably C 1-2 Alkyl), -C 1-2 Alkylene-(3-6 membered heterocyclic group) (more preferably -methyl-(4-5 membered heterocyclic group)), C 3-6 Cycloalkyl (more preferably C 3-4 cycloalkyl); the alkyl group is optionally substituted by one or more substituents selected from deuterium, halogen (more preferably fluorine), and cyano; the heteroatom in the heterocyclic group is O, and the number of heteroatoms is 1.

[0234] In a further preferred embodiment, wherein Rd2 Independently selected from: -CH2CH2SO2CH3, C 1-2 Alkyl, -CD3, -methyl-(4-5 membered heterocyclic group), cyclopropyl, cyclobutyl; the alkyl group is optionally substituted by one or more substituents selected from fluorine and cyano; the heteroatom in the heterocyclic group is O, and the number of heteroatoms is 1.

[0235] In a preferred embodiment of the present invention, wherein R d2 Independently selected from: -C 1-3 Alkylene-C 1-2 Alkoxy, -C 1-2 Alkylene-(3-6 membered heterocyclic group) (more preferably -methyl-(4-5 membered heterocyclic group)), C 3-6 Cycloalkyl (more preferably C 3-4 cycloalkyl), 3-6 membered heterocyclic group (more preferably 4-5 membered heterocyclic group); the heteroatom in the heterocyclic group is O, and the number of heteroatoms is 1.

[0236] In a further preferred embodiment, wherein R d2 Independently selected from: -C(O)NH2, -CD3, -CF3, -SCF3, -C(O)CH3, -C(O)CH2OH, -C(O)CH2N(CH3)2, -CH2CN, -CH2CH2CH2CN, -CH2CH2C(CH3)2OH, -CH2CH2CH2OH, -CH(CH3)CH2OCH3, -CH2CH2CH2OCH3, -CH2-C(O)OCH3, -C(O)NHCH3, -CH2-C(O)NH2, -S(O)2CH3, -C(O)N(CH3)2, -CH2CF3, -CH2CH2F, -CH2CHF2, -CH2CH2SO2CH3, methyl, ethyl, n-propyl, isopropyl, n-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl,

[0237] In a further preferred embodiment, wherein R d2 independently selected from the group consisting of hydrogen, -C(O)NH2, -CD3, -CF3, -SCF3, -C(O)CH3, -C(O)CH2OH, -C(O)CH2N(CH3)2, -CH2CN, -CH2-C(O)OCH3, -C(O)NHCH3, -CH2-C(O)NH2, -S(O)2CH3, -C(O)N(CH3)2, -CH2CF3, methyl, ethyl, n-propyl, isopropyl, n-butyl, cyclopropyl, cyclobutyl, cyclopentyl, phenyl,

[0238] In a preferred embodiment of the present invention, wherein R13 、R 14 、R 15 、R 16 are each independently selected from hydrogen.

[0239] In a preferred embodiment of the present invention, Cy2 is independently selected from: phenyl, 6-membered heteroaryl.

[0240] In a further preferred embodiment, wherein Cy2 is independently selected from: phenyl, pyridyl.

[0241] In a further preferred embodiment, wherein Cy2 is independently selected from: phenyl,

[0242] In a further preferred embodiment, wherein Cy2 is independently selected from phenyl.

[0243] In a preferred embodiment of the present invention, wherein R 17 Independently selected from: fluorine, chlorine.

[0244] In a preferred embodiment of the present invention, n and q are independently selected from 0 and 1 respectively.

[0245] In a further preferred embodiment, n and q are independently selected from 0.

[0246] The present invention provides a compound represented by formula (II), or its tautomers, stereoisomers, isotopic derivatives or pharmaceutically acceptable salts:

[0247] Among them, Cy1, Cy2, Y, Q, R 1 、R 13 、R 14 、R 15 、R 16 、R 17 , m and n are defined as those for the compound represented by formula (I) of the present invention.

[0248] The present invention provides a compound represented by formula (II-1), or its tautomers, stereoisomers, isotopic derivatives or pharmaceutically acceptable salts:

[0249] Among them, Cy2, Y, Q, R 1 、R 13 、R 14 、R 15 、R 16 、R 17 , m and n are defined as those for the compounds represented by formula (I) or (II) of the present invention.

[0250] The present invention provides a compound represented by formula (III), or its tautomers, stereoisomers, isotopic derivatives or pharmaceutically acceptable salts:

[0251] Among them, Cy2, Y, Q, R 1 、R 13 、R 14 、R 15 、R 16 、R 17 , m and n are defined as those for the compound represented by formula (I) of the present invention.

[0252] In a further preferred embodiment, wherein Cy2 is independently selected from: phenyl, 6-membered heteroaryl; the heteroatom of the heteroaryl is N;

[0253] R 1 Independently selected from: hydrogen, halogen, oxo, hydroxy, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 1-6 Halogenated alkyl, C 1-6 Alkyl, -S(O)2C 1-6 Alkyl, -C(O)C 1-6 Alkyl, -C(O)C 1-6 Haloalkyl, -C(O)OC 1-6 Alkyl, -C(O)NHC 1-6 Alkyl, -C(O)O-(C 1-6 alkyl)-OC(O)C 1-6 alkyl;

[0254] Q is selected from:

[0255] Y is independently selected from -S(O)(=NR d2 )-;

[0256] R d2 Independently selected from: hydrogen, -SC 1-4 Alkyl, -C(O)NH2, -C(O)NH(C 1-4 alkyl), -C(O)N(C 1-4 Alkyl)2, -C(O)C 1-4 Alkyl, -C(O)C 3-6 Cycloalkyl, -C(O)3-6 membered heterocyclic group, -C(O)-(C 1-4 Alkylene)-NH(C 1-4 alkyl), -C(O)-(C 1-4 Alkylene)-N(C 1-4Alkyl)2, -(C 1-4 Alkylene)-C(O)OC 1-4 Alkyl, -(C 1-4 Alkylene)-C(O)C 1-4 Alkyl, -(C 1-4 Alkylene)-C(O)NH2, -(C 1-4 Alkylene)-C(O)NH(C 1-4 Alkyl), -(C 1-4 Alkylene)-C(O)N(C 1-4 Alkyl)2, -S(O)2C 1-4 Alkyl, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, phenyl, 5-6 membered heteroaryl; the C 1-4 Alkyl, C 1-4 Alkylene, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, phenyl, 5-6 membered heteroaryl are optionally substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, hydroxyl, amino, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl;

[0257] R 13 、R 14 、R 15 、R 16 are independently selected from: hydrogen, deuterium, halogen, oxo; or R 13 and R 14 Together with the carbon atom to which they are attached, they form C 3-6 Cycloalkyl;

[0258] R 17 are independently selected from halogen.

[0259] The present invention provides a compound represented by formula (III-1), or its tautomers, stereoisomers, isotopic derivatives or pharmaceutically acceptable salts:

[0260] Among them, Cy2, Y, Q, R 1 、R 13 、R 14 、R 15 、R 16 、R 17 , m and n are defined as those for the compounds represented by formula (I) or formula (III) of the present invention.

[0261] The present invention provides a compound represented by formula (IV), or its tautomers, stereoisomers, isotopic derivatives or pharmaceutically acceptable salts:

[0262] Among them, X1 , X, Q, R 1 、R d2 and m are defined as those in the compound represented by formula (I) of the present invention; "*" indicates that the S atom has a chiral center, and the configuration is R, S or a mixture of the two.

[0263] The present invention provides a compound represented by formula (IV-a), or its tautomers, stereoisomers, isotopic derivatives or pharmaceutically acceptable salts:

[0264] Among them, Q, R 1 、R d2 and m are defined as those for the compounds of formula (I) or (IV) of the present invention; "*" indicates that the S atom has a chiral center with a configuration of R, S or a mixture of the two.

[0265] In a preferred embodiment of the present invention, Cy1 is selected from

[0266] In a preferred embodiment of the present invention, wherein R 1 Independently selected from: fluorine, chlorine, bromine, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, -C(O)C 1-3 Alkyl, -C(O)C 1-3 Haloalkyl, -C(O)OC 1-3 alkyl.

[0267] In a further preferred embodiment, wherein R 1 Selected from: fluorine, chlorine, bromine, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Fluoroalkyl, -C(O)C 1- 3 alkyl, -C(O)C 1-3 Fluoroalkyl, -C(O)OC 1-3 alkyl.

[0268] In a preferred embodiment of the present invention, wherein R 1 Independently selected from: fluorine, chlorine, bromine, methyl, ethyl, n-propyl, isopropyl, n-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, -CH2F, -CF2H, -CF3, -CH2CF3, -C(O)CH3, -C(O)CH2CH3, -C(O)CF3, -C(O)CF2H, -C(O)OCH3, -C(O)OCH2CH3.

[0269] In a preferred embodiment of the present invention, Q is independently selected from: 3-10 membered heterocyclyl, -NH-C0-4 Alkylene-C 3-10 Carbocyclic group, -NH-C 0-4 Alkylene-3-10 membered heterocyclic group; the alkylene group is optionally substituted by one or more substituents selected from halogen; the C 3-10 Carbocyclic group, 3-10 membered heterocyclic group are optionally substituted by one or more R c2 replace;

[0270] R c2 Independently selected from: halogen, hydroxy, amino, cyano, -OC 1-6 Alkyl, -C(O)OH, -C(O)OC 1-6 Alkyl, C 1-6 Alkyl, C 1- 6 haloalkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 alkyl.

[0271] In a further preferred embodiment, wherein Q is independently selected from: 3-8 membered heterocyclyl, -NH-C 0-2 Alkylene-C 3-6 Carbocyclic group, -NH-C 0- 2-alkylene-3-8 membered heterocyclic group; the alkylene group is optionally substituted by one or more substituents selected from halogen; the C 3-6 Carbocyclic group, 3-8 membered heterocyclic group are optionally substituted by one or more R c2 replace;

[0272] R c2 Independently selected from: halogen, hydroxy, amino, cyano, -OC 1-6 Alkyl, -C(O)OH, -C(O)OC 1-6 Alkyl, C 1-6 Alkyl, C 1-6 Haloalkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 alkyl.

[0273] In a further preferred embodiment, wherein Q is independently selected from: 3-6 membered heterocycloalkyl, 7-8 membered heterospirocyclyl, 7-8 membered bridged heterocyclyl, 6-10 membered heterocyclyl, -NH-C 0-2 Alkylene-C 3-6 Cycloalkyl, -NH-C 0-2 Alkylene-C 5-6 Bridged ring group, -NH-C 0-2 Alkylene-3-6 membered heterocyclic group, -NH-C 0-2 Alkylene-7-8 membered heterospirocyclic group; the cycloalkyl, heterocycloalkyl, heterospirocyclic group, bridged heterocyclic group, heterocyclic group, bridged heterocyclic group are optionally substituted by one or more R c2replace;

[0274] R c2 Independently selected from: halogen, hydroxy, amino, cyano, -OC 1-3 Alkyl, -C(O)OH, -C(O)OC 1-3 Alkyl, C 1-3 Alkyl, C 1- 3 haloalkyl, hydroxy substituted C 1-3 Alkyl, amino substituted C 1-3 alkyl.

[0275] In a further preferred embodiment, wherein Q is independently selected from: 3-6 membered heterocycloalkyl, 7-8 membered heterospirocyclyl, 7-8 membered bridged heterocyclyl, 6-10 membered heterocyclyl, -NH-C 0-2 Alkylene-C 3-6 Cycloalkyl, -NH-C 0-2 Alkylene-C 5-6 Bridged ring group, -NH-C 0-2 Alkylene-3-6 membered heterocyclic group, -NH-C 0-2 Alkylene-7-8 membered heterospirocyclic group; the cycloalkyl, heterocycloalkyl, heterospirocyclic group, bridged heterocyclic group, heterocyclic group, bridged heterocyclic group are optionally substituted by one or more R c2 Substitution; the heteroatoms in the 3-6 membered heterocycloalkyl, 7-8 membered heterospirocyclic group, 7-8 membered bridged heterocyclic group, and 6-10 membered heterocyclic group are N, O, and the number of heteroatoms is 1 or 2, and Connected to the N atom in Q;

[0276] R c2 Independently selected from: halogen, hydroxy, amino, cyano, -OC 1-3 Alkyl, -C(O)OH, -C(O)OC 1-3 Alkyl, C 1-3 Alkyl, C 1- 3 haloalkyl, hydroxy substituted C 1-3 Alkyl, amino substituted C 1-3 alkyl.

[0277] In a further preferred embodiment, wherein Q is independently selected from:

[0278] In a preferred embodiment of the present invention, wherein R d2 Independently selected from: -SC 1-6 Alkyl, -C(O)NH2, -C(O)NH(C 1-6 alkyl), -C(O)N(C 1-6 Alkyl)2, -C(O)C 1-6 Alkyl, -C(O)C 3-6Cycloalkyl, -C(O)3-6 membered heterocyclic group, -C(O)-(C 1-6 Alkylene)-NH(C 1-6 alkyl), -C(O)-(C 1-6 Alkylene)-N(C 1-6 Alkyl)2, -(C 1-6 Alkylene)-C(O)OC 1-6 Alkyl, -(C 1-6 Alkylene)-C(O)C 1-6 Alkyl, -(C 1-6 Alkylene)-S(O)2(C 1-6 Alkyl), -(C 1-6 Alkylene)-C(O)NH2, -(C 1-6 Alkylene)-C(O)NH(C 1-6 Alkyl), -(C 1-6 Alkylene)-C(O)N(C 1- 6alkyl)2, -S(O)2C 1-6 Alkyl, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group, phenyl, 5-6 membered heteroaryl; the C 1-6 Alkyl, C 1- 6 alkylene, C 3-6 Cycloalkyl, 3-8 membered heterocyclyl, phenyl, 5-6 membered heteroaryl, optionally substituted with one or more selected from deuterium, halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 The alkyl group is substituted by a cycloalkyl group or a 3- to 6-membered heterocyclic group.

[0279] In a further preferred embodiment, wherein R d2 Independently selected from: -SC 1-3 Alkyl, -C(O)NH2, -C(O)NH(C 1-3 alkyl), -C(O)N(C 1-3 Alkyl)2, -C(O)C 1-3 Alkyl, -C(O)C 3-6 Cycloalkyl, -C(O)3-6 membered heterocyclic group, -C(O)-(C 1-2 Alkylene)-NH(C 1-6 alkyl), -C(O)-(C 1-2 Alkylene)-N(C 1-3 Alkyl)2, -(C 1-2 Alkylene)-C(O)OC 1-3 Alkyl, -(C 1-2 Alkylene)-C(O)C 1-3 Alkyl, -(C 1-2Alkylene)-S(O)2(C 1-3 Alkyl), -(C 1-2 Alkylene)-C(O)NH2, -(C 1-2 Alkylene)-C(O)NH(C 1-3 Alkyl), -(C 1-2 Alkylene)-C(O)N(C 1- 3alkyl)2, -S(O)2C 1-3 Alkyl, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered monocyclic heterocyclic group, 7 membered spirocyclic heterocyclic group, 8 membered spirocyclic heterocyclic group, phenyl, 5-6 membered heteroaryl; the alkyl, alkylene, cycloalkyl, monocyclic heterocyclic group, spirocyclic heterocyclic group, phenyl, 5-6 membered heteroaryl are optionally substituted by one or more selected from deuterium, halogen, hydroxyl, amino, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 The alkyl group is substituted by a cycloalkyl group or a 3- to 6-membered heterocyclic group.

[0280] In a further preferred embodiment, wherein R d2 Independently selected from: -SC 1-3 Alkyl, -C(O)NH2, -C(O)NH(C 1-3 alkyl), -C(O)N(C 1-3 Alkyl)2, -C(O)C 1-3 Alkyl, -C(O)C 3-6 Cycloalkyl, -C(O)3-6 membered heterocyclic group, -C(O)-(C 1-2 Alkylene)-NH(C 1-3 alkyl), -C(O)-(C 1-2 Alkylene)-N(C 1-3 Alkyl)2, -(C 1-2 Alkylene)-C(O)OC 1-3 Alkyl, -(C 1-2 Alkylene)-C(O)C 1-3 Alkyl, -(C 1-2 Alkylene)-S(O)2(C 1-3 Alkyl), -(C 1-2 Alkylene)-C(O)NH2, -(C 1-2 Alkylene)-C(O)NH(C 1-3 Alkyl), -(C 1-2 Alkylene)-C(O)N(C 1- 3alkyl)2, -S(O)2C 1-3 Alkyl, C 1-6 Alkyl, C 3-6Cycloalkyl, 3-6 membered monocyclic heterocyclic group, 7 membered spirocyclic heterocyclic group, phenyl, 5-6 membered heteroaryl; the heteroatoms of the monocyclic heterocyclic group, spirocyclic heterocyclic group and heteroaryl are independently selected from O or N, and the number of heteroatoms is 1 or 2; the alkyl, alkylene, cycloalkyl, monocyclic heterocyclic group, spirocyclic heterocyclic group, phenyl and heteroaryl are optionally substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, hydroxyl, amino, cyano, methyl, ethyl, methoxy, ethoxy, cyclopropane, cyclobutane, oxirane and oxetane.

[0281] In a further preferred embodiment, wherein R d2 Independently selected from: -C(O)NH2, -CD3, -CF3, -SCF3, -C(O)CH3, -C(O)CH2OH, -C(O)CH2N(CH3)2, -CH2CN, -CH2CH2CH2CN, -CH2CH2C(CH3)2OH, -CH2CH2CH2OH, -CH(CH3)CH2OCH3, -CH2CH2CH2OCH3, -CH2-C(O)OCH3, -C(O)NHCH3, -CH2-C(O)NH2, -S(O)2CH3, -C(O)N(CH3)2, -CH2CF3, -CH2CH2F, -CH2CHF2, -CH2CH2SO2CH3, methyl, ethyl, n-propyl, isopropyl, n-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl,

[0282] In a preferred embodiment of the present invention, wherein R 1 Independently selected from: halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, -C(O)C 1-6 Alkyl, -C(O)C 1-6 Haloalkyl, -C(O)OC 1-6 alkyl;

[0283] m is selected from: 1, 2;

[0284] Q is independently selected from: C 3-8 Carbocyclic group, 3-10 membered heterocyclic group, -NH-C 0-4 Alkylene-C 3-8 Carbocyclic group, -NH-C 0-4 Alkylene-3-10 membered heterocyclic group; the alkylene group is optionally substituted by one or more substituents selected from halogen; the C 3-8 Carbocyclic group, 3-10 membered heterocyclic group are optionally substituted by one or more R c2 replace;

[0285] R c2Independently selected from: halogen, hydroxy, amino, cyano, -OC 1-6 Alkyl, -C(O)OH, -C(O)OC 1-6 Alkyl, C 1-6 Alkyl, C 1- 6 haloalkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 alkyl;

[0286] R d2 Independently selected from: -SC 1-6 Alkyl, -C(O)NH2, -C(O)NH(C 1-6 alkyl), -C(O)N(C 1-6 Alkyl)2, -C(O)C 1-6 Alkyl, -C(O)C 3-6 Cycloalkyl, -C(O)3-6 membered heterocyclic group, -C(O)-(C 1-4 Alkylene)-NH(C 1-6 alkyl), -C(O)-(C 1-4 Alkylene)-N(C 1-6 Alkyl)2, -(C 1-4 Alkylene)-C(O)OC 1-6 Alkyl, -(C 1-4 Alkylene)-C(O)C 1-6 Alkyl, -(C 1-4 Alkylene)-S(O)2(C 1-6 Alkyl), -(C 1-4 Alkylene)-C(O)NH2, -(C 1-4 Alkylene)-C(O)NH(C 1-6 Alkyl), -(C 1-4 Alkylene)-C(O)N(C 1-6 Alkyl)2, -S(O)2C 1-6 Alkyl, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group, phenyl, 5-6 membered heteroaryl; the C 1-6 Alkyl, C 1-4 Alkylene, C 3-6 Cycloalkyl, 3-8 membered heterocyclyl, phenyl, 5-6 membered heteroaryl, optionally substituted with one or more selected from deuterium, halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 The alkyl group is substituted by a cycloalkyl group or a 3- to 6-membered heterocyclic group.

[0287] In a preferred embodiment of the present invention, wherein R 1 Independently selected from: fluorine, chlorine, bromine, C1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkyl, -C(O)C 1-3 Alkyl, -C(O)C 1-3 Haloalkyl, -C(O)OC 1-3 alkyl;

[0288] m is selected from: 1, 2;

[0289] Q is independently selected from: C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, 7-8 membered heterospirocyclic group, 7-8 membered bridged heterocyclic group, 6-10 membered heterocyclic group, -NH-C 0-2 Alkylene-C 3-6 Cycloalkyl, -NH-C 0-2 Alkylene-C 5-6 Bridged ring group, -NH-C 0-2 Alkylene-3-6 membered heterocyclic group, -NH-C 0-2 Alkylene-7-8 membered heterospirocyclic group; the cycloalkyl, heterocycloalkyl, heterospirocyclic group, bridged heterocyclic group, heterocyclic group, bridged heterocyclic group are optionally substituted by one or more R c2 replace;

[0290] R c2 Independently selected from: halogen, hydroxy, amino, cyano, -OC 1-3 Alkyl, -C(O)OH, -C(O)OC 1-3 Alkyl, C 1-3 Alkyl, C 1- 3 haloalkyl, hydroxy substituted C 1-3 Alkyl, amino substituted C 1-3 alkyl;

[0291] R d2 Independently selected from: -SC 1-3 Alkyl, -C(O)NH2, -C(O)NH(C 1-3 alkyl), -C(O)N(C 1-3 Alkyl)2, -C(O)C 1-3 Alkyl, -C(O)C 3-6 Cycloalkyl, -C(O)3-6 membered heterocyclic group, -C(O)-(C 1-2 Alkylene)-NH(C 1-3 alkyl), -C(O)-(C 1-2 Alkylene)-N(C 1-3 Alkyl)2, -(C 1-2 Alkylene)-C(O)OC 1-3 Alkyl, -(C 1-2 Alkylene)-C(O)C 1-3 Alkyl, -(C1-2 Alkylene)-S(O)2(C 1-3 Alkyl), -(C 1-2 Alkylene)-C(O)NH2, -(C 1-2 Alkylene)-C(O)NH(C 1-3 Alkyl), -(C 1-2 Alkylene)-C(O)N(C 1-3 Alkyl)2, -S(O)2C 1-3 Alkyl, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered monocyclic heterocyclic group, 7 membered spirocyclic heterocyclic group, phenyl, 5-6 membered heteroaryl; the alkyl, alkylene, cycloalkyl, monocyclic heterocyclic group, spirocyclic heterocyclic group, phenyl, 5-6 membered heteroaryl are optionally substituted by one or more selected from deuterium, halogen, hydroxyl, amino, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, C 3-6 The alkyl group is substituted by a cycloalkyl group or a 3- to 6-membered heterocyclic group.

[0292] The present invention provides a compound represented by formula (IV-1) or formula (IV-2), or a tautomer, stereoisomer, isotopic derivative, or a pharmaceutically acceptable salt thereof:

[0293] Among them, Q, R 1 、R d2 and m are defined as those for the compounds represented by formula (I), formula (IV) or formula (IV-a) of the present invention; "*" indicates that the S atom has a chiral center with a configuration of R, S or a mixture of the two.

[0294] The present invention provides a compound represented by formula (IV-3), or its tautomers, stereoisomers, isotopic derivatives or pharmaceutically acceptable salts:

[0295] Among them, Q, R 1 and R d2 The definition is the same as that of the compounds represented by formula (I), formula (IV), formula (IV-a) or formula (IV-2) of the present invention; "*" indicates that there is a chiral center at the S atom, and the configuration is R, S or a mixture of the two.

[0296] The present invention provides a compound represented by formula (IV-4) or formula (IV-5), or a tautomer, stereoisomer, isotopic derivative, or a pharmaceutically acceptable salt thereof:

[0297] Among them, R 1 and R d2The definition is the same as that of the compounds represented by formula (I), formula (IV), formula (IV-a), formula (IV-2) or formula (IV-3) of the present invention; "*" indicates that there is a chiral center at the S atom, and the configuration is R, S or a mixture of the two.

[0298] The present invention provides a compound represented by formula (IV-6) or formula (IV-7), or a tautomer, stereoisomer, isotopic derivative, or a pharmaceutically acceptable salt thereof:

[0299] Among them, R d2 The definition is the same as that of the compounds represented by formula (I), formula (IV), formula (IV-a), formula (IV-2) or formula (IV-3) of the present invention; "*" indicates that there is a chiral center at the S atom, and the configuration is R, S or a mixture of the two.

[0300] The above preferred solutions can be combined arbitrarily.

[0301] Preferably, the compound provided by the present invention or its tautomer, stereoisomer, isotopic derivative or pharmaceutically acceptable salt, wherein the compound has the following structure:

[0302] The present invention also provides an intermediate for preparing a compound of formula (I), which has a structure as shown in formula (Ra):

[0303] Among them, R e is selected from a protecting group, hydrogen; R d2 As defined in the compounds of formula (I), formula (II), formula (II-1), formula (III), formula (III-1), formula (IV), formula (IV-a), formula (IV-1), formula (IV-2), formula (IV-3), formula (IV-4), formula (IV-5), formula (IV-6), and formula (IV-7); provided that R e and R d2 Not hydrogen at the same time.

[0304] In one embodiment of the present invention, the protecting group is selected from tert-butyloxycarbonyl (Boc), 9-fluorenylmethoxycarbonyl (FMOC), benzyloxycarbonyl (Cbz), p-methoxybenzyl (PMB), acetyl (Ac); preferably tert-butyloxycarbonyl (Boc).

[0305] In one embodiment of the present invention, the present invention also provides an intermediate for preparing a compound of formula (I), which has a structure as shown in formula (R-a5) or (R-a6):

[0306] Among them, R d2 As defined by compounds of formula (I), formula (II), formula (II-1), formula (III), formula (III-1), formula (IV), formula (IV-a), formula (IV-1), formula (IV-2), formula (IV-3), formula (IV-4), formula (IV-5), formula (IV-6), formula (IV-7), and formula (Ra).

[0307] The present invention also provides the following synthetic intermediates for preparing the target compound:

[0308] The present invention also aims to provide a method for preparing the compound represented by the general formula or its tautomers, stereoisomers, isotopic derivatives or pharmaceutically acceptable salts.

[0309] The method can be prepared, for example, using the method shown in the following scheme:

[0310] i) Compound R-a1 undergoes chemical conversion to obtain compound R-a2;

[0311] For example, compound R-a1 and amino derivatives are used as basic raw materials to obtain compound R-a2 through reaction;

[0312] ii) Compound R-a2 undergoes chemical conversion to obtain compound Ra;

[0313] For example, compound R-a2 and an amino derivative are used as basic raw materials to obtain compound (I) through reaction;

[0314] In the above general formula, Cy1, X, X 1 ,Q,R 1 , Het and m are defined as those for the compound represented by formula (I) of the present invention.

[0315] In one embodiment of the present invention, the method can be prepared, for example, using the method shown in the following scheme:

[0316] i) Compound R-a1 undergoes chemical conversion to obtain compound R-a2;

[0317] For example, compound R-a1 and amino derivatives are used as basic raw materials to obtain compound R-a2 through reaction;

[0318] ii) Compound R-a2 undergoes chemical conversion to obtain compound Ra;

[0319] For example, compound R-a2 and an amino derivative are used as basic raw materials to obtain compound (I) through reaction;

[0320] In the above general formula, Cy1, X, Q, R 1 , Het and m are defined as those for the compound represented by formula (I) of the present invention.

[0321] In one embodiment of the present invention, compound R-a2 and an amino derivative are used as basic raw materials to obtain a compound of formula (IV) by reaction as shown below:

[0322] i) Compound R-a3 undergoes oxidation reaction to obtain compound R-a4

[0323] For example, compound R-a3 can be reacted with iodobenzene acetate, ammonium carbonate and other basic raw materials to obtain R-a4 through chemical reaction;

[0324] ii) Compound R-a4 undergoes a substitution reaction to obtain compound R-a5

[0325] For example, compound R-a4 and methanesulfonate substituents are used as basic raw materials to obtain R-a5 through chemical reaction;

[0326] iii) Deprotection reaction of the nitrogen atom in compound R-a5 to obtain compound R-a6

[0327] For example, compound R-a5 and basic raw materials such as trifluoroacetic acid can be used to obtain R-a6 through chemical reaction;

[0328] iv) Compound R-a1 undergoes chemical conversion to obtain compound R-a2;

[0329] For example, compound R-a1 and amino derivatives are used as basic raw materials to obtain compound R-a2 through reaction;

[0330] v) chemical conversion of compounds R-a2 and R-a6 to obtain formula (IV);

[0331] For example, using compounds R-a2 and R-a6 as basic raw materials, a substitution reaction is performed to obtain compound (IV);

[0332] In the above general formula, Cy1, X, X 1 ,Q,R 1 、R d2 and m are defined as those for the compound represented by formula (I) of the present invention.

[0333] In one embodiment of the present invention, compound R-a2 and an amino derivative are used as basic raw materials to obtain a compound of formula (IV-a) by reaction as shown below:

[0334] i) Compound R-a3 undergoes oxidation reaction to obtain compound R-a4

[0335] For example, compound R-a3 can be reacted with iodobenzene acetate, ammonium carbonate and other basic raw materials to obtain R-a4 through chemical reaction;

[0336] ii) Compound R-a4 undergoes a substitution reaction to obtain compound R-a5

[0337] For example, compound R-a4 and methanesulfonate substituents are used as basic raw materials to obtain R-a5 through chemical reaction;

[0338] iii) Deprotection reaction of the nitrogen atom in compound R-a5 to obtain compound R-a6

[0339] For example, compound R-a5 and basic raw materials such as trifluoroacetic acid can be used to obtain R-a6 through chemical reaction;

[0340] iv) Compound R-a1 undergoes chemical conversion to obtain compound R-a2;

[0341] For example, compound R-a1 and amino derivatives are used as basic raw materials to obtain compound R-a2 through reaction;

[0342] v) chemical conversion of compounds R-a2 and R-a6 to obtain formula (IV-a);

[0343] For example, using compounds R-a2 and R-a6 as basic raw materials, a compound of formula (IV-a) is obtained through substitution reaction;

[0344] In the above general formula, Cy1, X, Q, R 1 、R d2 and m are defined as those for the compound represented by formula (I) of the present invention.

[0345] The present invention also provides a pharmaceutical composition comprising the compound of the present invention or its tautomer, stereoisomer, isotopic derivative or pharmaceutically acceptable salt.

[0346] The present invention also provides a pharmaceutical composition comprising the compound of the present invention or its tautomer, stereoisomer, isotopic derivative or pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier.

[0347] The administration of the compounds of the present invention or their tautomers, stereoisomers, isotopic derivatives or pharmaceutically acceptable salts thereof can be carried out in pure form or in the form of suitable pharmaceutical compositions by any acceptable mode of administration for drugs of similar use. The pharmaceutical compositions of the present invention can be prepared by combining the compounds of the present invention with suitable pharmaceutically acceptable excipients. The pharmaceutical compositions of the present invention can be formulated into solid, semi-solid, liquid or gaseous formulations. Generally, the above-mentioned pharmaceutical compositions can be prepared using conventional excipients in the field of pharmaceutical preparations by conventional preparation methods.

[0348] The purpose of the present invention also includes providing the use of the compound shown in the present invention or its tautomer, stereoisomer, isotope derivative or pharmaceutically acceptable salt or pharmaceutical composition in the preparation of a drug for preventing and / or treating diseases caused by RSV virus infection.

[0349] In another aspect, the present application provides a method for preventing and / or treating diseases caused by RSV virus infection, or for inhibiting RSV virus in patients or biological samples, which comprises administering the compound of the present invention or its tautomer, stereoisomer, isotope derivative or pharmaceutically acceptable salt or pharmaceutical composition of the present invention to an individual in need, or contacting the biological sample with the compound of the present invention or its pharmaceutical composition.

[0350] In another aspect, the present application provides a compound of the present invention or its tautomer, stereoisomer, isotope derivative or pharmaceutically acceptable salt or pharmaceutical composition of the present invention for preventing and / or treating diseases caused by RSV virus infection, or for inhibiting RSV virus in patients or biological samples.

[0351] Furthermore, the present invention provides uses or methods, wherein the compounds of the present invention or their tautomers, stereoisomers, isotopic derivatives or pharmaceutically acceptable salts or pharmaceutical compositions are used in combination with other drugs.

[0352] The present invention also provides a pharmaceutical composition comprising the compound of the present invention or its tautomer, stereoisomer, isotopic derivative, or pharmaceutically acceptable salt, or the pharmaceutical composition of the present invention, and other compounds selected from pharmaceutically active ingredients other than the compound of the present invention.

[0353] definition

[0354] “*” indicates that the atom has a chiral center, and the configuration is R, S or a mixture of the two.

[0355] The “plurality” in “optionally substituted with one or more substituents each independently selected from…” refers to 2, 3, 4, 5, 6, 7, 8, 9 or 10; preferably 2, 3 or 4; more preferably 2.

[0356] The terms "optional," "optionally," "optionally," or "optionally" mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.

[0357] The term "oxo" refers to a group in which two hydrogen atoms at the same substitution position are replaced by the same oxygen atom to form a double bond.

[0358] The term "thio" refers to a group in which two hydrogen atoms at the same substitution position are replaced by a sulfur atom to form a double bond.

[0359] Unless otherwise specified, the term "alkyl" refers to a monovalent saturated aliphatic hydrocarbon group, a straight or branched chain group containing 1 to 20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20) carbon atoms, preferably a group containing 1 to 18 carbon atoms (i.e., C 1-18 Alkyl) or 1-10 carbon atoms (ie C 1-10 Alkyl), further preferably containing 1 to 8 carbon atoms (C 1-8 Alkyl), more preferably containing 1-6 carbon atoms (ie C 1-6 alkyl), more preferably containing 1 to 4 carbon atoms (i.e., C 1-4 Alkyl), such as "C 1-6 "Alkyl" means that the group is an alkyl group and the number of carbon atoms in the carbon chain is between 1 and 6 (specifically 1, 2, 3, 4, 5 or 6). Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, neopentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, n-heptyl, n-octyl, and the like.

[0360] Unless otherwise specified, the term "alkenyl" refers to a straight or branched unsaturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms and having at least one double bond. The alkenyl group may contain 2 to 20 carbon atoms, preferably 2 to 10 carbon atoms (i.e., C 2-10 alkenyl), further preferably containing 2 to 8 carbon atoms (C 2-8 alkenyl), more preferably containing 2 to 6 carbon atoms (ie, C 2-6 alkenyl), 2-5 carbon atoms (ie C 2-5 alkenyl), 2-4 carbon atoms (ie C2-4 alkenyl), 2-3 carbon atoms (ie C 2-3 alkenyl), 2 carbon atoms (i.e., C2 alkenyl), for example, "C 2-6 The term "alkenyl" refers to an alkenyl group, and the number of carbon atoms in the carbon chain is between 2 and 6 (specifically 2, 3, 4, 5 or 6). Non-limiting examples of alkenyl groups include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, isobutenyl and 1,3-butadienyl.

[0361] Unless otherwise specified, the term "alkynyl" refers to a straight or branched unsaturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms and having at least one triple bond. The alkynyl group may contain 2 to 20 carbon atoms, preferably 2 to 10 carbon atoms (i.e., C 2-10 Alkynyl), further preferably containing 2 to 8 carbon atoms (C 2-8 Alkynyl), more preferably containing 2-6 carbon atoms (ie, C 2-6 Alkynyl), 2-5 carbon atoms (ie C 2-5 Alkynyl), 2-4 carbon atoms (ie C 2-4 Alkynyl), 2-3 carbon atoms (ie C 2-3 alkynyl), 2 carbon atoms (i.e., C2 alkynyl), for example, "C 2-6 "Alkynyl" means that the group is an alkynyl group, and the number of carbon atoms in the carbon chain is between 2 and 6 (specifically 2, 3, 4, 5 or 6). Non-limiting examples of alkynyl groups include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl and 1-butynyl.

[0362] Unless otherwise specified, the term "alkoxy" refers to an -O-alkyl group, wherein the alkyl group is as defined above, i.e., containing 1 to 20 carbon atoms, preferably 1 to 10 carbon atoms, more preferably 1 to 8 carbon atoms, and more preferably 1 to 6 carbon atoms (specifically 1, 2, 3, 4, 5 or 6). Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy, tert-butoxy, pentyloxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, 2,2-dimethylpropoxy, 1-ethylpropoxy, and the like.

[0363] Unless otherwise specified, the term "halogen" or "halo" refers to F, Cl, Br, I. The term "haloalkyl" refers to an alkyl group as defined above in which one, two or more hydrogen atoms or all of the hydrogen atoms are replaced by halogen. Representative examples of haloalkyl include CCl3, CF3, CHCl2, CH2Cl, CH2Br, CH2I, CH2CF3, CF2CF3, and the like.

[0364] Unless otherwise specified, the term "carbocyclyl" or "carbocycle" refers to a non-aromatic cyclic hydrocarbon group ("C 3-20 In some embodiments, the carbocyclyl group has 3-12 ring carbon atoms ("C 3-12 carbocyclyl”), or 4-12 ring carbon atoms (“C 4-12 carbocyclyl”), or 3 to 10 ring carbon atoms (“C 3-10 In some embodiments, a carbocyclyl group has 3 to 8 ring carbon atoms ("C 3-8 In some embodiments, a carbocyclyl group has 3 to 7 ring carbon atoms ("C 3-7 In some embodiments, a carbocyclyl group has 4 to 6 ring carbon atoms ("C 4-6 In some embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms ("C 5-10 carbocyclyl”), or 5 to 7 ring carbon atoms (“C 5-7 Carbocyclyl”). Exemplary C 3-6 Carbocyclyl groups include, but are not limited to, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), and the like. 3-8 Carbocyclyl groups include, but are not limited to, the aforementioned C 3-6 Carbocyclyl groups and cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), bicyclo [2.2.1] heptyl (C7), bicyclo [2.2.2] octyl (C8), etc. Exemplary C 3-10 Carbocyclyl groups include, but are not limited to, the aforementioned C 3-8 Carbocyclyl groups and cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C 10 ), cyclodecenyl (C 10 ), octahydro-1H-indenyl (C9), decahydronaphthyl (C 10 ), spiro[4.5]decyl (C 10) and the like. As illustrated in the above examples, in certain embodiments, the carbocyclyl group is a monocyclic ("monocyclic carbocyclyl") or a fused (and carbocyclyl), bridged (bridged cyclyl) or spiro-connected (spirocyclyl) ring system, such as a bicyclic system ("bicyclic carbocyclyl") and can be saturated or can be partially unsaturated. "Carbocyclyl" also includes ring systems in which the carbocyclyl ring as defined above is fused by one or more aryl or heteroaryl groups, wherein the point of attachment is on the carbocyclyl ring, and in such cases, the number of atoms of the carbocyclyl ring system is the number of carbons in the carbocyclyl system after fusion. In certain embodiments, each example of a carbocyclyl group is independently optionally substituted, for example, unsubstituted (a "unsubstituted carbocyclyl") or substituted by one or more substituents (a "substituted carbocyclyl"). In certain embodiments, the carbocyclyl group is an unsubstituted C 3-10 In certain embodiments, the carbocyclyl group is a substituted C 3-10 Carbocyclic group.

[0365] Unless otherwise specified, the term "cycloalkyl" refers to a monocyclic saturated aliphatic hydrocarbon group having a specified number of carbon atoms, preferably containing 3-12 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12) carbon atoms (i.e., C 3-12 cycloalkyl), more preferably containing 3 to 10 carbon atoms (C 3-10 cycloalkyl), further preferably 3-7 carbon atoms (C 3-7 Cycloalkyl), 4-6 carbon atoms (C 4-6 Cycloalkyl), 5-6 carbon atoms (C 5-6 Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methylcyclopropyl, 2-ethyl-cyclopentyl, dimethylcyclobutyl, and the like.

[0366] Unless otherwise specified, the term "heterocyclyl" or "heterocycle" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic non-aromatic substituent having ring carbon atoms and 1 to 4 ring heteroatoms, containing 3-20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20) ring atoms, of which 1, 2, 3 or more ring atoms are selected from N, O or S, and the remaining ring atoms are C. Preferably, the ring contains 3 to 18 ring atoms (3-18-membered heterocyclyl), more preferably 3 to 15 ring atoms (3-15-membered heterocyclyl), or 3 to 12 ring atoms (3-12-membered heterocyclyl), or 4 to 12 ring atoms (4-12-membered heterocyclyl), or 3 to 10 ring atoms (3-10-membered heterocyclyl), or 3 to 8 ring atoms (3-8-membered heterocyclyl), or 3 to 7 ring atoms (3-7-membered heterocyclyl), or 4 to 7 ring atoms (4-7-membered heterocyclyl), or 3 to 6 ring atoms (3-6-membered heterocyclyl), or 4 to 6 ring atoms (4-6-membered heterocyclyl), or 5 to 6 ring atoms (5-6-membered heterocyclyl). The number of heteroatoms is preferably 1 to 4, more preferably 1 to 3 (i.e., 1, 2, or 3). Examples of monocyclic heterocyclic groups include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, dihydropyrrolyl, piperidinyl, piperazinyl, pyranyl, etc. Polycyclic heterocyclic groups include cyclic, spirocyclic and bridged heterocyclic groups. "Heterocyclic group" can be a monocyclic ("monocyclic heterocyclic group") or a fused (cyclic heterocyclic group), bridged ("heterobridged heterocyclic group" or "bridged heterocyclic group") or spiro ("heterospirocyclic group", "spiroheterocyclic group" or "spirocyclic heterocyclic group") ring system, such as a bicyclic system ("bicyclic heterocyclic group"), and can be saturated or partially unsaturated. Heterocyclic bicyclic ring systems can include one or more heteroatoms in one or both rings. "Heterocyclyl" also includes ring systems in which the heterocyclyl ring, as defined above, is fused to one or more carbocyclyl groups, wherein the point of attachment is on the carbocyclyl or heterocyclyl ring, or "heterocyclyl" also includes ring systems in which the heterocyclyl ring, as defined above, is fused to one or more aryl or heteroaryl groups, or a cycloalkyl ring, as defined above, is fused to one or more heteroaryl groups, wherein the point of attachment is on the heterocyclyl or cycloalkyl ring, and in such cases, the number of members of the heterocyclyl ring system is the number of atoms in the ring system after fusion. In certain embodiments, each instance of heterocyclyl is independently optionally substituted, e.g., unsubstituted (an "unsubstituted heterocyclyl") or substituted (a "substituted heterocyclyl") with one or more substituents. Exemplary 3-membered heterocyclyl groups containing 1 heteroatom include, but are not limited to, aziridine, oxiranyl, and thiorenyl. Exemplary 4-membered heterocyclyl groups containing 1 heteroatom include, but are not limited to, azetidinyl, oxetanyl, and thietanyl.Exemplary 5-membered heterocyclyl groups containing one heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrophenylthio, dihydrophenylthio, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclyl groups containing two heteroatoms include, but are not limited to, dioxolanyl, oxathiolanyl, dithiolanyl, and oxazolidin-2-one. Exemplary 5-membered heterocyclyl groups containing three heteroatoms include, but are not limited to, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclyl groups containing one heteroatom include, but are not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithiolanyl, and dioxanyl. Exemplary 6-membered heterocyclyl groups containing 3 heteroatoms include, but are not limited to, triazacyclohexanyl, oxadiazinyl, thiadiazinyl, oxathiazinyl, and dioxazinanyl. Exemplary 7-membered heterocyclyl groups containing 1 heteroatom include, but are not limited to, azepanyl, oxepanyl, and thiepanyl. Exemplary 8-membered heterocyclyl groups containing 1 heteroatom include, but are not limited to, azocanyl, oxepanyl, and thiepanyl. Exemplary 5-membered heterocyclyl groups fused to a C6 aryl ring (also referred to herein as a 5,6-bicyclic heterocycle) include, but are not limited to, dihydroindolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinone, and the like. Exemplary 6-membered heterocyclyl groups fused to an aryl ring (also referred to herein as a 6,6-bicyclic heterocycle) include, but are not limited to, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.

[0367] Unless otherwise specified, the term "spirocyclyl" or "spiro ring" refers to a saturated, monovalent aliphatic hydrocarbon group containing only one spiro carbon atom, which may contain 6-20 ring carbon atoms, preferably 7-10 ring carbon atoms. Spirocyclyl includes 3-membered / 5-membered, 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered and 5-membered / 6-membered spirocyclyl, wherein the spiro atom is counted as one ring member. Illustrative examples of spirocyclyl include (but are not limited to) wait.

[0368] Unless otherwise specified, the term "heterospirocyclyl" or "spiroheterocyclyl" refers to a saturated, monovalent aliphatic group containing only one spiro carbon atom, which may contain 6-20 ring atoms, preferably 7-10 ring atoms, including 1-4 ring heteroatoms, preferably 1-3 (i.e., 1, 2, or 3) ring heteroatoms, and the heteroatoms are independently selected from N, O, and S. Heterospirocyclyl includes 3-membered / 5-membered, 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 5-membered, and 5-membered / 6-membered heterospirocyclyl, etc., wherein the spiro atom is counted in the number of members of each ring. Illustrative examples of heterospirocyclyl include (but are not limited to) wait.

[0369] The carbocyclyl group may contain 5-14 ring atoms, preferably 6-12 ring atoms, more preferably 7-10 ring atoms. The carbocyclyl group includes a bicyclic, tricyclic, tetracyclic or polycyclic carbocyclyl group, preferably a bicyclic, tricyclic or tetracyclic carbocyclyl group, more preferably a bicyclic or tricyclic carbocyclyl group. Illustrative examples of carbocyclyl groups include (but are not limited to) wait.

[0370] The heterocyclic group may contain 5-14 ring atoms, preferably 6-12 ring atoms, more preferably 7-10 ring atoms, including 1-4 ring heteroatoms, preferably 1-3 (i.e., 1, 2, or 3) ring heteroatoms, and the heteroatoms are independently selected from N, O, and S. The heterocyclic group includes a bicyclic, tricyclic, tetracyclic, or polycyclic heterocyclic group, preferably a bicyclic, tricyclic, or tetracyclic heterocyclic group, more preferably a bicyclic or tricyclic heterocyclic group. Illustrative examples of heterocyclic groups include (but are not limited to) wait.

[0371] Unless otherwise specified, the term "bridged ring group" refers to a polycyclic, monovalent aliphatic hydrocarbon group in which any two rings share two ring carbon atoms that are not directly connected, which may contain 5-20 ring carbon atoms, preferably 6-14 ring carbon atoms, more preferably 7-10 ring carbon atoms, and may contain one or more double bonds, but no ring has a completely conjugated π electron system. Bridged ring groups include bicyclic, tricyclic, tetracyclic or polycyclic bridged ring groups, preferably bicyclic, tricyclic or tetracyclic bridged ring groups, more preferably bicyclic or tricyclic bridged ring groups. Illustrative examples of bridged ring groups include (but are not limited to)

[0372] Unless otherwise specified, the term "heterobridged cyclic group" refers to a polycyclic, monovalent aliphatic group in which any two rings share two ring atoms that are not directly connected, which may contain 5-14 ring atoms, preferably 6-14 ring atoms, more preferably 7-10 ring atoms, wherein 1-4 ring heteroatoms, preferably 1-3 (i.e., 1, 2 or 3) ring heteroatoms, and the heteroatoms are independently selected from N, O and S, and may contain one or more double bonds, but no ring has a completely conjugated π electron system. Heterobridged cyclic groups include bicyclic, tricyclic, tetracyclic or polycyclic heterobridged cyclic groups, preferably bicyclic, tricyclic or tetracyclic heterobridged cyclic groups, more preferably bicyclic or tricyclic heterobridged cyclic groups. Illustrative examples of heterobridged cyclic groups include (but are not limited to)

[0373] Unless otherwise specified, the term "aryl" or "aromatic ring group" refers to a monocyclic, bicyclic and tricyclic aromatic carbocyclic ring system containing 6-16 (e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16) carbon atoms, or 6-14 carbon atoms, or 6-12 carbon atoms, or 6-10 carbon atoms, preferably 6-10 carbon atoms, more preferably 6-8 carbon atoms, more preferably phenyl. The term "aryl" can be used interchangeably with the term "aromatic ring". Examples of aryl groups can include, but are not limited to, phenyl, naphthyl, anthracenyl, phenanthrenyl or pyrenyl.

[0374] Unless otherwise specified, the term "heteroaryl" or "heteroaromatic ring group" refers to an aromatic monocyclic or polycyclic ring system containing 5-20 members (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 members), or preferably 5-18 members, or preferably 5-12 members, or preferably 5-10 members, or preferably 5-8 members, more preferably 5-6 members, wherein 1, 2, 3 or more ring atoms are heteroatoms and the remaining atoms are carbon, the heteroatoms are independently selected from O, N or S, and the number of heteroatoms is preferably 1, 2 or 3. Polycyclic heteroaryl is a fused heteroaryl. Examples of heteroaryl groups include, but are not limited to, furyl, thienyl, oxazolyl, thiazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiodiazolyl, triazinyl, phthalazinyl, quinolyl, isoquinolyl, pteridinyl, purinyl, indolyl, isoindolyl, indazolyl, benzofuranyl, benzothiophenyl, benzopyridinyl, benzopyrimidinyl, benzo pyrazinyl, benzimidazolyl, benzophthalazinyl, pyrrolo[2,3-b]pyridinyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-b]pyridazinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[1,5-a]pyridinyl, etc.

[0375] In various parts of this invention, linking substituents are described. When the structure clearly requires a linking group, the Markush variable listed for that group should be understood to be the linking group. For example, if the structure requires a linking group and the Markush group definition for that variable lists "alkyl" or "aryl", it should be understood that the "alkyl" or "aryl" represents a linking alkylene group or arylene group, respectively. The definition of the linking group, such as alkylene, is the same as the definition of the term "alkyl", which is a divalent alkyl group as defined above. Wherein, C 0-6 The definition of alkylene includes C0 (i.e. the connecting group is only a bond) and C 1-6 Alkylene. 1-6 The definition of alkylene is the same as that of C 1-6 alkyl.

[0376] Unless otherwise specified, the term "pharmaceutically acceptable salt" or "pharmaceutically acceptable salt" refers to a salt that is suitable for use in contact with mammalian tissues, particularly human tissues, without excessive toxicity, irritation, allergic response, etc., and is commensurate with a reasonable benefit / risk ratio, within the scope of sound medical judgment. For example, pharmaceutically acceptable salts of amines, carboxylic acids, and other types of compounds are well known in the art. The salts can be prepared in situ during the final isolation and purification of the compounds of the present invention, or separately by reacting the free base or free acid with a suitable reagent.

[0377] Unless otherwise specified, the term "isotopic derivative" means that the compounds of the present invention may exist in isotopically labeled or enriched form, containing one or more atoms whose atomic mass or mass number is different from the atomic mass or mass number of the largest atom found in nature. Isotopes may be radioactive or non-radioactive. Isotopes commonly used as isotopic labels are: hydrogen isotopes, 2 H and 3 H; Carbon isotope: 13 C and 14 C; Chlorine isotope: 35 Cl and 37 Cl; Fluorine isotope: 18 F; Iodine isotope: 123 I and 125 I; Nitrogen isotopes: 13 N and 15 N; oxygen isotopes: 15 O. 17 O and 18 O and sulfur isotopes 35 These isotope-labeled compounds can be used to study the distribution of pharmaceutical molecules in tissues. 3 H and 13 C, because they are easy to label and detect, they are more widely used. Some heavy isotopes, such as deuterium ( 2 H) substitution can enhance metabolic stability and prolong half-life, thereby achieving the goal of reducing dosage and providing therapeutic advantages. Isotope-labeled compounds are generally synthesized from labeled starting materials using known synthetic techniques similar to those used for synthesizing non-isotope-labeled compounds.

[0378] Unless otherwise specified, the compounds of the present invention also include their "solvates" or "solvates". The terms "solvate" and "solvate" mean the physical association of a compound of the present invention with one or more solvent molecules (whether organic or inorganic). This physical association includes hydrogen bonding. In certain cases, for example, when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid, the solvate will be able to be separated. The solvent molecules in the solvate may be present in a regular and / or disordered arrangement. The solvate may contain stoichiometric or non-stoichiometric amounts of solvent molecules. "Solvate" encompasses solution phase and separable solvates. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Solvation methods are well known in the art. The term "hydrate" refers to a substance formed by water molecules being bound to cations or anions in a compound by coordinate bonds or covalent bonds, or by water ions that are not directly bound to cations or anions but are present in a certain proportion at defined positions in the solid crystal lattice.

[0379] Unless otherwise specified, the term "stereoisomer" refers to compounds that have the same chemical constitution but differ in the arrangement of the atoms or groups in space. Stereoisomers include enantiomers, diastereomers, conformers (rotamers), geometric isomers (cis / trans) isomers, atropisomers, and the like. Any resulting mixture of stereoisomers can be separated into pure or substantially pure geometric isomers, enantiomers, and diastereomers based on differences in the physicochemical properties of the components, for example, by chromatography and / or fractional crystallization. Unless otherwise specified, the term "geometric isomer (cis / trans) isomer" may contain carbon-carbon double bonds or carbon-nitrogen double bonds in the E or Z configuration, where the term "E" represents higher-order substituents on opposite sides of the carbon-carbon or carbon-nitrogen double bond, and the term "Z" represents higher-order substituents on the same side of the carbon-carbon or carbon-nitrogen double bond (determined using the Cahn-Ingold Prelog priority rules). The compounds of the present invention may also exist as a mixture of "E" and "Z" isomers.

[0380] Unless otherwise specified, the term "tautomer" refers to structural isomers of different energies that are interconvertible through a low energy barrier. If tautomerism is possible (e.g., in solution), a chemical equilibrium of the tautomers can be achieved. For example, proton tautomers (also known as prototropic tautomers) include interconversions that occur via proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers include interconversions that occur via reorganization of some of the bonding electrons.

[0381] Unless otherwise indicated, the structural formulas described herein include all isomeric forms (e.g., enantiomers, diastereomers, and geometric isomers (or conformers)): for example, R and S configurations containing asymmetric centers, (Z) and (E) isomers of double bonds, and (Z) and (E) conformers. Therefore, single stereochemical isomers of the compounds of the present invention or mixtures of their enantiomers, diastereomers, or geometric isomers (or conformers) are within the scope of the present invention.

[0382] Unless otherwise specified, the compounds of the present invention also include "prodrugs" thereof. The term "prodrug" refers to a drug that is converted into the parent drug in vivo. Prodrugs are generally useful because they can improve certain, undesirable physical or biological properties. Physical properties are often related to solubility (excessive or insufficient lipid or water solubility) or stability, while problematic biological properties include rapid metabolism or poor bioavailability, which may themselves be related to physicochemical properties. For example, they may be bioavailable orally, whereas the parent drug is not. Prodrugs also have improved solubility in pharmaceutical compositions compared to the parent drug. An example, but not limited to, of a prodrug is any compound of the present invention administered as an ester ("prodrug") to facilitate transport across cell membranes, where water solubility is detrimental to mobility, but once inside the cell, water solubility is beneficial, which is then metabolically hydrolyzed to the carboxylic acid, the active entity. Another example of a prodrug is a short peptide (polyamino acid) conjugated to an acid group, where the peptide is metabolized to reveal the active moiety.

[0383] Unless otherwise specified, the term "treat," "treatment," "treatment," or "treating" encompasses any treatment of a disease, disorder, or condition in a patient, including: (a) inhibiting the symptoms of the disease, disorder, or condition, i.e., arresting its development; or (b) relieving the symptoms of the disease, disorder, or condition, i.e., causing regression of the disease or symptoms; or (c) ameliorating or eliminating the disease, disorder, or condition or one or more symptoms associated with the disease.

[0384] Abbreviations used in the Preparation Examples, Examples, and elsewhere herein are:

[0385] DCM: dichloromethane; TEA: triethylamine; DIEA: N,N-diisopropylethylamine; DMF: N,N-dimethylformamide; EtOAc: ethyl acetate; H: hour; mL: milliliter; MeOH: methanol; TFA: trifluoroacetic acid; NBSN-bromosuccinimide; NIS: N-iodosuccinimide; THF: tetrahydrofuran; Pd(dppf)Cl2: [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride; DMSO-d6: deuterated dimethyl sulfoxide; Toluene: toluene; mCPBA: m-chloroperbenzoic acid; PE: petroleum ether; EA: ethyl acetate; LAH: lithium aluminum hydride.

[0386] The beneficial effects of the present invention are:

[0387] The present invention designs a class of novel compounds. In vitro cell studies have shown that the compounds of the present invention have a good inhibitory effect on RSV. Human ergosterol (hERG) assays have shown that the compounds of the present invention have a low risk of cardiotoxicity and a good safety profile. In vivo studies have demonstrated that the compounds of the present invention have good pharmacokinetic properties and a good in vivo antiviral effect. Furthermore, the present invention has developed a specific synthesis method that is simple in process and easy to operate, facilitating large-scale industrial production and application. DETAILED DESCRIPTION

[0388] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. Experimental methods in the following examples where specific conditions are not specified are generally performed under conventional conditions or according to the conditions recommended by the manufacturer. Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to professionals in the field. In addition, any methods and materials similar or equivalent to those described herein can be applied to the present invention. The preferred embodiments and materials shown herein are for demonstration purposes only.

[0389] The chiral compounds involved in the present invention can be separated and purified using supercritical chromatography equipment, chiral chromatography columns, and conventional solvents as mobile phases to obtain optically pure monomeric compounds.

[0390] The following are examples of the preparation of exemplary compounds of the present application.

[0391] Intermediate Preparation Example 1-1: Synthesis of 2,4-dichloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine

[0392] Step 1: Synthesis of 2,4-dichloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine

[0393] In a 100 mL reaction flask, tert-butyl 2,4-dichloro-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate (0.5 g, 1.64 mmol), DCM (5 mL), and trifluoroacetic acid (2 mL) were added sequentially. The reaction solution was stirred at room temperature for 3 h. LCMS showed that the reaction was complete. After post-treatment, the mixture was concentrated to dryness under reduced pressure to obtain crude 2,4-dichloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine, which was used directly in the next reaction without further purification. ESI-MS (m / z): 204.00 [M+H] + .

[0394] Step 2: Synthesis of 2,4-dichloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine

[0395] To the crude 2,4-dichloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine obtained in step 1, DCM (4 mL) and methanol (1 mL) were added. The pH of the reaction solution was adjusted to 9 with triethylamine, and glacial acetic acid was then added dropwise to a pH of 5. Paraformaldehyde (0.45 g) was added with stirring at room temperature. Stirring was continued for 1 hour, followed by sodium cyanoborohydride (0.31 g, 4.9 mmol). The mixture was stirred at room temperature overnight. LCMS indicated the reaction was complete. The reaction solution was diluted with dichloromethane, washed with water, and concentrated to dryness under reduced pressure. The concentrate was purified by column chromatography (DCM:MeOH = 40:1 (v / v)) to yield 2,4-dichloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine (0.4 g). ESI-MS (m / z): 218.02 [M+H] + .

[0396] Intermediate Preparation Example 2-3: 2,3,4,5-Tetrahydrobenzo[f][1,4]thiazepine Synthesis of 1,1-dioxide

[0397] Step 1: 3.4-Dihydrobenzo[f][1,4]thiazepine Synthesis of -5(2H)-ketone

[0398] Methyl 2-mercaptobenzoate (3.00 g, 17.8 mmol), 2-chloroethylamine hydrochloride (2.07 g, 17.8 mmol), DMF (10 mL), and THF (10 mL) were added to a 100 mL reaction flask. Sodium hydride (2.22 g, 55.5 mmol) was slowly added at 0°C. After LCMS analysis, water was added to the reaction solution and the mixture was extracted with ethyl acetate. The organic phase was concentrated under reduced pressure, slurried with a mixed solution (EA:PE = 1:1), and filtered to obtain 3,4-dihydrobenzo[f][1,4]thiazepine. -5(2H)-one (1.30 g). ESI-MS (m / z): 180.05 [M+H] + .

[0399] Step 2: 2,3,4,5-Tetrahydrobenzo[f][1,4]thiazepine Synthesis

[0400] Add 3,4-dihydrobenzo[f][1,4]thiazepine to a 100 mL reaction flask. -5(2H)-one (1.30 g, 7.3 mmol) and THF (20 mL). Lithium aluminum tetrahydride was slowly added at 0°C and reacted at 60°C for 7 h. After the reaction was completed by LCMS, water was slowly added at 0°C, and the reaction was quenched with 15% sodium hydroxide solution and water. Filtered, the filtrate was concentrated under reduced pressure to obtain 2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine (1.10g). ESI-MS(m / z):166.06[M+H] + .

[0401] Step 3: 1-(2,3-dihydrobenzo[f][1,4]thiazepine) Synthesis of 4-(5H)-1,4-dimethyl-1-ethan-1-one

[0402] Add 2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine into a 50 mL reaction flask. (1.10 g, 5.3 mmol), triethylamine (1.11 mL, 6.3 mmol) and dichloromethane (10 mL). Acetic anhydride (0.75 mL, 6.3 mmol) was added dropwise at 0 ° C. The reaction was allowed to react for 1 h at room temperature. After the reaction was completed by LCMS, the reaction solution was washed with a saturated sodium chloride solution and dried over sodium sulfate. The organic phase was concentrated under reduced pressure to obtain 1-(2,3-dihydrobenzo[f][1,4]thiazepine) -4(5H)-yl)ethan-1-one (1.08 g). ESI-MS (m / z): 208.08 [M+H] + .

[0403] Step 4: 1-(1,1-dioxido-2,3-dihydrobenzo[f][1,4]thiazepine) Synthesis of 4-(5H)-1,4-dimethyl-1-ethan-1-one

[0404] Add 1-(2,3-dihydrobenzo[f][1,4]thiazepine) into a 50 mL reaction flask. -4(5H)-yl)ethane-1-one (1.08g, 5.2mmol) and dichloromethane (10mL), mCPBA (2.69g, 15.6mmol) dissolved in dichloromethane was slowly added dropwise at 0℃ and reacted at room temperature for 2h. After LCMS detection, the reaction was completed, washed with saturated sodium carbonate aqueous solution, washed with sodium thiosulfate, and then washed with sodium chloride aqueous solution. The organic phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure, washed with diethyl ether, and filtered to obtain 1-(1,1-dioxido-2,3-dihydrobenzo[f][1,4]thiazepine -4(5H)-yl)ethan-1-one (1.00 g). ESI-MS (m / z): 240.18 [M+H] + .

[0405] Step 5: 2,3,4,5-Tetrahydrobenzo[f][1,4]thiazepine Synthesis of 1,1-dioxide

[0406] Add 1-(1,1-dioxido-2,3-dihydrobenzo[f][1,4]thiazepine) into a 50 mL reaction bottle. -4(5H)-yl)ethane-1-one (1.00 g, 4.2 mmol), sodium hydroxide (0.84 g, 21.0 mmol), ethanol (10 mL) and water (7 mL) were reacted at 80 ° C for 16 h. After the reaction was completed by LCMS, the organic solvent was dried by spin drying. Water was added to slurry and filtered to obtain 2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine -1,1-dioxide (0.66 g). ESI-MS (m / z): 198.11 [M+H] + .

[0407] Intermediate Preparation Example 2-5: 2,3,4,5-tetrahydropyrido[2,3-f][1,4]thiazepine Synthesis of 1,1-dioxide

[0408] Step 1: Synthesis of methyl 3-((2-((tert-butoxycarbonyl)amino)ethyl)thio)picolinate

[0409] Methyl 3-chloropicolinate (8 g, 46.63 mmol) was added to DMF (80 mL). KCO (8 g, 46.63 mmol, 3 eq) and tert-butyl (2-mercaptoethyl)carbamate (8.26 g, 46.63 mmol) were added sequentially to the reaction solution, which was stirred at 110°C for 16 hours. LCMS analysis indicated product formation. The reaction solution was extracted with water and ethyl acetate, and the organic phase was washed with semi-saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford the crude product. Column chromatography (PE:EA = 1:1) afforded methyl 3-((2-((tert-butoxycarbonyl)amino)ethyl)thio)picolinate (2.8 g). ESI-MS (m / z): 313.38 [M+H]. + .

[0410] Step 2: Synthesis of methyl 3-((2-aminoethyl)thio)picolinate

[0411] Methyl 3-((2-((tert-butoxycarbonyl)amino)ethyl)thio)picolinate (2.8 g, 8.96 mmol) was dissolved in DCM (28 mL) and HCl / 1,4-dioxane (14 mL). The mixture was stirred at 20°C for 2 h. TLC indicated complete reaction of the starting material. The mixture was concentrated under reduced pressure to yield methyl 3-((2-aminoethyl)thio)picolinate hydrochloride (2.5 g). ESI-MS (m / z): 213.27 [M+H] + .

[0412] Step 3: 3,4-Dihydropyrido[2,3-f][1,4]thiazepine Synthesis of -5(2H)-ketone

[0413] Methyl 3-((2-aminoethyl)thio)picolinate hydrochloride (2.5 g, 10.05 mmol) was dissolved in THF (125 mL) and MeOH (125 mL). CH3ONa (3.26 g, 60.31 mmol) was added to the reaction solution at 0°C, and the mixture was stirred at 48°C for 16 hours. LCMS detected that the reaction of the raw material was complete. After the reaction solution was distilled under reduced pressure to remove the solvent, it was extracted with water and dichloromethane. The organic phase was dried over anhydrous sodium sulfate and distilled under reduced pressure to obtain 3,4-dihydropyrido[2,3-f][1,4]thiazepine. -5(2H)-ketone (1.3 g). ESI-MS (m / z): 181.23 [M+H] + .

[0414] Step 4: 2,3,4,5-Tetrahydropyrido[2,3-f][1,4]thiazepine Synthesis

[0415] 3,4-dihydropyrido[2,3-f][1,4]thiazepine -5(2H)-one (1.1 g, 6.10 mmol) was dissolved in THF (22 mL). LAH (463.30 mg, 12.21 mmol) was added to the reaction mixture at 0°C. The mixture was stirred at 60°C for 4 h. LCMS confirmed the complete reaction of the starting material. The reaction mixture was purified by column chromatography (DCM:MeOH = 10:1) to obtain 2,3,4,5-tetrahydropyrido[2,3-f][1,4]thiazepine. (577.7 mg). ESI-MS(m / z):167.24[M+H] + .

[0416] Step 5: 1-(2,3-dihydropyrido[2,3-f][1,4]thiazepine Synthesis of 4-(5H)-1,4-dimethyl-1-ethan-1-one

[0417] 2,3,4,5-tetrahydropyrido[2,3-f][1,4]thiazepine (577.7 mg, 3.48 mmol) was dissolved in DCM (20 mL), triethylamine (0.6 mL, 4.8 mmol) and acetic anhydride (0.3 mL, 4.2 mmol) were added at 0 ° C, and the mixture was heated to room temperature and stirred for 2 hours. LCMS detected that the reaction of the raw material was complete. After the solvent was removed by distillation under reduced pressure, the reaction solution was extracted with water and dichloromethane. The organic phase was dried and purified by silica gel column chromatography (DCM: MeOH = 30: 1) to obtain 1-(2,3-dihydropyrido[2,3-f][1,4]thiazepine -4(5H)-yl)ethan-1-one (347.4 mg). ESI-MS (m / z): 209.28 [M+H] + .

[0418] Step 6: 1-(1,1-dioxo-2,3-dihydropyrido[2,3-f][1,4]thiazepine Synthesis of 4-(5H)-1,4-dimethyl-1-ethan-1-one

[0419] 1-(2,3-dihydropyrido[2,3-f][1,4]thiazepine -4(5H)-yl)ethane-1-one (347.4 mg, 1.67 mmol) was dissolved in DCM (20 mL), mCPBA (0.86 g, 4.9 mmol) was added at 0°C, and the mixture was heated to room temperature and stirred for 2 hours. LCMS detected that the reaction of the raw materials was complete. After the solvent was removed by distillation under reduced pressure, the reaction solution was extracted with water and dichloromethane. The organic phase was dried and purified by silica gel column chromatography (DCM:MeOH=30:1) to obtain 1-(1,1-dioxo-2,3-dihydropyrido[2,3-f][1,4]thiazepine -4(5H)-yl)ethan-1-one (289.1 mg). ESI-MS (m / z): 241.28 [M+H]+.

[0420] Step 7: 2,3,4,5-Tetrahydropyrido[2,3-f][1,4]thiazepine Synthesis of 1,1-dioxide

[0421] 1-(1,1-dioxo-2,3-dihydropyrido[2,3-f][1,4]thiazepine 2,3,4,5-tetrahydropyrido[2,3-f][1,4]thiazepine was obtained by LCMS. -1,1-dioxide (110.2 mg). ESI-MS (m / z): 199.24 [M+H] + .

[0422] Intermediate Preparation Example 2-6: 2,3,4,5-tetrahydropyrido[3,4-f][1,4]thiazepine Synthesis of 1,1-dioxide

[0423] The synthesis method is the same as that of the intermediate preparation example 2-5, except that 4-chloronicotinate methyl ester is used as the starting material instead of 3-chloropicolinate methyl ester to obtain 2,3,4,5-tetrahydropyrido[3,4-f][1,4]thiazepine -1,1-dioxide (98.2 mg). Intermediate Preparation Example 2-14: 1-Imino-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0424] Step 1: 2,3-Dihydrobenzo[f][1,4]thiazepine Synthesis of tert-butyl 4(5H)-carboxylate

[0425] Add 2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine into a 50 mL reaction flask. (1g, 6mmol), DCM (10ml), TEA (1.2g, 12mmol) and Boc anhydride (1.6g, 7.2mmol). After the reaction, H2O was added, extracted with DCM, and the organic phase was washed with saturated sodium chloride solution. The organic phase was collected and dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain 2,3-dihydrobenzo[f][1,4]thiazepine. -tert-Butyl 4(5H)-carboxylate (1.6 g, crude product). ESI-MS (m / z): 266.11 [M+H] + .

[0426] Step 2: 1-Imino-1,2,3,5-tetrahydro-4H-1λ 4-Benzo[f][1,4]thiazepine -Synthesis of tert-butyl 4-carboxylate-1-oxide

[0427] In a 50 mL reaction flask, 2,3-dihydrobenzo[f][1,4]thiazepine Tert-butyl-4(5H)-carboxylate (1.6 g, 6 mmol) was added to MeOH (20 ml), followed by ammonium carbonate (864 mg, 9 mmol). After stirring for 5 minutes, iodophenyl diacetic acid (4.4 g, 13.8 mmol) was added. The mixture was allowed to react overnight at room temperature and concentrated under reduced pressure to obtain a crude product. The crude product was chromatographed on silica gel (EA:PE=1:1) to obtain 1-imino-1,2,3,5-tetrahydro-4H-1λ 4 -Benzo[f][1,4]thiazepine -tert-Butyl 4-carboxylate 1-oxide (1.3 g). ESI-MS (m / z): 297.12 [M+H] + .

[0428] Step 3: 1-Imino-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0429] Add 1-imino-1,2,3,5-tetrahydro-4H-1λ into a 50 mL reaction bottle. 4 -Benzo[f][1,4]thiazepine -4-carboxylic acid tert-butyl ester-1-oxide (1.3 g, 4.4 mmol), then HCl / 1,4-dioxane (15 mL, 4 M) was added and the reaction was allowed to proceed at room temperature for 14 h. After the reaction was completed, the crude product was concentrated under reduced pressure to obtain a crude product, which was added to water, and a saturated potassium carbonate solution was added to adjust the pH to 9-10. The product was extracted with ethyl acetate, and the organic phase was washed with a saturated sodium chloride solution. The organic phase was collected and dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain 1-imino-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine -1-oxide (560 mg). ESI-MS (m / z): 197.07 [M+H] + .

[0430] Intermediate Preparation Example 2-15: 1-(Methylimino)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0431] Step 1: 1-(Methylimino)-1,2,3,5-tetrahydro-4H-1λ 4 -Benzo[f][1,4]thiazepine -Synthesis of tert-butyl 4-carboxylate-1-oxide

[0432] Add 1-imino-1,2,3,5-tetrahydro-4H-1λ into a 50 mL reaction flask 4 -Benzo[f][1,4]thiazepine -4-carboxylic acid tert-butyl ester-1-oxide (2g, 6.7mmol), THF (20mL). Sodium hydride (400mg, 10mmol) was slowly added at 0℃. The reaction was carried out at room temperature for 0.5h, and then iodomethane (1.05g, 7.4mmol) was added. The reaction was carried out at room temperature for 2h. After the reaction was completed, water was added to the reaction solution and extracted with ethyl acetate. The organic phase was concentrated under reduced pressure to obtain a crude product, which was chromatographed on silica gel (EA:PE=1:1) to obtain 1-(methylimino)-1,2,3,5-tetrahydro-4H-1λ 4 -Benzo[f][1,4]thiazepine -tert-Butyl 4-carboxylate-1-oxide (1.7 g). ESI-MS (m / z): 311.14 [M+H] + .

[0433] Step 2: 1-(Methylimino)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0434] Add 1-(methylimino)-1,2,3,5-tetrahydro-4H-1λ into a 50 mL reaction flask. 4 -Benzo[f][1,4]thiazepine -4-carboxylic acid tert-butyl ester-1-oxide (1.7 g, 5.5 mmol) was added, and then HCl / 1,4-dioxane (20 mL, 4 M) was added and reacted at room temperature for 14 h. After the reaction was completed, the crude product was concentrated under reduced pressure to obtain a crude product, which was added to water, and a saturated potassium carbonate solution was added to adjust the pH to 9-10. The product was extracted with ethyl acetate, and the organic phase was washed with a saturated sodium chloride solution. The organic phase was collected and dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain 1-(methylimino)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine -1-oxide (630 mg). ESI-MS (m / z): 211.08 [M+H] + .

[0435] Intermediate Preparation Example 2-16: N-(1-oxido-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of cyanamide

[0436] Step 1: (E)-1-(Cyanoimido)-1,2,3,5-tetrahydro-4H-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of tert-butyl-4-carboxylate

[0437] In a 50 mL reaction flask, 2,3-dihydrobenzo[f][1,4]thiazepine Tert-butyl-4(5H)-carboxylate (1.7 g, 6.4 mmol) was added to MeOH (20 ml), followed by the addition of ammonium cyanide (422 mg, 9.6 mmol). After stirring for 5 minutes, iodophenyl diacetic acid (2.3 g, 7 mmol) was added. The mixture was allowed to react overnight at room temperature and concentrated under reduced pressure to obtain a crude product. The crude product was chromatographed on silica gel (EA:PE=2:1) ​​to obtain (E)-1-(cyanoimino)-1,2,3,5-tetrahydro-4H-1λ 4 -Benzo[f][1,4]thiazepine -tert-Butyl 4-carboxylate (1.4 g). ESI-MS (m / z): 306.12 [M+H] + .

[0438] Step 2: 1-(Cyanoimido)-1,2,3,5-tetrahydro-4H-1λ 4 -Benzo[f][1,4]thiazepine -Synthesis of tert-butyl 4-carboxylate-1-oxide

[0439] In a 50 mL reaction flask, (E)-1-(cyanoimino)-1,2,3,5-tetrahydro-4H-1λ 4 -Benzo[f][1,4]thiazepine Tert-butyl-4-carboxylate (1.4 g, 4.6 mmol) was added to ACN (70 ml) and DCM (7 ml), and then ruthenium chloride (9.5 mg, 0.046 mmol) and sodium periodate (1.5 g, 6.9 mmol) were added. The reaction was allowed to proceed overnight at room temperature and concentrated under reduced pressure to obtain a crude product. The crude product was chromatographed on silica gel (EA:PE=2:1) ​​to obtain 1-(cyanoimino)-1,2,3,5-tetrahydro-4H-1λ 4 -Benzo[f][1,4]thiazepine -tert-Butyl 4-carboxylate-1-oxide (1.1 g). ESI-MS (m / z): 322.11 [M+H] +.

[0440] Step 3: N-(1-oxy-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of cyanamide

[0441] Add 1-(cyanoimino)-1,2,3,5-tetrahydro-4H-1λ into a 50 mL reaction flask. 4 -Benzo[f][1,4]thiazepine -4-carboxylic acid tert-butyl ester-1-oxide (1.1 g, 3.4 mmol), then added HCl / 1,4-dioxane (15 mL, 4 M), and reacted at room temperature for 14 h. After the reaction was completed, it was concentrated under reduced pressure to obtain a crude product, which was added to water, and a saturated potassium carbonate solution was added to adjust the pH to 9-10. The product was extracted with ethyl acetate, and the organic phase was washed with a saturated sodium chloride solution. The organic phase was collected and dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain N-(1-oxidized-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine -1-ylidene)cyanamide (300 mg). ESI-MS (m / z): 222.06 [M+H] + .

[0442] Intermediate Preparation Example 2-19: 1-(Cyclopropylimino)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0443] Step 1: 1-(Cyclopropylimino)-1,2,3,5-tetrahydro-4H-1λ 4 -Benzo[f][1,4]thiazepine -Synthesis of tert-butyl 4-carboxylate-1-oxide

[0444] Add 1-imino-1,2,3,5-tetrahydro-4H-1λ into a 50 mL reaction flask 4 -Benzo[f][1,4]thiazepine -4-carboxylic acid tert-butyl ester-1-oxide (200 mg, 0.7 mmol), Cu(OAc)2 (200 mg, 1.1 mmol), cyclopropylboronic acid (120 mg, 1.4 mmol), pyridine (134 mg, 1.7 mmol), 1,4-dioxane (20 mL). The reaction was carried out at 100°C for 8 h. After the reaction was completed, water was added to the reaction solution and extracted with ethyl acetate. The organic phase was concentrated under reduced pressure to obtain a crude product, which was chromatographed on silica gel (EA:PE = 1:1) to obtain 1-(cyclopropylimino)-1,2,3,5-tetrahydro-4H-1λ 4 -Benzo[f][1,4]thiazepine -tert-Butyl 4-carboxylate-1-oxide (150 mg). ESI-MS (m / z): 337.15 [M+H] + .

[0445] Step 2: 1-(cyclopropylimino)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0446] Add 1-(cyclopropylimino)-1,2,3,5-tetrahydro-4H-1λ into a 50 mL reaction flask. 4 -Benzo[f][1,4]thiazepine -4-carboxylic acid tert-butyl ester-1-oxide (150 mg) was then added, followed by the addition of HCl / 1,4-dioxane (20 mL, 4 M) and the reaction was allowed to proceed at room temperature for 14 h. After completion of the reaction, the crude product was concentrated under reduced pressure to obtain a crude product, which was added to water, and a saturated potassium carbonate solution was added to adjust the pH to 9-10. The product was extracted with ethyl acetate, and the organic phase was washed with a saturated sodium chloride solution. The organic phase was collected and dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain 1-(cyclopropylimino)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine -1-oxide (100 mg). ESI-MS (m / z): 237.10 [M+H] + .

[0447] Intermediate Preparation Example 3-1: Synthesis of 4-methoxybenzyl (3-(aminomethyl)oxetane-3-yl)carbamate

[0448] Step 1: Synthesis of 3-(bromomethyl)oxetane-3-carboxylic acid

[0449] To a 500 mL reaction flask were added (3-(bromomethyl)oxetane-3-yl)methanol (8.5 g, 46.95 mmol), acetonitrile (25 mL), water (130 mL), and KBr (0.57 g, 4.79 mmol) in sequence. A 7% aqueous sodium hypochlorite solution (120 mL) was added dropwise to the reaction solution at a temperature below 30°C. After the addition was complete, the mixture was allowed to react at room temperature for 4 h. LCMS indicated the reaction was complete. Aqueous sodium bicarbonate solution was added to adjust the pH of the system to 10, and the system was then extracted with ethyl acetate. The resulting aqueous phase was adjusted to pH 2 with 5N sulfuric acid, then extracted with dichloromethane and concentrated to dryness under reduced pressure to give 3-(bromomethyl)oxetane-3-carboxylic acid (5.6 g).

[0450] Step 2: Synthesis of 4-methoxybenzyl (3-(bromomethyl)oxetan-3-yl)carbamate

[0451] To a 500 mL reaction flask were added 3-(bromomethyl)oxetane-3-carboxylic acid (5 g, 25.77 mmol), toluene (50 mL), N-methylmorpholine (3.1 g, 30.65 mmol), (4-methoxyphenyl)methanol (3.6 g, 26.06 mmol), and DPPA (7.8 g, 28.34 mmol) in sequence. The reaction mixture was heated to 80°C for 4 h. LCMS indicated the reaction was complete. The mixture was cooled to room temperature and diluted with ethyl acetate. The resulting mixture was washed with saturated aqueous sodium bicarbonate, water, and saturated brine, respectively. The organic phase was concentrated under reduced pressure to yield 4-methoxybenzyl (3-(bromomethyl)oxetane-3-yl)carbamate (7.8 g). ESI-MS (m / z): 330.03 [M+H]. + .

[0452] Step 3: Synthesis of 4-methoxybenzyl (3-((1,3-dioxoisoindolin-2-yl)methyl)oxetane-3-yl)carbamate

[0453] To a 250 mL reaction flask, 4-methoxybenzyl (3-(bromomethyl)oxetane-3-yl)carbamate (7.8 g, 23.71 mmol), DMF (50 mL), and potassium phthalimide (4.4 g, 23.78 mmol) were added sequentially. The reaction mixture was heated to 60°C for 3 h. LCMS indicated the reaction was complete. The mixture was extracted with ethyl acetate, and the organic phase was concentrated to dryness under reduced pressure. The concentrate was then slurried with methyl tert-butyl ether to yield 4-methoxybenzyl (3-((1,3-dioxoisoindolin-2-yl)methyl)oxetane-3-yl)carbamate (3.1 g). ESI-MS (m / z): 397.13 [M+H]. + .

[0454] Step 4: Synthesis of 4-methoxybenzyl (3-(aminomethyl)oxetane-3-yl)carbamate

[0455] To a 250 mL reaction flask, 4-methoxybenzyl (3-((1,3-dioxoisoindolin-2-yl)methyl)oxetane-3-yl)carbamate (3 g, 7.57 mmol), ethanol (30 mL), and 80% hydrazine hydrate (2.3 g, 37.88 mmol) were added sequentially. The temperature was raised to 80°C and the reaction was allowed to react for 2 h. LCMS indicated the reaction was complete. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure to yield 4-methoxybenzyl (3-(aminomethyl)oxetane-3-yl)carbamate (2.0 g). ESI-MS (m / z): 267.13 [M+H] + .

[0456] Intermediate Preparation Example 3-2: Synthesis of 3-(aminomethyl)-N,N-dibenzyloxetane-3-amine

[0457] Step 1: Synthesis of 3-(dibenzylamino)oxetane-3-carbonitrile

[0458] To a 250 mL reaction flask, oxetane-3-one (2 g, 27.6 mmol), AcOH (80 mL), dibenzylamine (9.9 g, 55.2 mmol), and TMSCN (5.5 g, 55.2 mmol) were added sequentially. The mixture was allowed to react at room temperature for 3 hours. LCMS indicated the reaction was complete. The acetic acid was evaporated to dryness, diluted with water, and the pH was adjusted to 8 with sodium bicarbonate. Ethyl acetate (200 mL) was then added, extracted, and separated. The resulting organic phase was washed with water and saturated brine, respectively, and then purified by medium pressure (PE:EA = 3:1) to yield 3-(dibenzylamino)oxetane-3-carbonitrile (5.2 g). ESI-MS (m / z): 279.14 [M+H]. + .

[0459] Step 2: Synthesis of 3-(aminomethyl)-N,N-dibenzyloxetane-3-amine

[0460] To a 250 mL reaction flask, 3-(dibenzylamino)oxetane-3-carbonitrile (5.2 g, 18.7 mmol) was added sequentially, then dissolved in 100 mL of tetrahydrofuran. LiAlH₄ (0.85 g, 22.4 mmol) was slowly added portionwise at room temperature and allowed to react for 4 hours. LCMS indicated the reaction was complete. Under an ice bath, water (0.9 mL), 15% NaOH (0.9 mL), and water (2.7 mL) were slowly added. The mixture was then dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Medium-pressure preparative separation (DCM:MeOH = 20:1) was performed to afford 3-(aminomethyl)-N,N-dibenzyloxetane-3-amine (3 g, 10.6 mmol). ESI-MS (m / z): 283.17 [M+H]. + .

[0461] Intermediate Preparation 4-1: Synthesis of 2,4-dichloro-6-(difluoromethyl)quinazoline

[0462] Step 1: Synthesis of 5-difluoromethyl-2-fluorobenzonitrile

[0463] 2-Fluoro-5-formyl-benzonitrile (1.49 g) was added to a 100 mL reaction flask, dissolved in DCM solution, and diethylaminosulfur trifluoride (1.77 g) was slowly added at 0°C. After the addition was complete, the mixture was reacted at room temperature. LCMS detection showed that the reaction was complete. Ice water was added, extracted with ethyl acetate, and the organic phases were combined and dried under reduced pressure to give 5-difluoromethyl-2-fluorobenzonitrile (1.5 g). ESI-MS (m / z): 172.03 [M+H] + .

[0464] Step 2: Synthesis of 5-difluoromethyl-2-aminobenzonitrile

[0465] 5-Difluoromethyl-2-fluorobenzonitrile (1.49 g) was added to a 20 mL reaction flask, dissolved in THF, and slowly added with aqueous ammonia (1.77 g). After the addition was complete, the mixture was reacted at 100°C. LCMS confirmed the reaction was complete. Extraction was performed with ethyl acetate, and the organic phases were combined and dried under reduced pressure to yield 5-difluoromethyl-2-aminobenzonitrile (0.3 g). ESI-MS (m / z): 169.03 [M+H] + .

[0466] Step 3: Synthesis of 6-(difluoromethyl)quinazoline-2,4-diol

[0467] To a 20 mL reaction flask, 5-difluoromethyl-2-aminobenzonitrile (0.3 g) and DBU (2 mL) were added to a DMSO solution and dissolved. The CO2 atmosphere was slowly replaced three times. The reaction was allowed to proceed at 100°C. LCMS confirmed the reaction was complete. Water was added, and the mixture was extracted with ethyl acetate. The combined organic phases were dried under reduced pressure to obtain 6-(difluoromethyl)quinazoline-2,4-diol (0.1 g). ESI-MS (m / z): 213.04 [M+H] + .

[0468] Step 4: Synthesis of 2,4-dichloro-6-(difluoromethyl)quinazoline

[0469] 6-(Difluoromethyl)quinazoline-2,4-diol (0.1 g), phosphorus trichloride (2 mL), and phosphorus pentachloride (2 mL) were added sequentially to a 20 mL reaction flask. The reaction was allowed to proceed at 100°C. LCMS confirmed the reaction was complete. Water was added, and the mixture was extracted with ethyl acetate. The combined organic phases were dried under reduced pressure to afford 2,4-dichloro-6-(difluoromethyl)quinazoline (0.05 g). ESI-MS (m / z): 248.97 [M+H] + .

[0470] Example 1-1: 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine Synthesis of 1,1-dioxide

[0471] Step 1: Synthesis of 2-chloro-N-((3-(dibenzylamino)oxetan-3-yl)methyl)-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine

[0472] To a 100 mL reaction flask, 3-(aminomethyl)-N,N-dibenzyloxetane-3-amine (517 mg, 1.83 mmol) and methanol (10 mL) were added, followed by 2,4-dichloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine (400 mg, 1.83 mmol) and triethylamine (270 mg, 2.67 mmol). The reaction mixture was allowed to react at room temperature for 3 hours. LCMS indicated the reaction was complete. After post-treatment, the reaction mixture was concentrated to dryness under reduced pressure and purified by column chromatography (DCM:MeOH = 30:1) to afford 2-chloro-N-((3-(dibenzylamino)oxetane-3-yl)methyl)-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine (130 mg). ESI-MS (m / z): 464.21 [M+H]+ .

[0473] Step 2: 4-(4-(((3-(dibenzylamino)oxetan-3-yl)methyl)amino)-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine Synthesis of 1,1-dioxide

[0474] In a 25 mL reaction flask, 2-chloro-N-((3-(dibenzylamino)oxetane-3-yl)methyl)-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine (100 mg, 0.22 mmol), 2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine The reaction mixture was stirred at 120°C for 4 hours with 47 mg of 4-(((3-(dibenzylamino)oxetane-3-yl)methyl)amino)-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine for 4 hours. LCMS indicated the reaction was complete. After post-treatment, the mixture was diluted with ethyl acetate and the resulting organic phase was washed with saturated aqueous sodium bicarbonate and then water. The organic phase was concentrated to dryness under reduced pressure. The concentrate was analyzed by TLC (DCM:MeOH = 10:1) to yield 4-(4-(((3-(dibenzylamino)oxetane-3-yl)methyl)amino)-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine. -1,1-dioxide (60 mg). ESI-MS (m / z): 625.29 [M+H] + .

[0475] Step 3: 4-(4-(((3-aminooxetan-3-yl)methyl)amino)-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine Synthesis of 1,1-dioxide

[0476] In a 25 mL reaction flask, 4-(4-(((3-(dibenzylamino)oxetane-3-yl)methyl)amino)-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine was added. -1,1-dioxide (60 mg, 0.096 mmol) was dissolved in methanol (5 ml), and 20% carbon-supported Pd(OH)2 (40 mg) was added. The mixture was allowed to react overnight at room temperature under a hydrogen atmosphere. LCMS showed that the reaction was complete. The filtrate was filtered, collected, concentrated under reduced pressure, and then prepared by TLC (DCM:MeOH=10:1) to give 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine -1,1-dioxide (20 mg). ESI-MS (m / z): 445.19 [M+H] + ; 1 H NMR (600MHz, CDCl3) δ8.05(d,J=7.7Hz,1H),7.72(d,J=7.4Hz,1H),7.52(t,J=7.3Hz,1H),7.40(t,J=7.6Hz,1H),5.12(s,2H),4.80(s,1H),4.5 1(dd,J=26.3,6.0Hz,4H),3.88(s,2H),3.43(s,2H),3.23(s,2H),3.12( q,J=7.3Hz,2H),2.81–2.61(m,4H),2.51(s,3H),1.43(t,J=7.3Hz,2H).

[0477] Example 1-32: 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-(trifluoromethyl)quinazolin-2-yl)-1-((methyl-D3)imino)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine -1-Oxide Synthesis

[0478] The synthesis method is the same as that of Example 2-5, except that 2,4-dichloro-6-trifluoromethylquinazoline is used in step 1 instead of 2,4-dichloro-6-methylquinazoline, and 1-((methyl-D3)imino)-2,3,4,5-tetrahydro-1H-1λ is used in step 2. 4 -Benzo[f][1,4]thiazepine -1-oxide instead of 2,3,4,5-tetrahydropyrido[3,4-f][1,4]thiazepine -1,1-dioxide to obtain the target compound (19 mg). ESI-MS (m / z): 510.57 [M+H] + ; 1H NMR (600MHz, CD3OD) δ8.32(s,1H),7.95(s,1H),7.88(d,J=5.9Hz,1H),7.67(d,J=8.0Hz,1H),7.58(s,1H),7.42(s,2H),5.51–5.39(m,1H),4.76( d,J=14.5Hz,1H),4.63(d,J=5.9Hz,2H),4.55(s,1H),3.94(s,1H),3.62( d,J=14.1Hz,1H),3.49(s,1H),1.32–1.23(m,3H),0.89(t,J=6.6Hz,2H).

[0479] Example 2-5: 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-2,3,4,5-tetrahydropyrido[3,4-f][1,4]thiazepine Synthesis of 1,1-dioxide

[0480] Step 1: Synthesis of 4-methoxybenzyl (3-(((2-chloro-6-methylquinazolin-4-yl)amino)methyl)oxetan-3-yl)carbamate

[0481] To a 100 mL reaction flask, 4-methoxybenzyl (3-(aminomethyl)oxetane-3-yl)carbamate (260 mg, 0.98 mmol) and methanol (10 mL) were added, followed by 2,4-dichloro-6-methylquinazoline (210 mg, 0.98 mmol) and triethylamine (200 mg, 1.98 mmol). The reaction mixture was allowed to react at room temperature for 4 hours. LCMS indicated the reaction was complete. After post-treatment, the reaction mixture was directly concentrated to dryness under reduced pressure. The concentrate was purified on a silica gel column (DCM:MeOH = 30:1) to give 4-methoxybenzyl (3-(((2-chloro-6-methylquinazolin-4-yl)amino)methyl)oxetane-3-yl)carbamate (260 mg). ESI-MS (m / z): 443.90 [M+H]. + .

[0482] Step 2: 4-methoxybenzyl(3-((2-(1,1-dioxo-2,3-dihydropyrido[3,4-f][1,4]thiazepine) Synthesis of 4-(5H)-6-methylquinazolin-4-yl)amino)methyl)oxetane-3-yl)carbamate

[0483] In a 25 mL reaction flask, 4-methoxybenzyl (3-(((2-chloro-6-methylquinazolin-4-yl)amino)methyl)oxetane-3-yl)carbamate (260 mg, 0.60 mmol), 2,3,4,5-tetrahydropyrido [3,4-f][1,4]thiazepine were added in sequence. -1,1-dioxide (120 mg, 0.60 mmol), NH4Cl (8 mg, 0.15 mmol), ethanol (10 mL), the reaction solution was heated to 78 ° C for 30 hours. LCMS showed that the reaction was complete. The reaction solution was concentrated under reduced pressure, and the concentrate was purified by silica gel column chromatography (DCM: MeOH = 30:1 to 20:1) to obtain 4-methoxybenzyl (3-((2-(1,1-dioxo-2,3-dihydropyrido [3,4-f][1,4]thiazepine) (4-(5H)-yl)-6-methylquinazolin-4-yl)amino)methyl)oxetan-3-yl)carbamate (100 mg). ESI-MS (m / z): 605.68 [M+H] + .

[0484] Step 3: 4-(4-(((3-aminooxetan-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-2,3,4,5-tetrahydropyrido[3,4-f][1,4]thiazepine Synthesis of 1,1-dioxide

[0485] In a 100 mL reaction flask, 4-methoxybenzyl (3-((2-(1,1-dioxo-2,3-dihydropyrido [3,4-f][1,4]thiazepine) -4(5H)-yl)-6-methylquinazolin-4-yl)amino)methyl)oxetane-3-yl)carbamate (100 mg, 0.16 mmol), DCM (4 mL), trifluoroacetic acid (1 mL), the reaction solution was stirred at room temperature for 1 hour. LCMS showed that the reaction was complete, post-processed, concentrated to dryness under reduced pressure, the concentrate was dissolved in methanol, and ammonia methanol was added to adjust the solution pH to 10. The resulting solution was concentrated to dryness under reduced pressure and then prepared by liquid phase preparation to obtain 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-2,3,4,5-tetrahydropyrido[3,4-f][1,4]thiazepine -1,1-dioxide (15 mg). ESI-MS (m / z): 441.52 [M+H] + ; 1H NMR (600MHz, CD3OD) δ9.01(s,1H),8.76(s,1H),7.96(d,J=4.8Hz,1H),7.73(s,1H),7.44(d,J=7.8Hz,1H),7.38(d,J=8.5Hz,1H),5.52(s ,1H),5.21(d,J=19.4Hz,2H),4.74–4.63(m,3H),4.59(d,J=6.8Hz,3H),4.12(s,2H),3.70–3.65(m,2H),3.09–3.05(m,2H),2.42(s,3H).

[0486] Example 2-14: 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-(methylimino)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of 1-oxide

[0487] The synthesis method is the same as that of Example 2-5, except that 1-(methylimino)-2,3,4,5-tetrahydro-1H-1λ is used in step 2. 4 -Benzo[f][1,4]thiazepine -1-oxide instead of 2,3,4,5-tetrahydropyrido[3,4-f][1,4]thiazepine 1,1-dioxide to obtain 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-(methylimino)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine -1-oxide (52 mg). ESI-MS (m / z): 453.2 [M+H] + . 1 H NMR (600MHz, DMSO-d6) δ7.85(dd,J=20.1,7.2Hz,4H),7.56(t,J=7.1Hz,1H),7.46(s,1H),7.36(d,J=8.2Hz,1H),7.22(s,1H),5.31(s,1H),4.97( s,1H),4.69(d,J=13.7Hz,1H),4.50(s,2H),4.37(s,2H),3.91(d,J=42. 8Hz, 3H), 3.68 (d, J = 58.2Hz, 2H), 2.92 (s, 2H), 2.44 (s, 3H), 2.34 (s, 3H).

[0488] Example 2-16: 1-(4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-oxido-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of urea

[0489] The synthesis method is the same as that of Example 2-5, except that N-(1-oxy-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine -1-ylidene) cyanamide instead of 2,3,4,5-tetrahydropyrido[3,4-f][1,4]thiazepine -1,1-dioxide to obtain 1-(4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-oxido-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine -1-ylidene) urea (43 mg). ESI-MS (m / z): 482.18 [M+H] + . 1 H NMR(600MHz,DMSO-d6)δ8.07(s,1H),7.93(s,1H),7.89–7.80(m,2H),7.60(t ,J=7.2Hz,1H),7.49(s,1H),7.39(s,1H),7.31(s,1H),6.60(s,1H),6.14(s, 1H),5.34(s,1H),5.08(s,1H),4.87(s,1H),4.57(d,J=5.9Hz,2H),4.44(s,2 H), 4.07 (d, J = 39.7Hz, 3H), 3.84 (s, 1H), 3.52 (s, 1H), 2.38 (d, J = 24.8Hz, 3H).

[0490] Example 2-23: 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-imino-2,3,4,5-tetrahydro-1H-1λ 4 - Benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0491] The synthesis method is the same as that of Example 2-5, except that 1-imino-2,3,4,5-tetrahydro-1H-1λ is used in step 2. 4-Benzo[f][1,4]thiazepine -1-oxide instead of 2,3,4,5-tetrahydropyrido[3,4-f][1,4]thiazepine -1,1-dioxide to obtain 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-imino-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine -1-oxide (32 mg). ESI-MS (m / z): 439.18 [M+H] + . 1 H NMR (600MHz, DMSO-d6) δ7.94(d,J=12.9Hz,1H),7.86–7.76(m,3H),7.52(t,J=6.9Hz,1H),7.42(s,1H),7.36(d,J=7.9Hz,1H),7.23(s, 1H), 5.08 (s, 2H), 4.62 (s, 1H), 4.49 (s, 2H), 4.36 (s, 3H), 3.89 (d, J = 95.3Hz, 3H), 3.38 (s, 1H), 2.89 (s, 1H), 2.73 (s, 1H), 2.34 (s, 3H).

[0492] Example 2-24: 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-((deuterated methyl)imino)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0493] The synthesis method is the same as that of Example 2-5, except that 1-((deuterated methyl)imino)-2,3,4,5-tetrahydro-1H-1λ is used in step 2. 4 -Benzo[f][1,4]thiazepine -1-oxide instead of 2,3,4,5-tetrahydropyrido[3,4-f][1,4]thiazepine -1,1-dioxide to give 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-((deuterated methyl)imino)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine -1-oxide (32 mg). ESI-MS (m / z): 456.22 [M+H] + .1 H NMR (600MHz, CD3OD) δ7.97(d,J=7.7Hz,1H),7.89(d,J=7.4Hz,1H),7.69(s,1H),7.58(t,J=7.3Hz ,1H),7.44(t,J=7.6Hz,1H),7.38(d,J=8.5Hz,1H),7.32(d,J=8.5Hz,1H),5.53–5.39(m,1H),4.78 (d,J=14.9Hz,1H),4.67(d,J=5.7Hz,1H),4.64(d,J=6.2Hz,1H),4.55(s,2H),4.12(d,J=12.0Hz, 1H),4.06–3.93(m,2H),3.62(d,J=14.7Hz,1H),3.52(t,J=12.5Hz,1H),3.33(s,2H),2.38(s,3H).

[0494] Example 2-25: 4-(4-(((3-aminooxetan-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-(oxetan-3-ylimino)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0495] The synthesis method is the same as that of Example 2-5, except that 1-(oxetanylimino)-2,3,4,5-tetrahydro-1H-1λ is used in step 2. 4 -Benzo[f][1,4]thiazepine -1-oxide instead of 2,3,4,5-tetrahydropyrido[3,4-f][1,4]thiazepine -1,1-dioxide to give 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-(oxetane-3-ylimino)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine -1-oxide (32 mg). ESI-MS (m / z): 495.21 [M+H] + . 1H NMR(600MHz, Methanol-d4)δ7.99(dd,J=7.9,1.3Hz,1H),7.92–7.88(m,1H),7.71–7.68(m,1H),7.64–7.58( m,1H),7.48(td,J=7.7,1.3Hz,1H),7.38(dd,J=8.6,1.9Hz,1H),7.32(d,J=8.6Hz,1H),5.45(d,J=15.2Hz,1 H),5.08(s,1H),4.98–4.84(m,2H),4.83–4.73(m,2H),4.64(dd,J=20.2,6.3Hz,2H),4.53(dd,J=6.3,3.5Hz ,2H),4.05(dd,J=63.1,12.8Hz,2H),3.68–3.48(m,2H),3.24–2.86(m,2H),2.73–2.60(m,1H),2.37(s,3H).

[0496] Example 2-26: 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0497] The synthesis method is the same as that of Example 2-5, except that 1-(cyclopropylimino)-2,3,4,5-tetrahydro-1H-1λ is used in step 2. 4 -Benzo[f][1,4]thiazepine -1-oxide instead of 2,3,4,5-tetrahydropyrido[3,4-f][1,4]thiazepine -1,1-dioxide to give 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine -1-oxide (80 mg). ESI-MS (m / z): 479.45 [M+H] + ; 1H NMR(600MHz,Methanol-d4)δ8.03(d,J=7.9Hz,1H),7.87(d,J=7.9Hz,1H),7.70(s,1H),7.5 9(t,J=7.5Hz,1H),7.45(t,J=7.1Hz,1H),7.39(dd,J=8.6,1.9Hz,1H),7.33(d,J=8.5Hz,1H) ,4.82(d,J=15.1Hz,2H),4.66(dd,J=20.6,6.4Hz,2H),4.57–4.53(m,2H),4.19–3.92(m,4H ),3.63–3.43(m,2H),2.38(s,3H),2.38–2.32(m,1H),0.55–0.39(m,2H),0.29–0.18(m,2H).

[0498] Example 2-29: 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-((trifluoromethyl)imino)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine -1-Oxide synthesis error! Bookmark not defined.

[0499] Step 1: 3-(((6-methyl-2-(1-oxido-1-((trifluoromethyl)imine)-1,2,3,5-tetrahydro-4H-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of (4-methoxy)benzyl (4-methyl)quinazoline-4-yl)amino)methyl)oxetane-3-ylcarbamate

[0500] In a 25 mL flask, add 3-(((2-(1-imino-1-oxido)-1,2,3,5-tetrahydro-4H-1λ 4 -Benzo[f][1,4]thiazepine The mixture was added with (4-methoxy)benzyl)-6-methylquinazolin-4-yl)amino)methyl)oxetane-3-ylcarbamate (120 mg, 0.2 mmol), TMSCF3 (142 mg, 1.0 mmol), Ag2CO3 (11 mg, 0.04 mmol), 1,10-phenanthroline (14 mg, 0.08 mmol) and 1,4-dioxane (4.0 mL). The mixture was purged with oxygen three times and stirred at 60°C for 12 h. LCMS detection showed that the reaction was complete. The solvent was removed by rotary evaporation and purified by thin layer chromatography (DCM:MeOH=10:1) to obtain 3-(((6-methyl-2-(1-oxido-1-((trifluoromethyl)imine)-1,2,3,5-tetrahydro-4H-1λ)-1,2,3,5-tetrahydro-4H-1λ 4 -Benzo[f][1,4]thiazepine (4-Methoxy)benzyl (4-yl)quinazolin-4-yl)amino)methyl)oxetan-3-ylcarbamate (28 mg).

[0501] Step 2: 4-(4-(((3-aminooxetan-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-((trifluoromethyl)imino)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0502] In a 25 mL flask, 3-(((6-methyl-2-(1-oxido-1-((trifluoromethyl)imino)-1,2,3,5-tetrahydro-4H-1λ 4 -Benzo[f][1,4]thiazepine To the mixture of (4-methoxy)benzyl quinazolin-4-yl)amino)methyl)oxetane-3-ylcarbamate (134 mg, 0.2 mmol) and DCM (8 mL) was stirred and TFA (1 mL) was added, followed by stirring at room temperature for 2 h. LCMS analysis showed that the reaction was complete, and the solvent was removed by rotary evaporation. The product was purified by thin layer chromatography (DCM:MeOH = 10:1) to obtain 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-((trifluoromethyl)imino)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine -1-oxide (20 mg). ESI-MS (m / z): 507.17 [M+H] + .

[0503] Example 2-30: 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-((trifluoromethylthio)imino)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0504] The synthesis method is the same as that of Example 2-5, except that 1-((trifluoromethylthio)imino)-2,3,4,5-tetrahydro-1H-1λ is used in step 2. 4 -Benzo[f][1,4]thiazepine -1-oxide instead of 2,3,4,5-tetrahydropyrido[3,4-f][1,4]thiazepine -1,1-dioxide to give 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-((trifluoromethylthio)imino)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine -1-oxide (32 mg). ESI-MS (m / z): 539.14 [M+H] + .

[0505] Example 2-31: N-(4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-oxide-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of acetamide

[0506] The synthesis method is the same as that of Example 2-5, except that N-(1-oxide-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine -1-ylidene)acetamide instead of 2,3,4,5-tetrahydropyrido[3,4-f][1,4]thiazepine -1,1-dioxide to obtain N-(4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-oxide-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine -1-ylidene)acetamide (32 mg). ESI-MS (m / z): 481.19 [M+H] + . 1H NMR (600MHz, Methanol-d4) δ8.07(d,J=7.9Hz,1H),7.89(d,J=7.6Hz,1H),7.70( s,1H),7.65-7.59(m,1H),7.48(t,J=7.7Hz,1H),7.40(dd,J=8.6,1.9Hz,1H),7. 34(d,J=8.5Hz,1H),5.04-4.97(m,2H),4.65(dd,J=13.3,6.4Hz,2H),4.54(t,J= 6.7Hz,2H),4.23-3.98(m,4H),3.21(q,J=7.3Hz,2H),2.39(s,3H),2.08(s,3H).

[0507] Example 2-32: N-(4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-oxide-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of 1-fluorocyclopropane-1-carboxamide

[0508] The synthesis method is the same as that of Example 2-5, except that N-(1-oxide-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine -1-ylidene)-1-fluorocyclopropane-1-carboxamide instead of 2,3,4,5-tetrahydropyrido[3,4-f][1,4]thiazepine -1,1-dioxide to obtain N-(4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-oxide-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine -1-ylidene)-1-fluorocyclopropane-1-carboxamide (32 mg). ESI-MS (m / z): 525.21 [M+H] +. 1H NMR(600MHz,CD3OD)δ8.11(d,J=7.7Hz,1H),7.92(d,J=7.4Hz,1H),7.72(s,1H ),7.65(t,J=7.2Hz,1H),7.51(t,J=7.4Hz,1H),7.44–7.40(m,1H),7.35(d,J= 8.5Hz,1H),5.55–5.40(m,3H),4.66(dd,J=13.2,6.2Hz,2H),4.55(t,J=6.7Hz ,2H),4.12–4.03(m,4H),3.81(s,1H),2.41(s,3H),0.93(s,2H),0.91(s,2H).

[0509] Example 2-33: N-(4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-oxide-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of 2-hydroxyacetamide

[0510] The synthesis method is the same as that of Example 2-5, except that N-(1-oxide-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine -1-ylidene)-2-hydroxyacetamide instead of 2,3,4,5-tetrahydropyrido[3,4-f][1,4]thiazepine -1,1-dioxide to obtain N-(4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-oxide-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine -1-ylidene)-2-hydroxyacetamide (32 mg). ESI-MS (m / z): 497.19 [M+H] + .

[0511] Example 2-34: N-(4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-oxide-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of 2-(dimethylamino)acetamide

[0512] The synthesis method is the same as that of Example 2-5, except that N-(1-oxide-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine -1-ylidene)-2-(dimethylamino)acetamide instead of 2,3,4,5-tetrahydropyrido[3,4-f][1,4]thiazepine -1,1-dioxide to obtain N-(4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-oxide-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine -1-ylidene)-2-(dimethylamino)acetamide (32 mg). ESI-MS (m / z): 524.24 [M+H] + . 1 H NMR(600MHz, Methanol-d4)δ8.10(d,J=8.4Hz,1H),7.89(d,J=7.5Hz,1H),7.70(s,1H),7. 65-7.60(t,J=7.5Hz,1H),7.49(t,J=7.5Hz,1H),7.40(dd,J=8.6,1.9Hz,1H),7.33(d,J=8. 6Hz,1H),5.42(d,J=15.5Hz,2H),4.97(d,J=15.5Hz,2H),4.63(dd,J=13.1,6.2Hz,2H),4.5 5(t,J=6.9Hz,2H),4.21-3.96(m,4H),3.76(s,2H),3.27(s,3H),2.39(s,3H),2.33(s,3H).

[0513] Example 2-37: 1-(4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-oxide-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of 3-methylurea

[0514] The synthesis method is the same as that of Example 2-5, except that 1-methyl-3-(1-oxide-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine -1-ylidene) urea instead of 2,3,4,5-tetrahydropyrido[3,4-f][1,4]thiazepine -1,1-dioxide to obtain 1-(4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-oxide-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine -1-ylidene)-3-methylurea (32 mg). ESI-MS (m / z): 496.22 [M+H] + . 1 H NMR (600MHz, CD3OD) δ8.08(d,J=7.8Hz,1H),7.88(d,J=7.4Hz,1H),7.72(s,1H),7.59(t,J=7.3Hz,1H),7.49–7.41(m,2H),7.36(d,J=8.5Hz, 1H),5.53–5.41(m,1H),5.06(s,1H),4.96(s,1H),4.68(dd,J=14.3,6.3Hz,2H),4.57(t,J=6.2Hz,2H),4.18–3.97(m,4H),3.65(s,1H),2.66 (s,3H),2.41(s,3H).

[0515] Example 2-38: 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-((1-methyl-1H-pyrazol-4-yl)imine)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0516] The synthesis method is the same as that of Example 2-5, except that 1-((1-methyl-1H-pyrazol-4-yl)imine)-2,3,4,5-tetrahydro-1H-1λ is used in step 2. 4 -Benzo[f][1,4]thiazepine -1-oxide instead of 2,3,4,5-tetrahydropyrido[3,4-f][1,4]thiazepine -1,1-dioxide to give 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-((1-methyl-1H-pyrazol-4-yl)imine)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine -1-oxide (32 mg). ESI-MS (m / z): 519.22 [M+H] + . 1H NMR (600MHz, CD3OD) δ7.99(d,J=7.6Hz,1H),7.83(d,J=7.3Hz,1H),7.70(s,1H),7.54(t,J=7.2H z,1H),7.39(t,J=7.4Hz,2H),7.33(d,J=8.5Hz,1H),7.20(s,1H),7.08(s,1H),5.55-5.36(m,1H ),4.94(d,J=14.0Hz,2H),4.65(dd,J=19.2,5.8Hz,2H),4.54(s,2H),4.11(d,J=12.7Hz,2H),4. 02(d,J=13.4Hz,1H),3.80(d,J=14.2Hz,1H),3.69(s,3H),3.62(d,J=12.1Hz,1H),2.39(s,3H).

[0517] The preparation methods of the target compounds of Examples 2-27, 2-28, 2-35, 2-36, 2-39 and 2-40 are shown in the table below:

[0518] Example 2-41: N-(4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-oxido-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of methylsulfonamide

[0519] The synthesis method is the same as that of Example 2-5, except that N-(1-oxy-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine -1-yl)methanesulfonamide instead of 2,3,4,5-tetrahydropyrido[3,4-f][1,4]thiazepine -1,1-dioxide to obtain N-(4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-oxido-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine -1-yl)methanesulfonamide (32 mg). ESI-MS (m / z): 517.16 [M+H] + . 1H NMR(600MHz,CD3OD)δ8.05(d,J=7.5Hz,1H),7.94(d,J=7.4Hz,1H),7.71(s,1H), 7.66(t,J=7.3Hz,1H),7.49(t,J=7.6Hz,1H),7.40(d,J=8.4Hz,1H),7.34(d,J=8 .5Hz,1H),5.50(s,1H),5.02(s,2H),4.65(dd,J=15.1,6.1Hz,2H),4.54(t,J=5. 6Hz, 2H), 4.11 (dd, J = 49.8, 35.4Hz, 4H), 3.84 (s, 1H), 3.10 (s, 3H), 2.40 (s, 3H).

[0520] Example 2-42: 3-(4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-oxido-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of 1,1-dimethylurea

[0521] The synthesis method is the same as that of Example 2-5, except that 1,1-dimethyl-3-(1-oxy-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine -1-yl) urea instead of 2,3,4,5-tetrahydropyrido[3,4-f][1,4]thiazepine -1,1-dioxide to obtain 3-(4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-oxido-2,3,4,5-tetrahydro-1λ 4 -Benzo[f][1,4]thiazepine -1-amino)-1,1-dimethylurea (32 mg). ESI-MS (m / z): 510.22 [M+H] +. H NMR(600MHz,Methanol-d4)δ8.06(d,J=7.9Hz,1H),7.86(d,J=7.5Hz,1H),7.69(s, 1H),7.58(t,J=7.5Hz,1H),7.45(t,J=7.7Hz,1H),7.39(d,J=8.6Hz,1H),7.33(d,J =8.5Hz,1H),5.43(d,J=14.5Hz,2H),5.00(d,J=14.5Hz,2H),4.64(dd,J=14.5,6.3 Hz, 2H), 4.52 (t, J = 6.9 Hz, 2H), 4.07 (m, 4H), 3.07 (s, 3H), 2.83 (s, 3H), 2.38 (s, 3H).

[0522] The preparation methods of the target compounds of Examples 2-43 and 2-44 are as follows:

[0523] Example 2-46: 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-(difluoromethyl)quinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of 1-oxide

[0524] The synthesis method of this compound is the same as that of Example 2-5, ESI-MS (m / z): 515.20 [M+H] + . 1 H NMR (600MHz, DMSO-d6) δ8.35(d,J=29.5Hz,1H),8.28(s,1H),7.94(d,J=13.2Hz,1H),7.86(s,1H),7.67 (d,J=11.8Hz,1H),7.59(s,1H),7.45(dd,J=40.9,34.2Hz,2H),7.02(t,J=56.2Hz,1H),5.51–5.28(m,1H ),4.99(s,1H),4.75(d,J=13.0Hz,1H),4.56(dd,J=45.8,31.5Hz,3H),4.33–4.19(m,1H),4.10–3.84(m, 2H), 3.60 (dd, J=57.4, 37.4Hz, 2H), 2.20 (s, 1H), 1.17 (t, J=7.3Hz, 1H), 0.39 (s, 2H), 0.25–0.04 (m, 2H).

[0525] The preparation methods of the target compounds of Examples 2-47 to 2-51, 2-26A, and 2-26B are as follows:

[0526] Example 3-22: 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methyl-5,6,7,8-tetrahydropyridin-2-yl)-1-(methylimino)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine Synthesis of 1-oxide

[0527] The synthesis method of the compound is the same as that of Example 1-1, except that 1-(methylimino)-2,3,4,5-tetrahydro-1H-1λ is used in the second step. 4 -Benzo[f][1,4]thiazepine -1-oxide instead of 2,3,4,5-tetrahydropyrido[3,4-f][1,4]thiazepine -1,1-dioxide to give 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)-1-(methylimino)-2,3,4,5-tetrahydro-1H-1λ 4 -Benzo[f][1,4]thiazepine 1-oxide. ESI-MS (m / z): 458.23 [M+H] + . 1 H NMR (600MHz, CD3OD) δ7.96(d,J=7.6Hz,1H),7.78(d,J=6.2Hz,1H),7.56(t,J=7.2Hz,1H),7.45(t, J=7.4Hz,1H),5.29(d,J=14.9Hz,1H),4.92(s,1H),4.71(d,J=14.9Hz,1H),4.56(dd,J=19.8,5.7Hz ,2H),4.47(s,2H),3.97–3.83(m,2H),3.81(d,J=13.6Hz,1H),3.55(d,J=14.6Hz,1H),3.42(t,J=12 .3Hz,1H),3.22(s,2H),2.68(s,2H),2.67(s,1H),2.64(d,J=7.9Hz,1H),2.53(s,3H),2.45(s,3H).

[0528] Example 3-27: 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-(trifluoromethyl)quinazolin-2-yl)-2,3,4,5-tetrahydropyrido[2,3-f][1,4]thiazepine Synthesis of 1,1-dioxide

[0529] The synthesis method of the compound is the same as that of Example 1-1, except that 2,4-dichloro-6-(trifluoromethyl)quinazoline is used in the first step instead of 2,4-dichloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine, and 1-(methylimino)-2,3,4,5-tetrahydro-1H-1λ is used in the second step. 4 -Benzo[f][1,4]thiazepine -1-oxide instead of 2,3,4,5-tetrahydropyrido[3,4-f][1,4]thiazepine 4-(4-(((3-aminooxetan-3-yl)methyl)amino)-6-(trifluoromethyl)quinazolin-2-yl)-2,3,4,5-tetrahydropyrido[2,3-f][1,4]thiazepine -1,1-dioxide (23 mg). ESI-MS (m / z): 507.17 [M+H] + .

[0530] Example 4-2: 4-(4-(3-(aminomethyl)-3-hydroxyazetidin-1-yl)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0531] Step 1: tert-Butyl (1-(2-chloro-6-methylquinazolin-4-yl)-3-hydroxyazetidin-3-yl)methyl)carbamate

[0532] 2,4-Dichloro-6-methylquinazoline (100 mg), methanol (13 mL), tert-butyl (3-hydroxyazetidin-3-yl)methylcarbamate (87 mg), and triethylamine (130 μL) were added sequentially to a 25 mL reaction bottle and reacted at room temperature for 1 h. After the reaction was complete, water was added to quench the reaction, and the methanol was spin-dried. The product was extracted twice with DCM, and the organic phases were combined, washed with saturated brine, dried, and then spin-dried to obtain a crude product, which was slurried with petroleum ether / ethyl acetate (1:3) to obtain the product (125 mg).

[0533] Step 2: ((1-(2-(1-(cyclopropylimino)-1-oxido-1,2,3,5-tetrahydro-benzo[f][1,4]thiazepine) tert-Butyl (6-methylquinazolin-4-yl)-3-hydroxyazetidin-3-yl)methyl)carbamate

[0534] In a 50 mL reaction bottle, tert-butyl (1-(2-chloro-6-methylquinazolin-4-yl)-3-hydroxyazetidin-3-yl)methyl)carbamate (76 mg), 1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine were added in sequence. 1-oxide (52 mg), ammonium chloride (10 mg), ethanol (10 mL), reflux reaction until the starting material disappears. Add a small amount of water to quench, spin dry ethanol, extract the aqueous phase twice with DCM, combine the organic phases, wash with saturated brine, and spin dry to obtain a crude product (130 mg).

[0535] Step 3: 4-(4-(3-(Aminomethyl)-3-hydroxyazetidin-1-yl)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine 1-oxide

[0536] ((1-(2-(1-(cyclopropylimino)-1-oxido-1,2,3,5-tetrahydro-benzo[f][1,4]thiazepine Tert-butyl (1,4-dimethyl-6-quinazolin-4-yl)-3-hydroxyazetidin-3-yl)methyl)carbamate (100 mg) was dissolved in ethyl acetate (12 mL), 4 M hydrochloric acid / ethyl acetate solution (10 mL) was added, and the mixture was reacted at room temperature until the starting material disappeared. The filter cake was collected by suction filtration, and the ethyl acetate was removed under reduced pressure to obtain the crude hydrochloride. The crude product was dissolved in water, the pH was adjusted to 8-9 with saturated sodium bicarbonate, filtered, and dried to obtain the product (60 mg). ESI-MS (m / z): 479.22 [M+H]+; 1H NMR (600MHz, CD3OD) δ8.03(d,J=7.4Hz,1H),7.80(d,J=7.4Hz,1H),7.60(t,J=7.3Hz,1H),7.51(s,1H),7.46( t,J=7.5Hz,1H),7.36(dt,J=19.9,5.0Hz,2H),5.42(d,J=15.0Hz,1H),5.00(s,1H),4.79(d,J=15.0Hz,1H),4. 53(dd,J=21.9,8.8Hz,2H),4.33(d,J=9.2Hz,1H),4.27(d,J=9.3Hz,1H),3.94(s,1H),3.63–3.47(m,2H),3.01 (s,2H),2.36(s,3H),2.28(dd,J=13.6,10.3Hz,1H),0.60–0.50(m,1H),0.50–0.39(m,1H),0.33–0.17(m,2H).

[0537] Example 4-3: 4-(4-(azetidin-3-ylamino)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0538] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 449.20 [M+H] + , 1 H NMR(600MHz, CDCl3)δ8.05(d,J=7.0Hz,1H),7.80(s,1H),7.67(s,1H),7.51(t,J=7.4Hz,1 H),7.36(dd,J=19.2,7.9Hz,3H),5.37(s,2H),4.82(d,J=14.7Hz,2H),4.51(s,2H),4.27( d,J=35.7Hz,2H),4.01(s,1H),3.57(d,J=14.2Hz,1H),3.41(s,1H),2.34(s,2H),2.28(s, 1H), 2.07 (s, 1H), 0.57 (d, J = 4.4Hz, 1H), 0.46 (dd, J = 15.5, 5.8Hz, 1H), 0.33–0.19 (m, 2H).

[0539] Example 4-4: 1-(cyclopropylimino)-4-(6-methyl-4-(2,6-diazaspiro[3.3]heptane-2-yl)quinazolin-2-yl)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0540] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 475.22 [M+H] + , 1 H NMR(600MHz, CDCl3)δ8.11(s,1H),7.56(s,2H),7.44(s,1H),7.38(s,1H),7.31(s,1H),4.72(s,4H),4.39(s,3H),4.11–3.9 6(m,2H),3.81–3.68(m,2H),3.44(dd,J=44.7,37.7Hz,4H),2.27(s,3H),0.58(s,1H),0.47(s,1H),0.28(d,J=28.9Hz,2H).

[0541] Example 4-5: 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-((2-fluoroethyl)imino)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine Synthesis of 1-oxide

[0542] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 485.23 [M+H] + ; 1H NMR(600MHz, Methanol-d4)δ7.99–7.95(m,1H),7.87(d,J=7.5Hz,1H),7.68(s,1H),7.58(t,J=7.5Hz,1H),7.46–7.4 1(m,1H),7.38(dd,J=8.6,1.9Hz,1H),7.31(d,J=8.5Hz,1H),5.44(d,J=15.1Hz,1H),5.07(s,1H),4.64(dd,J=20.3,6 .3Hz,2H),4.53(dd,J=6.3,3.7Hz,2H),4.51–4.32(m,2H),4.00(d,J=13.8Hz,2H),3.63(ddd,J=14.7,3.7,2.0Hz,1H) ,3.52(t,J=13.1Hz,1H),3.14(ddt,J=28.7,13.9,4.8Hz,1H),3.01–2.87(m,1H),2.38(s,3H),1.29(t,J=4.1Hz,2H).

[0543] Example 4-6: 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-1-((2,2-difluoroethyl)imino)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine Synthesis of 1-oxide

[0544] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 503.23 [M+H] + ; 1 H NMR(600MHz, Methanol-d4)δ7.97(dd,J=7.9,1.3Hz,1H),7.90–7.86(m,1H),7.70–7.67(m,1H),7.62–7 .56(m,1H),7.44(td,J=7.7,1.3Hz,1H),7.37(dd,J=8.6,1.9Hz,1H),7.31(d,J=8.6Hz,1H),6.00–5.67 (m,1H),5.45(d,J=15.2Hz,1H),5.08(s,1H),4.64(dd,J=20.2,6.3Hz,2H),4.53(dd,J=6.3,3.5Hz,2H) ,4.05(dd,J=63.1,12.8Hz,2H),3.68–3.48(m,2H),3.24–2.86(m,2H),2.37(s,3H),1.35–1.26(m,2H).

[0545] Example 4-7: 4-(4-(((R)-2-(aminomethyl)pyrrolidin-1-yl)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine Synthesis of 1-oxides.

[0546] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 477.28 [M+H] + ; 1 H NMR(600MHz,Methanol-d4)δ8.00–7.96(m,1H),7.80(d,J=7.5Hz,1H),7.73(s,1 H),7.58–7.53(m,1H),7.43–7.37(m,1H),7.35(d,J=1.2Hz,2H),5.40(d,J=15.0H z,1H),4.80(d,J=15.1Hz,1H),4.65(s,1H),4.02(td,J=9.6,6.5Hz,1H),3.85(dd d,J=10.4,7.7,3.1Hz,1H),3.63(dt,J=15.1,2.6Hz,1H),3.55(ddd,J=14.4,10.9 ,3.0Hz,1H),3.09(dd,J=13.0,3.4Hz,1H),2.80(dd,J=12.7,7.6Hz,1H),2.36(s ,3H),2.28(dq,J=7.4,3.8Hz,1H),2.22–2.14(m,1H),2.05(ddq,J=13.9,7.4,4.8 ,3.9Hz,1H),1.97–1.88(m,1H),1.85–1.75(m,1H),1.37–1.24(m,2H),0.92–0.85 (m,1H),0.55–0.48(m,1H),0.43(dtd,J=9.8,6.8,4.7Hz,1H),0.30–0.19(m,1H).

[0547] Example 4-8: 4-(4-(6-amino-3-azabicyclo[3.1.0]hexan-3-yl)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine -1-oxide

[0548] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 475.63 [M+H] + ;1 H NMR (600MHz, CD3OD) δ7.96(d,J=7.7Hz,1H),7.75(d,J=7.4Hz,1H),7.68(s,1H),7.54(t,J=7.3Hz,1H),7.38(t,J=7.6 Hz,1H),7.31–7.26(m,2H),5.34(d,J=15.1Hz,1H),4.91(s,1H),4.72(d,J=15.0Hz,1H),4.19(t,J=12.1Hz,2H),3.86( d,J=10.9Hz,3H),3.55(dd,J=12.4,3.0Hz,1H),3.51–3.46(m,1H),3.33(dt,J=3.2,1.6Hz,1H),2.30(s,3H),2.28–2.2 4(m,1H),1.92(s,1H),1.73(s,1H),0.52(dq,J=6.5,4.5Hz,1H),0.43(ddd,J=9.5,8.3,4.3Hz,1H),0.29–0.19(m,2H).

[0549] Example 4-9: 4-(4-(3-(aminomethyl)azetidin-1-yl)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0550] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 463.22 [M+H] +; 1H NMR (600MHz, CD3OD) δ8.01(d,J=7.3Hz,1H),7.79(d,J=7.4Hz,1H),7.58(t,J=7.3Hz,1 H),7.48(s,1H),7.44(t,J=7.5Hz,1H),7.33(dt,J=15.9,5.1Hz,2H),5.40(d,J=15.0H z,1H),4.99(s,1H),4.77(d,J=14.9Hz,1H),4.56(d,J=31.1Hz,2H),4.20(d,J=25.1Hz ,2H),3.89(d,J=40.0Hz,1H),3.54(dd,J=26.2,7.2Hz,2H),2.99(d,J=7.2Hz,2H),2.87 (dt,J=7.6,5.4Hz,1H),2.34(s,3H),2.31–2.24(m,1H),0.54(td,J=5.7,2.0Hz,1H),0.49–0.37(m,1H),0.32–0.13(m,2H).

[0551] Example 4-10: 1-(Cyclopropylimino)-4-(4-(((3R,4R)-4-hydroxypyrrolidin-3-yl)amino)-6-methylquinazolin-2-yl)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0552] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 479.22 [M+H] + , 1 H NMR (600MHz, CDCl3) δ7.87 (dd, J=72.0, 36.2Hz, 4H), 7.51 (d, J=7.3Hz, 1H), 7.30 (s, 3H), 5.44 (s, 1H), 5.04 (s, 1H), 4.79 (s, 2H) ,4.51(s,1H),3.92(s,2H),3.70(s,2H),3.47(s,3H),2.29(d,J=32.3Hz,4H),0.52(s,1H),0.43(s,1H),0.22(d,J=29.5Hz,2H).

[0553] Example 4-11: 4-(4-(((S)-3-aminopyrrolidin-1-yl)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine -1-Oxide synthesis.

[0554] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 463.24 [M+H] + ; 1 H NMR(600MHz, Methanol-d4)δ7.97(dd,J=7.8,1.4Hz,1H),7.78–7.75(m,2H),7.59–7.54(m,1H),7.38(td,J=7.6 ,1.3Hz,1H),7.30(d,J=1.2Hz,2H),5.39(d,J=15.1Hz,1H),5.02–4.90(m,1H),4.77–4.72(m,1H),4.10–3.99(m ,2H),3.94–3.84(m,2H),3.70–3.62(m,2H),3.58–3.47(m,2H),2.30(s,3H),2.27–2.15(m,2H),1.86(dt,J=13. 2,6.6Hz,1H),0.50–0.43(m,1H),0.40(dtd,J=9.8,6.8,4.8Hz,1H),0.23(dddd,J=23.2,10.4,6.2,4.4Hz,2H).

[0555] Example 4-12: 4-(4-(((R)-3-aminopyrrolidin-1-yl)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine -1-Oxide synthesis.

[0556] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 463.27 [M+H] + ; 1H NMR(600MHz, Methanol-d4)δ7.99(dd,J=7.8,1.4Hz,1H),7.79–7.76(m,2H),7.58–7.53(m,1H),7.41(td,J=7.6 ,1.3Hz,1H),7.33(d,J=1.2Hz,2H),5.41(d,J=15.1Hz,1H),5.05–4.93(m,1H),4.79–4.74(m,1H),4.11–4.00(m ,2H),3.95–3.85(m,2H),3.71–3.64(m,2H),3.59–3.47(m,2H),2.34(s,3H),2.28–2.16(m,2H),1.89(dt,J=13. 2,6.6Hz,1H),0.55–0.48(m,1H),0.42(dtd,J=9.8,6.8,4.8Hz,1H),0.24(dddd,J=23.2,10.4,6.2,4.4Hz,2H).

[0557] Example 4-13: 4-(4-(((1R,3S)-3-aminocyclobutyl)amino)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0558] ESI-MS(m / z):463.2[M+H]+.1H NMR(600MHz,DMSO-d6)δ7.92(d,J=6.8Hz,1H),7.86(d,J=6.3Hz,1H),7.84(s,1H),7.57(s,1H),7.4 6(s,1H),7.33(d,J=8.2Hz,1H),7.20(s,1H),5.30(d,J=12.1Hz,1H),4.90(s,1H),4.70(d,J=13.4H z,1H),3.83(s,1H),3.65(d,J=13.2Hz,2H),2.65(d,J=4.2Hz,2H),2.52–2.50(m,2H),2.33(s,3H), 2.20(d,J=22.3Hz,1H),1.82(dd,J=12.3,5.9Hz,2H),0.43–0.34(m,2H),0.19(s,1H),0.11(s,1H).

[0559] Example 4-14: 1-(Cyclopropylimino)-4-(4-(((3R,4S)-4-hydroxypyrrolidin-3-yl)amino)-6-methylquinazolin-2-yl)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of 1-oxide

[0560] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 479.2 [M+H] + . 1 H NMR (600MHz, CD3OD) δ8.01(dd,J=7.6,3.9Hz,1H),7.78(d,J=7.4Hz,1H),7.65(s,0.5H),7.61(s,0.5H),7.57(dd,J=8.5,5.3Hz ,1H),7.44(dd,J=11.9,7.6Hz,1H),7.37(t,J=8.7Hz,1H),7.31(d,J=8.6Hz,1H),5.42(d,J=15.0Hz,1H),5.01(s,1H),4.79(d,J =14.8Hz,1H),4.69(s,1H),4.44(d,J=41.1Hz,1H),3.95(s,1H),3.60(dd,J=14.6,2.0Hz,1H),3.56–3.46(m,1H),3.38–3.34(m ,2H),3.07–2.98(m,2H),2.37(d,J=6.6Hz,3H),2.27(s,1H),0.52(dd,J=6.1,4.0Hz,1H),0.46–0.40(m,1H),0.29–0.19(m,2H).

[0561] Example 4-15: 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-5,6-dimethylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0562] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 493.23 [M+H] +; 1H NMR (600MHz, CD3OD) δ8.04(d,J=7.7Hz,1H),7.87(d,J=7.4Hz,1H),7.60(t,J=7.2Hz,1H),7.48(t,J=7.4Hz,1H ),7.34(d,J=8.5Hz,1H),7.20(d,J=8.5Hz,1H),5.46(d,J=14.8Hz,1H),5.02(s,1H),4.83(d,J=15.2Hz,1H),4. 72–4.49(m,4H),4.08(d,J=13.7Hz,1H),3.97(d,J=13.4Hz,2H),3.63(d,J=15.9Hz,1H),3.57–3.47(m,1H),2.6 6(s,3H),2.33(s,3H),2.28(dd,J=14.6,11.0Hz,1H),0.61–0.50(m,1H),0.50–0.39(m,1H),0.33–0.18(m,2H).

[0563] Example 4-16: 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-6-(difluoromethyl)quinazolin-2-yl)-1-(cyclobutylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0564] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 529.21 [M+H] + , 1 H NMR(600MHz,DMSO-d6)δ8.31(s,1H),8.20(d,J=25.8Hz,1H),7.92–7.79(m,2H),7.61(dd,J=37.4,7.4Hz ,2H),7.41(dd,J=59.4,16.6Hz,2H),7.00(t,J=56.2Hz,1H),5.36(d,J=13.6Hz,1H),4.97(dd,J=20.9,13 .5Hz,1H),4.79(d,J=12.5Hz,1H),4.54–4.27(m,4H),4.07–3.82(m,3H),3.80–3.52(m,2H),3.42(d,J=21 .9Hz,1H),2.07–1.90(m,2H),1.69(d,J=36.6Hz,2H),1.53(d,J=9.2Hz,1H),1.42(dd,J=18.1,8.9Hz,1H)

[0565] Example 4-17: 4-(4-(3-aminoazetidin-1-yl)-6-(difluoromethyl)quinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine -1-oxide

[0566] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 485.18 [M+H] +; 1 H NMR(600MHz,Methanol-d4)δ8.04(d,J=7.8Hz,1H),7.82(dd,J=14.8,4.8Hz,2H ),7.73–7.57(m,2H),7.48(t,J=7.7Hz,2H),6.77(t,J=56.3Hz,1H),5.42(d,J= 15.0Hz,1H),5.06(s,1H),4.81(d,J=15.2Hz,3H),4.10(dd,J=139.9,32.5Hz,4 H),3.68–3.42(m,2H),2.34–2.23(m,1H),0.64–0.40(m,2H),0.33–0.16(m,2H).

[0567] Example 4-19: 4-(4-((1S,4S)-2,5-diazabicyclo[2.2.1]heptane-2-yl)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0568] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 475.22 [M+H] + , 1H NMR (600MHz, CDCl3) δ8.08(d,J=8.2Hz,1H),7.49(dd,J=15.6,7.7Hz,1H),7.44(d,J=14.0 Hz,2H),7.41–7.36(m,3H),5.39(d,J=13.3Hz,1H),5.22(s,1H),4.99(s,1H),4.86(d,J=1 4.8Hz,1H),4.35(s,1H),4.14–4.01(m,4H),3.56–3.42(m,3H),2.37(s,3H),2.30(s,1H), 2.20–2.08(m,2H),1.91(s,1H),0.64–0.57(m,1H),0.49–0.44(m,1H),0.32–0.22(m,2H).

[0569] Example 4-21: 1-(4-(3-aminoazetidin-1-yl)-2-(1-(cyclopropylimino)-1-oxido-1,2,3,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of 6-(5H)-yl)-7,8-dihydropyrido[4,3-d]pyrimidin-2,2,2-trifluoroethane-1-one

[0570] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 536.20 [M+H] +; 1 H NMR(600MHz,CD3OD)δ8.02(d,J=7.3Hz,1H),7.71(d,J=7.4Hz,1H),7.59(t,J=7.4Hz,1H), 7.48(t,J=7.5Hz,1H),5.27(d,J=14.9Hz,1H),4.89(s,1H),4.75(d,J=15.0Hz,1H),4.63–4 .28(m,4H),4.06–3.68(m,6H),3.54(d,J=14.7Hz,1H),3.49–3.37(m,1H),2.80–2.57(m,2 H),2.27(s,1H),0.53(ddd,J=10.2,6.5,4.6Hz,1H),0.48–0.38(m,1H),0.34–0.15(m,2H).

[0571] Example 4-22: 4-(4-(3-amino-4-fluoropyrrolidin-1-yl)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0572] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 481.21 [M+H] +; 1 H NMR(600MHz,CD3OD)δ8.01(dd,J=7.3,3.1Hz,1H),7.81(t,J=7.5Hz,1H),7.76(d,J=9.0Hz,1H),7 .58(dd,J=13.6,6.5Hz,1H),7.44(t,J=7.6Hz,1H),7.39–7.33(m,2H),5.49–5.34(m,1H),5.10–4. 89(m,2H),4.80(dd,J=14.7,7.3Hz,1H),4.35–4.00(m,3H),3.95(s,1H),3.86–3.72(m,1H),3.69 –3.46(m,3H),2.37(s,3H),2.28(s,1H),0.64–0.49(m,1H),0.49–0.37(m,1H),0.36–0.13(m,2H).

[0573] Example 4-23: 4-(4-((3R,4S)-3-amino-4-methylpyrrolidin-1-yl)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine 1-oxide

[0574] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 477.24 [M+H] + ; 1H NMR(600MHz,CD3OD)δ8.01(s,1H),7.81(d,J=7.5Hz,2H),7.58(s,1H),7.45(s,1H),7.35(d,J=2.0Hz, 2H),5.43(dd,J=14.9,6.6Hz,1H),5.01(s,1H),4.25–4.10(m,2H),3.95(s,1H),3.59(d,J=2.2Hz,4H), 3.18–3.05(m,1H),2.28(dd,J=6.8,3.4Hz,1H),2.07(tt,J=13.1,6.7Hz,1H),1.31(d,J=11.7Hz,3H), 1.20(t,J=6.8Hz,3H),0.92(s,1H),0.53(dt,J=8.8,4.9Hz,1H),0.47–0.42(m,1H),0.30–0.20(m,2H).

[0575] Example 4-24: 1-(Cyclopropylimino)-4-(4-(((3S,4S)-4-fluoropyrrolidin-3-yl)amino)-6-methylquinazolin-2-yl)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine Synthesis of -1-oxide

[0576] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 481.20 [M+H] + ; 1H NMR (600MHz, Methanol-d4) δ8.04–7.99(m,1H),7.88–7.83(m,1H),7.68(tt,J=1.9,0.9Hz,1H),7.60–7.52(m,1H),7.44(tt,J=7.9 ,2.9Hz,1H),7.38(dd,J=8.6,1.9Hz,1H),7.32(d,J=8.5Hz,1H),5.50–5.43(m,1H),5.09–5.06(m,2H),4.79(d,J=16.4Hz,2H),3.95 (s,1H),3.61–3.48(m,2H),3.23(dd,J=24.3,18.3Hz,1H),3.01(td,J=12.3,4.4Hz,1H),2.37(t,J=1.2Hz,3H),2.27(tt,J=7.0,3.6 Hz,1H),1.35–1.27(m,2H),0.56–0.50(m,1H),0.43(dddd,J=9.7,6.8,5.7,1.9Hz,1H),0.25(dddd,J=17.1,14.5,10.8,5.8Hz,2H).

[0577] Example 4-25: 1-(Cyclopropylimino)-4-(4-(((3R,4R)-4-fluoropyrrolidin-3-yl)amino)-6-methylquinazolin-2-yl)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine Synthesis of -1-oxide

[0578] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 481.18 [M+H] + ; 1H NMR (600MHz, Methanol-d4) δ8.01(d,J=7.6Hz,1H),7.88–7.83(m,1H),7.70–7.67(m,1H),7.60–7.52(m,1H),7.44(td,J=7.8, 3.6Hz,1H),7.37(dd,J=8.6,1.9Hz,1H),7.32(d,J=8.5Hz,1H),5.47(t,J=10.9Hz,1H),5.07(s,2H),4.80(t,J=14.2Hz,2H),3 .95(s,1H),3.61–3.48(m,2H),3.26–3.07(m,1H),3.00(td,J=12.7,4.4Hz,1H),2.37(t,J=1.1Hz,3H),2.27(dq,J=6.8,3.7Hz ,1H),1.38–1.11(m,2H),0.53(dddd,J=10.0,8.1,5.3,3.0Hz,1H),0.43(dtdd,J=8.9,6.8,4.7,1.9Hz,1H),0.31–0.14(m,2H).

[0579] Example 4-26: 1-(Cyclopropylimino)-4-(4-(((3S,4R)-4-fluoropyrrolidin-3-yl)amino)-6-methylquinazolin-2-yl)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0580] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 481.21 [M+H] +; 1H NMR (600MHz, CD3OD) δ8.02(d,J=7.7Hz,1H),7.77(d,J=7.0Hz,1H),7.74(s,1H),7.59(dt,J=14.7,7.5Hz,1H),7.45(t,J=7.6Hz,1H),7.3 9(dt,J=8.5,2.1Hz,1H),7.33(dd,J=8.5,3.6Hz,1H),5.43(d,J=15.1Hz,1H),5.35–5.18(m,1H),5.08(d,J=60.0Hz,2H),4.81(d,J=13.5H z,1H),3.97(s,1H),3.61(dd,J=14.6,1.5Hz,1H),3.57–3.48(m,1H),3.39(ddd,J=18.9,15.9,7.8Hz,2H),3.28(ddd,J=26.7,13.9,4.1H z,1H),3.07(dd,J=19.0,10.2Hz,1H),2.39(s,3H),2.28(dd,J=6.6,3.4Hz,1H),0.62–0.47(m,1H),0.48–0.37(m,1H),0.34–0.15(m,2H).

[0581] Example 4-27: 1-(Cyclopropylimino)-4-(4-((cis-4-fluoropyrrolidin-3-yl)amino)-6-methylquinazolin-2-yl)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine 1-oxide

[0582] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 481.21 [M+H] + ; 1H NMR(600MHz,CD3OD)δ8.03(d,J=7.7Hz,1H),7.78(d,J=6.8Hz,1H),7.74(s,1H),7.64– 7.56(m,1H),7.46(s,1H),7.40(d,J=8.5Hz,1H),7.36–7.31(m,1H),5.46(t,J=23.6Hz, 1H),3.98(s,1H),3.61(s,1H),3.50(d,J=33.6Hz,2H),3.38(dd,J=21.9,11.0Hz,2H), 3.10(dd,J=18.9,10.0Hz,1H),2.29(d,J=2.7Hz,1H),1.38–1.26(m,6H),0.94–0.84(m, 1H), 0.53 (s, 1H), 0.45 (dd, J=9.8, 4.9Hz, 1H), 0.26 (d, J=24.3Hz, 2H).

[0583] Example 4-28: 4-(4-(((R)-3-aminopyrrolidin-1-yl)-6-(difluoromethyl)quinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of 1-oxide

[0584] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 499.2 [M+H] + . 1 H NMR (600MHz, Methanol-d4) δ8.09(d,J=83.1Hz,2H),7.82(s,1H),7.54(d,J=87.1Hz,4H),6.78(t,J=55.4Hz,1H),5.45(s,1H),5.05 (s,1H),4.02(d,J=76.9Hz,4H),3.64(d,J=40.2Hz,4H),2.27(s,2H),1.91(s,1H),1.30(s,1H),0.49(d,J=53.9Hz,2H),0.26(s,2H).

[0585] Example 4-29: 4-(4-(((R)-3-aminopyrrolidin-1-yl)-6-(difluoromethyl)quinazolin-2-yl)-1-((2,2-difluoroethyl)imino)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine Synthesis of -1-oxide

[0586] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 523.13 [M+H] + ; 1 H NMR(600MHz,Methanol-d4)δ8.15(s,1H),7.97(d,J=7.8Hz,1H),7.82(d,J=7.5Hz,1H), 7.64–7.57(m,2H),7.50–7.42(m,2H),6.77(t,J=56.4Hz,1H),5.84(tt,J=56.5,4.1Hz,1 H),5.43(d,J=15.1Hz,1H),4.04(q,J=39.9,38.7Hz,4H),3.86–3.45(m,4H),3.24–3.14 (m,1H),2.93(d,J=15.0Hz,1H),2.27(s,1H),1.98(d,J=45.1Hz,1H),1.42–1.29(m,2H).

[0587] Example 4-30: 4-(4-((3-aminobicyclo[1.1.1]pentan-1-yl)amino)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine Synthesis of -1-oxide

[0588] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 475.24 [M+H] + ; 1 H NMR (600MHz, Methanol-d4) δ7.96(d,J=7.8Hz,1H),7.80(d,J=7.5Hz,1H),7.61(s,1H),7.50(t,J=7.5Hz,1 H),7.36(t,J=7.7Hz,1H),7.30(t,J=6.8Hz,2H),5.40(d,J=14.9Hz,1H),4.99(s,1H),4.77(d,J=15.0Hz,1 H),3.98(s,1H),3.65–3.59(m,1H),3.44(t,J=13.0Hz,1H),3.31(d,J=2.9Hz,1H),2.31(s,3H),2.23(q,J= 9.5Hz, 6H), 0.52 (dt, J=10.1, 5.3Hz, 1H), 0.42 (ddd, J=11.6, 7.2, 4.7Hz, 1H), 0.26 (tt, J=11.1, 5.7Hz, 2H).

[0589] Example 4-31: 1-(Cyclopropylimino)-4-(4-(((3R,4R)-4-methoxypyrrolidin-3-yl)amino)-6-methylquinazolin-2-yl)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0590] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 493.23 [M+H] + , 1 H NMR (600MHz, Methanol-d4) δ8.02 (s, 1H), 7.86 (dd, J = 28.0, 6.3Hz, 1H), 7.72 ( d,J=4.5Hz,1H),7.59(s,1H),7.48–7.39(m,2H),7.37(s,1H),5.46(t,J=13.4 Hz,1H),5.06(s,1H),4.24(s,1H),3.99(s,1H),3.79(s,1H),3.64–3.40(m,10 H), 2.40 (s, 3H), 2.29 (s, 1H), 0.50 (d, J = 54.2Hz, 2H), 0.27 (d, J = 22.6Hz, 2H).

[0591] Example 4-32: 4-(4-(3-amino-3-(hydroxymethyl)azetidin-1-yl)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0592] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 479.22 [M+H] + .

[0593] Example 4-33: 4-((2-(1-(cyclopropylimino)-1-oxido-1,2,3,5-tetrahydro-4H-benzo[f][1,4]thiazolin-4-yl)-6-methylquinazolin-4-yl)amino)pyrrolidine-3-carbonitrile

[0594] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 488.22 [M+H] + ; 1H NMR(600MHz,CD3OD)δ8.05(d,J=7.6Hz,1H),7.86–7.79(m,2H),7.62(dd,J=14.2,7.2Hz,1H),7.48(t,J=7.5Hz ,1H),7.44–7.42(m,1H),7.37(dd,J=8.5,5.9Hz,1H),5.51(s,1H),5.47(d,J=14.8Hz,1H),5.09(s,2H),4.01( s,1H),3.69–3.63(m,1H),3.61(d,J=9.7Hz,1H),3.55(s,2H),3.46(d,J=7.2Hz,1H),3.14(s,1H),2.42(s,3H) ,2.30(dd,J=6.6,3.1Hz,1H),2.07–2.02(m,1H),0.55(d,J=4.5Hz,1H),0.47–0.43(m,1H),0.32–0.19(m,2H).

[0595] Example 4-34: 4-(4-((3S,5S)-3-amino-5-methylpiperidin-1-yl)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0596] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 491.25 [M+H] +; 1 H NMR (600MHz, CD3OD) δ8.03(d,J=7.7Hz,1H),7.83(d,J=7.4Hz,1H),7.62(t,J=10.9Hz,2H),7.46(t,J=7.4Hz,1H),7 .41(s,2H),5.44(d,J=14.9Hz,1H),5.03(s,1H),3.99(s,1H),3.83(dd,J=28.9,12.5Hz,2H),3.62(d,J=14.6Hz,2H) ,3.53(dd,J=22.5,11.6Hz,2H),3.34(s,1H),3.09–2.92(m,1H),2.41(s,3H),2.33–2.20(m,2H),1.84(t,J=13.1Hz ,1H),1.64(t,J=9.6Hz,1H),1.03(td,J=18.7,6.5Hz,3H),0.60–0.50(m,1H),0.50–0.40(m,1H),0.34–0.17(m,2H).

[0597] Example 4-37: 4-(4-((3S,4S)-3-amino-4-fluoropyrrolidin-1-yl)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of 1-oxide

[0598] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 481.2 [M+H] + . 1 H NMR(600MHz,Methanol-d4)δ8.01(s,1H),7.80(s,2H),7.58(s,1H),7.44(s,1H),7.37(s,2H),5.44(s,1H),5.10(s,1H),5.01(s,1H),4 .45-4.22(m,3H),4.09-3.96(m,2H),3.86-3.74(m,2H),3.59(s,2H),2.38(s,3H),2.28(s,1H),0.54(s,1H),0.45(s,1H),0.25(s,2H).

[0599] Example 4-38: 4-(4-(trans-4-amino-3-fluoropiperidin-1-yl)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine 1-oxide

[0600] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 495.23 [M+H] + ; 1H NMR (600MHz, CD3OD) δ8.04(d,J=7.7Hz,1H),7.82(d,J=6.9Hz,1H),7.61(s,1H),7.51(s,1H),7.48(d,J=7.5Hz ,1H),7.42(s,2H),5.51(s,1H),5.42(d,J=13.4Hz,1H),5.05(s,1H),4.63–4.47(m,1H),4.42(s,2H),4.14(dd ,J=25.2,12.9Hz,1H),4.00(s,1H),3.62(s,1H),3.54(d,J=11.5Hz,1H),3.23(s,1H),3.16–3.03(m,2H),2.40 (s,3H),2.29(s,1H),2.04(d,J=12.1Hz,1H),1.68–1.57(m,2H),0.59–0.51(m,1H),0.45(s,1H),0.24(s,2H).

[0601] Example 4-39: 4-(4-(((R)-3-aminopyrrolidin-1-yl)-6-methylquinazolin-2-yl)-1-((oxetan-2-ylmethyl)imino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of 1-oxide

[0602] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 493.2 [M+H] + .

[0603] Example 4-40: 4-(4-(((R)-3-aminopyrrolidin-1-yl)-6-methylquinazolin-2-yl)-1-((2,2,2-trifluoroethyl)imino)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine Synthesis of 1-oxide

[0604] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 505.20 [M+H] + ; 1H NMR (600MHz, Methanol-d4) δ7.94(d,J=7.8Hz,1H),7.79(d,J=7.5Hz,1H),7.76(s,1H),7.57(t d,J=7.5,3.1Hz,1H),7.40(t,J=7.6Hz,1H),7.32(s,2H),5.40(d,J=15.1Hz,1H),5.01(s,1H), 4.78(d,J=15.2Hz,1H),4.10–4.00(m,2H),3.94(s,2H),3.72–3.54(m,4H),3.43(dq,J=14.0,9 .4Hz,1H),3.18(s,1H),2.33(s,3H),2.21(p,J=7.3,6.8Hz,1H),1.89(dq,J=13.3,6.8Hz,1H).

[0605] Example 4-41: 4-(4-((3S,5R)-3-amino-5-fluoropiperidin-1-yl)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0606] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 495.23 [M+H] + , 1 H NMR(600MHz,Methanol-d4)δ7.98(t,J=6.9Hz,1H),7.84–7.79(m,1H),7.58(d,J=9.4Hz,2H),7.4 4–7.36(m,3H),5.38(dt,J=20.7,10.4Hz,1H),5.08–4.92(m,1H),4.83–4.78(m,1H),4.14–3.87(m ,3H),3.60(d,J=14.6Hz,1H),3.54–3.36(m,2H),3.26–3.16(m,1H),3.16–3.01(m,2H),2.40(d,J =14.5Hz,1H),2.38(s,3H),2.27(s,1H),1.81–1.68(m,1H),0.55–0.40(m,2H),0.30–0.19(m,2H).

[0607] Example 4-42: 1-(Cyclopropylimino)-4-(4-((((2S,4R)-4-fluoropyrrolidin-2-yl)methyl)amino)-6-methylquinazolin-2-yl)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0608] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 495.23 [M+H] + , 1 H NMR (600MHz, Methanol-d4) δ8.07–8.01(m,1H),7.82(t,J=7.5Hz,1H),7.68(s,1H),7.61(t,J=7.5Hz,1H),7.50–7.43(m ,2H),7.38(dd,J=8.5,1.8Hz,1H),5.47(ddd,J=26.7,12.3,6.7Hz,2H),4.95(d,J=34.6Hz,1H),4.27(ddd,J=30.3,18.4 ,6.6Hz,1H),4.15–3.90(m,3H),3.66–3.50(m,4H),3.23(q,J=7.3Hz,1H),2.63–2.51(m,1H),2.41(s,3H),2.32–2.25(m ,1H),2.11(ddd,J=37.4,26.1,11.3Hz,1H),0.47(ddd,J=24.9,19.1,14.2Hz,2H),0.27(ddd,J=24.9,14.3,5.3Hz,2H).

[0609] Example 4-43: 4-(4-(((R)-3-aminopyrrolidin-1-yl)-6-methylquinazolin-2-yl)-1-((tetrahydrofuran-3-yl)imino)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine Synthesis of 1-oxide

[0610] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 493.17 [M+H] + ; 1H NMR(600MHz,Methanol-d4)δ8.13–7.98(m,1H),7.97–7.84(m,2H),7.72–7.60(m,2H),7.60–7.44 (m,2H),5.51(t,J=16.5Hz,1H),5.11-4.90(m,2H),4.55–4.31(m,2H),4.29–4.03(m,4H),3.87(d t,J=15.5,7.9Hz,1H),3.78–3.60(m,4H),3.56(dd,J=8.5,4.9Hz,1H),3.48(s,1H),2.56(dd,J=1 3.6, 6.7Hz, 1H), 2.43 (s, 3H), 2.34 (dt, J=12.2, 5.5Hz, 1H), 2.13–1.89 (m, 1H), 1.88–1.65 (m, 1H).

[0611] Example 4-44: 1-(Cyclopropylimino)-4-(4-(((3S,5S)-5-fluoropiperidin-3-yl)amino)-6-methylquinazolin-2-yl)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine Synthesis of 1-oxide

[0612] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 495.19 [M+H] + ; 1H NMR (600MHz, Methanol-d4) δ8.00(t,J=7.0Hz,1H),7.88(dd,J=49.8,7.5Hz,1H),7.67–7.64(m,1H),7.58(dt,J=15.4,7.6Hz,1H),7.43(t ,J=7.7Hz,1H),7.35(dt,J=8.6,2.0Hz,1H),7.29(dd,J=8.5,5.9Hz,1H),5.56–5.35(m,1H),5.11–4.93(m,2H),4.76(q,J=19.6,18.0Hz,2H ),4.03–3.80(m,1H),3.62–3.46(m,2H),3.29–3.22(m,2H),2.86(ddd,J=37.6,14.1,3.2Hz,1H),2.66(t,J=11.7Hz,1H),2.35(s,3H),2.2 6(dp,J=10.9,4.4Hz,1H),1.95–1.67(m,1H),1.39–1.29(m,1H),0.51(ddd,J=10.3,6.4,3.2Hz,1H),0.46–0.39(m,1H),0.30–0.20(m,2H).

[0613] Example 4-45: 1-(Cyclopropylimino)-4-(4-(((5,5-difluoropiperidin-3-yl)amino)-6-methylquinazolin-2-yl)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine Synthesis of -1-oxide

[0614] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 513.16 [M+H] + ; 1H NMR (600MHz, Methanol-d4) δ8.04(dd,J=8.0,3.5Hz,1H),7.86(dd,J=45.2,7.5Hz,1H),7.67(d,J=2.6Hz,1H),7.65–7.56( m,1H),7.51–7.44(m,1H),7.40(dt,J=8.6,1.8Hz,1H),7.33(dd,J=8.6,4.1Hz,1H),5.59–5.39(m,1H),5.03(d,J=13.4Hz, 1H),4.81(d,J=15.6Hz,1H),4.07–3.90(m,1H),3.68–3.45(m,2H),3.22(d,J= 13.8Hz,2H),3.02–2.81(m,1H),2.71–2.55(m,1H),2.39(s,3H),2.28(tt,J=7. 2,3.8Hz,1H),2.05(d,J=5.4Hz,1H),1.63–1.60(m,1H),1.42–1.39(m,1H),0.5 4(h,J=4.1,3.7Hz,1H),0.45(ddd,J=11.5,9.1,5.7Hz,1H),0.32–0.22(m,2H).

[0615] Example 4-46: 1-(Cyclopropylimino)-4-(4-((3-fluoropiperidin-4-yl)amino)-6-methylquinazolin-2-yl)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0616] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 495.23 [M+H] +; 1H NMR (600MHz, CD3OD) δ8.03(d,J=7.7Hz,1H),7.83–7.70(m,2H),7.57(dd,J=14.4,7.1Hz,1H),7.46(t,J=7.5Hz,1H),7.38(d,J=8.4Hz,1H),7. 32(d,J=8.4Hz,1H),5.43(dd,J=14.8,6.8Hz,1H),4.96(d,J=49.1Hz,2H),4.81(d,J=14.1Hz,1H),4.63(d,J=30.3Hz,1H),3.96(s,1H),3.63( dd,J=12.0,2.5Hz,1H),3.58–3.46(m,1H),3.43–3.34(m,1H),3.20(dd,J=22.9,13.4Hz,1H),3.12–2.95(m,1H),2.88(dd,J=24.7,12.5Hz,1H ),2.39(s,3H),2.29(s,1H),2.11–1.99(m,1H),1.82(dd,J=36.2,11.7Hz,1H),0.53(s,1H),0.44(dt,J=11.5,6.6Hz,1H),0.32–0.16(m,2H).

[0617] Example 4-47: 4-((4-(4-(((R)-3-aminopyrrolidin-1-yl)-6-methylquinazolin-2-yl)-1-oxido-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine Synthesis of 1-(1-ylidene)amino)butyronitrile

[0618] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 490.18 [M+H] + ; 1H NMR (600MHz, Methanol-d4) δ7.96(dd,J=7.8,1.3Hz,1H),7.79(d,J=6.4Hz,2H),7.56(tdd,J=7.6,3.1,1.4Hz,1H),7.42(t ,J=7.7Hz,1H),7.34(d,J=1.9Hz,2H),5.41(d,J=15.1Hz,1H),4.99(s,1H),4.82–4.77(m,1H),4.15–3.86(m,4H),3.69(ddd d,J=20.2,15.1,11.4,4.9Hz,2H),3.64–3.49(m,2H),2.97(dt,J=12.6,6.3Hz,1H),2.80(dt,J=13.0,6.3Hz,1H),2.56(td ,J=7.0,3.3Hz,2H),2.35(s,3H),2.21(ddd,J=25.5,13.9,6.9Hz,1H),1.91(dt,J=13.2,6.5Hz,1H),1.79(p,J=6.7Hz,2H).

[0619] Example 4-48: 4-amino-1-(2-(1-(cyclopropylimino)-1-oxido-1,2,3,5-tetrahydro-4H-benzo[f][1,4]thiazepine Synthesis of 6-methylquinazolin-4-yl)pyrrolidine-3-carboxylic acid

[0620] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 507.2 [M+H] + . 1 H NMR(600MHz,DMSO-d6)δ7.91(s,1H),7.76(s,1H),7.72-7.78(m,2H),7.56(s,1H),7.44(s,1H),7.32–7.23(m,1H),5.27(s,1H),4.89 (s,1H),4.70(s,1H),4.04-3.80(m,8H),2.81-2.92(m,1H),2.31(s,3H),2.16(s,1H),0.38(d,J=19.4Hz,2H),0.14(d,J=42.9Hz,2H).

[0621] Example 4-49: 4-(4-(((R)-3-aminopyrrolidin-1-yl)-6-methylquinazolin-2-yl)-1-((oxetan-3-ylmethyl)imino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of 1-oxide

[0622] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 493.2 [M+H] + .

[0623] Example 4-50: 4-(4-(2,5-diazabicyclo[2.2.2]oct-2-yl)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0624] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 489.24 [M+H] + , 1 H NMR (600MHz, Methanol-d4) δ8.04–8.00(m,1H),7.79(d,J=7.2Hz,1H),7.65(s,1H),7.58(t,J=7.4Hz,1H),7.45(dd,J=12.1,7.3 Hz,1H),7.40(d,J=8.1Hz,2H),5.41(d,J=14.8Hz,1H),5.00(s,1H),4.81(d,J=15.0Hz,1H),4.74(s,1H),4.21(dd,J=18.7,11.6 Hz,1H),4.05(dd,J=16.7,11.8Hz,1H),3.97(s,1H),3.61(d,J=14.8Hz,1H),3.56–3.46(m,2H),3.40(s,1H),3.29(d,J=11.8Hz, 1H),2.38(d,J=9.2Hz,3H),2.28(s,2H),2.11–2.00(m,2H),1.91(dd,J=22.4,12.2Hz,1H),0.56–0.41(m,2H),0.29–0.20(m,2H).

[0625] Example 4-51: 4-(4-(((R)-3-aminopyrrolidin-1-yl)-6-methylquinazolin-2-yl)-1-((3-hydroxypropyl)imino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine 1-oxide

[0626] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 481.23 [M+H] + .1 H NMR(600MHz, Methanol-d4)δ7.98(d,J=7.8Hz,1H),7.81(d,J=9.2Hz,2H),7.60–7.54(m,1H),7.47–7 .41(m,1H),7.36(d,J=1.9Hz,2H),5.44(d,J=15.0Hz,1H),5.03(s,1H),4.83(d,J=15.2Hz,1H),4.23– 4.05(m,2H),4.04–3.89(m,2H),3.80–3.40(m,6H),2.99(dd,J=12.7,6.4Hz,1H),2.81(dt,J=12.3,6. 6Hz, 1H), 2.38 (s, 3H), 2.26 (dq, J=13.2, 6.8Hz, 1H), 1.94 (dt, J=13.2, 6.9Hz, 1H), 1.81–1.67 (m, 2H).

[0627] Example 4-52: 1-(Cyclopropylimino)-4-(6-methyl-4-((pyrrolidin-2-ylmethyl)amino)quinazolin-2-yl)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of 1-oxides.

[0628] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 477.2 [M+H] + . 1H NMR (600MHz, Methanol-d4) δ8.02(d,J=7.7Hz,1H),7.81(d,J=7.4Hz,1H),7.63(s,1H),7.58(t,J=7.1Hz,1H),7.45(t,J=7.5Hz,1 H),7.35(d,J=8.4Hz,1H),7.30(d,J=8.4Hz,1H),5.44(dd,J=14.0,10.0Hz,1H),5.02(s,1H),4.80(d,J=14.8Hz,1H),3.96(s,1H) ,3.70(s,1H),3.61(d,J=14.4Hz,1H),3.58–3.48(m,2H),3.09-3.03(m,1H),3.01–2.91(m,1H),2.37(s,3H),2.29(s,1H),2.03(s ,1H),1.95–1.81(m,2H),1.64(s,1H),0.90(dd,J=17.2,9.8Hz,1H),0.54(d,J=4.4Hz,1H),0.48–0.41(m,1H),0.31–0.22(m,2H).

[0629] Example 4-53: 1-(cyclopropylimino)-4-(4-(hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-6-methylquinazolin-2-yl)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine 1-oxide

[0630] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 489.24 [M+H] + ; 1H NMR(600MHz,CD3OD)δ8.04(d,J=7.8Hz,1H),7.82(d,J=7.7Hz,2H),7.62–7.57(m,1H), 7.47(t,J=7.6Hz,1H),7.41–7.36(m,2H),5.51(s,2H),5.44(d,J=14.6Hz,1H),4.16–4. 10(m,3H),4.07(s,1H),3.95–3.89(m,1H),3.61(d,J=15.0Hz,1H),3.55(d,J=10.9Hz,1 H),3.24–3.17(m,2H),3.11(s,1H),2.40(s,3H),2.29(s,1H),2.21(dd,J=14.5,6.8Hz, 1H), 1.99 (d, J = 3.8Hz, 1H), 1.94 (s, 2H), 0.57–0.52 (m, 1H), 0.48–0.42 (m, 1H), 0.31–0.21 (m, 2H).

[0631] Example 4-54: 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-5-methoxy-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0632] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 509.23 [M+H] +; 1H NMR (600MHz, CD3OD) δ8.04(d,J=7.8Hz,1H),7.89(d,J=7.5Hz,1H),7.60(t,J=7.4Hz,1H),7.47(t,J=7.5Hz,1H),7.29(d,J =8.0Hz,1H),6.52(d,J=8.1Hz,1H),5.47(d,J=14.9Hz,1H),5.16(s,1H),4.82(d,J=15.1Hz,1H),4.75–4.46(m,4H),4.06(d ,J=15.3Hz,1H),3.97(d,J=13.3Hz,2H),3.81(s,1H),3.63(d,J=15.2Hz,1H),3.54(s,1H),2.43(s,3H),2.29(s,1H),2.05( dd,J=12.2,6.4Hz,1H),1.62(s,1H),0.61–0.51(m,1H),0.45(dt,J=11.6,6.7Hz,1H),0.27(ddd,J=13.9,10.8,5.9Hz,2H).

[0633] Example 4-55: 4-(4-(3-amino-4-(trifluoromethyl)pyrrolidin-1-yl)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine 1-oxide

[0634] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 531.21 [M+H] + ; 1 H NMR(600MHz,CD3OD)δ8.05(d,J=5.7Hz,1H),7.80(d,J=7.6Hz,1H),7.61–7.57(m,1H),7 .50–7.46(m,2H),7.42(t,J=7.5Hz,2H),4.32(dd,J=12.7,6.0Hz,3H),3.88(dd,J=21.7, 8.4Hz,3H),3.66–3.57(m,3H),3.09(s,2H),2.41(s,3H),2.32–2.27(m,2H),2.05(dd,J= 12.7,6.5Hz,3H),1.62(s,3H),0.57–0.52(m,1H),0.48–0.42(m,1H),0.31–0.21(m,2H).

[0635] Example 4-56: 4-(4-(((R)-3-aminopyrrolidin-1-yl)-6-methylquinazolin-2-yl)-1-((3-hydroxy-3-methylbutyl)imino)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine Synthesis of 1-oxide

[0636] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 509.27 [M+H] + ; 1 H NMR (600MHz, Methanol-d4) δ7.91(dd,J=7.8,2.7Hz,1H),7.77(d,J=7.5Hz,1H),7.72(s,1H),7.53(td,J=7.4,4.3Hz,1H),7.36(dt,J= 9.6,4.7Hz,1H),7.33–7.26(m,2H),5.38(d,J=15.0Hz,1H),4.98(s,1H),4.78(d,J=15.5Hz,1H),4.05–3.96(m,2H),3.95–3.76(m,2H) ,3.56(dddd,J=34.6,25.7,13.0,4.6Hz,4H),3.03(dddd,J=12.2,9.4,6.1Hz,1H),2.85–2.69(m,1H),2.30(s,3H),2.16(dt,J=13.0,6. 4Hz,1H),1.83(dt,J=13.3,6.8Hz,1H),1.74(ddd,J=13.6,9.6,6.1Hz,1H),1.65(ddd,J=14.0,9.6,5.6Hz,1H),1.11(d,J=12.7Hz,6H).

[0637] Example 4-57: 3-(aminomethyl)-1-(2-(1-cyclopropylimino)-1-oxido-1,2,3,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of methyl 6-methylquinazolin-4-yl)azetidine-3-carboxylate

[0638] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 521.23 [M+H] + , 1H NMR (600MHz, Methanol-d4) δ8.01(d,J=7.5Hz,1H),7.79(d,J=7.4Hz,1H),7.58(t,J=7.3Hz,1H),7.46–7.42(m,2H),7.36– 7.32(m,2H),5.39(d,J=15.0Hz,1H),4.99(s,1H),4.77(d,J=15.0Hz,1H),4.68(dd,J=18.7,8.4Hz,2H),4.41(s,2H),3.92 (s,1H),3.59–3.55(m,1H),3.53–3.48(m,1H),3.36(d,J=11.5Hz,3H),3.25(s,2H ),2.34(d,J=4.3Hz,3H),2.29–2.26(m,1H),0.55–0.43(m,2H),0.28–0.22(m,2H).

[0639] Example 4-58: Synthesis of methyl (3S, 4R)-4-((2-(1-(cyclopropylimino)-1-oxido-1,2,3,5-tetrahydro-benzo[f][1,4]thiazopyridin-4-yl)-6-methylquinazolin-4-yl)amino)pyrrolidine-3-carboxylate

[0640] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 521.23 [M+H] + , 1 H NMR (600MHz, Methanol-d4) δ8.02(t,J=7.8Hz,1H),7.86(dd,J=22.6,7.4Hz,1H),7.69(d,J=4.7Hz,1H),7.60(d,J=7. 2Hz,1H),7.45(dd,J=16.0,7.9Hz,1H),7.39(d,J=8.5Hz,1H),7.36–7.30(m,1H),5.53–5.38(m,1H),5.06(d,J=45.8Hz ,2H),4.80(dd,J=28.2,15.4Hz,1H),3.95(s,1H),3.72(d,J=19.0Hz,3H),3.57(dd,J=20.3,17.2Hz,2H),3.49–3.40(m ,2H),3.30–3.20(m,1H),3.14–3.00(m,2H),2.39(s,3H),2.28(d,J=3.1Hz,1H),0.56–0.42(m,2H),0.31–0.21(m,2H).

[0641] Example 4-59: 4-(4-(3-(aminomethyl)-3-fluoroazetidin-1-yl)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine Synthesis of -1-oxide

[0642] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 481.20 [M+H] + ; 1 H NMR (600MHz, Methanol-d4) δ7.99(d,J=7.8Hz,1H),7.77(d,J=8.0Hz,1H),7.57(t,J=7.5Hz,1H),7.42(d,J=8.0Hz,2H),7.36–7 .29(m,2H),5.38(d,J=15.1Hz,1H),4.98(d,J=14.8Hz,1H),4.76(d,J=15.1Hz,1H),4.54(dddt,J=51.1,31.5,20.9,10.8Hz,3H) ,3.90(d,J=13.4Hz,1H),3.56(dt,J=14.8,2.8Hz,1H),3.49(ddd,J=14.5,11.1,3.0Hz,1H),3.14(d,J=22.2Hz,2H),2.35(d,J= 9.1Hz,1H),2.33(s,3H),2.26(dt,J=7.1,3.5Hz,1H),0.55–0.48(m,1H),0.42(ddd,J=11.5,9.1,5.7Hz,1H),0.29–0.19(m,2H).

[0643] Example 4-60: 4-(4-(3-(2-aminopropan-2-yl)azetidin-1-yl)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine 1-oxide

[0644] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 491.25 [M+H] + ; 1H NMR (600MHz, CD3OD) δ8.04(d,J=7.8Hz,1H),7.82(d,J=7.2Hz,1H),7.60(t,J=7.9Hz,1H),7.5 4(s,1H),7.47(d,J=7.4Hz,1H),7.40(d,J=8.6Hz,1H),7.35(d,J=8.6Hz,1H),4.57(d,J=36.7H z,3H),4.41(s,2H),3.57(dd,J=35.5,13.1Hz,3H),2.38(s,3H),2.04(d,J=8.2Hz,1H),1.32(s ,6H),0.92(t,J=7.0Hz,1H),0.55(d,J=4.7Hz,1H),0.49–0.42(m,2H),0.28(d,J=17.9Hz,1H).

[0645] Example 4-61: 4-(4-(((S)-3-aminopyrrolidin-1-yl)-6-methylquinazolin-2-yl)-1-((oxetan-2-ylmethyl)imino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine 1-oxide

[0646] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 493.23 [M+H] + , 1H NMR (600MHz, Methanol-d4) δ7.99–7.93(m,1H),7.82–7.75(m,2H),7.60–7.53(m,1H),7.41(dh,J=10.2,2.6Hz,1H),7.34(s,2H),5.39(d,J=15.1 Hz,1H),5.01(s,1H),4.95–4.88(m,1H),4.83(ddd,J=12.1,5.3,3.4Hz,1 H),4.66–4.59(m,1H),4.50(ddt,J=47.3,9.1,5.9Hz,1H),4.17–4.02(m, 3H),3.93(ddt,J=33.4,12.3,7.5Hz,1H),3.78–3.49(m,4H),3.09(ddd,J=26.6,13.1,5.0Hz,1H),2.90(ddd,J=19.2,13.1,5.7Hz,1H),2.64(dtd ,J=14.3,7.9,4.0Hz,1H),2.48(dddt,J=65.0,11.1,9.0,7.0Hz,1H),2.3 5(s,3H),2.23(dp,J=9.9,5.2,3.9Hz,1H),1.91(dt,J=13.3,6.8Hz,1H).

[0647] Example 4-62: 4-(4-((S)-3-aminopyrrolidin-1-yl)-6-(difluoromethyl)quinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0648] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 499.20 [M+H] + , 1H NMR(600MHz, Methanol-d4)δ8.16(s,1H),8.03(d,J=7.7Hz,1H),7.82(d,J=7.3Hz,1H),7.65–7.57(m,2 H),7.51–7.43(m,2H),6.78(t,J=56.4Hz,1H),5.45(d,J=14.9Hz,1H),5.06(s,1H),4.82(d,J=14.8Hz,1 H),4.11(dd,J=26.7,9.0Hz,2H),3.95(s,2H),3.79–3.67(m,2H),3.61(d,J=13.3Hz,1H),3.57–3.48(m ,1H),2.29(d,J=3.2Hz,2H),2.00–1.90(m,1H),0.56–0.42(m,2H),0.27(ddd,J=17.7,11.2,5.6Hz,2H).

[0649] Example 4-63: 4-(4-((S)-3-aminopyrrolidin-1-yl)-6-(difluoromethyl)quinazolin-2-yl)-1-((4,4,4-trifluoro-3-hydroxy-3-methylbutyl)imino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0650] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 599.21 [M+H] +; 1 H NMR (600MHz, CD3OD) δ8.16(s,1H),7.99(d,J=7.5Hz,1H),7.83(d,J=7.1Hz,1H),7.69–7.54(m,2H),7.52–7.39(m,2 H),6.78(t,J=54.0Hz,1H),5.43(t,J=16.2Hz,1H),5.07(s,1H),4.83(s,1H),4.28–4.04(m,2H),3.96(d,J=19.2Hz, 2H),3.83–3.67(m,2H),3.64(d,J=14.0Hz,1H),3.53(td,J=14.8,7.6Hz,1H),3.10(dd,J=9.7,6.0Hz,1H),2.91(s,1 H),2.28(s,1H),2.05–1.91(m,2H),1.86(ddd,J=20.8,15.8,14.3Hz,1H),1.83–1.67(m,1H),1.25(d,J=7.2Hz,3H).

[0651] Example 4-64: 4-(4-(((S)-3-aminopyrrolidin-1-yl)-6-methylquinazolin-2-yl)-1-((3-hydroxypropyl)imino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0652] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 481.23 [M+H] +; 1 H NMR (600MHz, CD3OD) δ7.97(d,J=7.7Hz,1H),7.80(d,J=8.5Hz,2H),7.57(t,J=5.5Hz,1H) ,7.43(t,J=7.5Hz,1H),7.35(s,2H),5.43(d,J=14.9Hz,1H),5.02(s,1H),4.82(d,J=15. 4Hz,1H),4.20–3.82(m,4H),3.75–3.47(m,6H),3.07–2.93(m,1H),2.87–2.71(m,1H),2. 37(s,3H),2.23(dd,J=12.1,5.8Hz,1H),1.89(dd,J=11.9,6.1Hz,1H),1.81–1.65(m,2H).

[0653] Example 4-65: 4-(4-(((S)-3-aminopyrrolidin-1-yl)-6-methylquinazolin-2-yl)-1-((2-(methylsulfonyl)ethyl)imino)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine Synthesis of 1-oxide

[0654] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 529.17 [M+H] + ; 1H NMR(600MHz,Methanol-d4)δ8.00–7.96(m,2H),7.82–7.78(m,2H),7.60–7.55(m,1H), 7.47–7.42(m,1H),7.41–7.32(m,1H),5.40(d,J=15.2Hz,1H),4.19–3.92(m,4H),3.74 (ddd,J=23.4,11.0,5.1Hz,2H),3.67–3.62(m,2H),3.60–3.52(m,2H),3.29–3.17(m,1 H),2.99(s,3H),2.37(s,3H),2.32–2.13(m,2H),1.92–2.08(m,2H),1.57–1.65(m,1H).

[0655] Example 4-66: 4-(4-(((S)-3-aminopyrrolidin-1-yl)-6-(difluoromethyl)quinazolin-2-yl)-1-((3-hydroxypropyl)imino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0656] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 517.21 [M+H] +; 1 H NMR (600MHz, CD3OD) δ8.17(s,1H),7.99(d,J=7.7Hz,1H),7.83(d,J=7.1Hz,1H),7.64(d,J=8.6Hz,1H),7.59 (s,1H),7.50(d,J=8.5Hz,1H),7.45(t,J=7.4Hz,1H),6.79(t,J=60.0Hz,1H),5.45(d,J=15.0Hz,1H),5.09( s,1H),4.84(s,2H),4.05(dd,J=87.4,28.2Hz,4H),3.84–3.58(m,4H),3.56–3.42(m,1H),3.02(ddd,J=18.7 ,13.7,7.0Hz,1H),2.82(d,J=5.9Hz,1H),2.25(d,J=33.5Hz,1H),1.96(d,J=5.1Hz,1H),1.81–1.68(m,2H).

[0657] Example 4-67: 4-(4-(((S)-3-aminopyrrolidin-1-yl)-6-methylquinazolin-2-yl)-1-((tetrahydrofuran-3-yl)imino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0658] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 493.23 [M+H] + , 1 H NMR (600MHz, Methanol-d4) δ7.97(dd,J=14.2,7.7Hz,1H),7.82–7.78(m,2H),7.58(t,J=7.0Hz,1H),7.43(dd,J=13.3,7.2Hz ,1H),7.34(s,2H),5.47–5.39(m,1H),5.01(s,1H),4.78(dd,J=48.6,15.1Hz,1H),4.07(ddd,J=16.6,13.6,5.3Hz,2H),3.99– 3.87(m,3H),3.79–3.73(m,1H),3.70(dd,J=14.5,7.8Hz,1H),3.65(t,J=9.0Hz,1H),3.58(ddd,J=20.6,8.1,3.9Hz,2H),3.55 –3.51(m,1H),3.50–3.46(m,1H),2.36(s,3H),2.22(dt,J=12.6,6.9Hz,1H),2.07–1.83(m,3H),1.76(dt,J=19.1,6.3Hz,1H).

[0659] Example 4-68: 1-(2-oxaspiro[3.3]heptane-6-yl)imino)-4-(4-(((S)-3-aminopyrrolidin-1-yl)-6-methylquinazolin-2-yl)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of 1-oxide

[0660] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 519.2 [M+H] + .

[0661] Example 4-69: 4-(4-(((S)-3-aminopyrrolidin-1-yl)-6-methylquinazolin-2-yl)-1-((1-methoxyprop-2-yl)imino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of 1-oxide

[0662] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 495.2 [M+H]+ . 1 H NMR(600MHz, Methanol-d4)δ7.96(d,J=7.2Hz,1H),7.78(d,J=7.0Hz,1H),7.76(s,1H),7.55(s,1H),7.39(d, J=5.8Hz,1H),7.32(s,2H),5.39(dd,J=32.7,14.8Hz,1H),5.06(d,J=15.2Hz,1H),5.00(s,1H),4.10–3.83(m ,4H),3.62(dd,J=26.8,16.3Hz,3H),3.51(dd,J=28.8,16.8Hz,2H),3.33(s,1H),3.28–3.22(m,1H),3.17(s, 2H), 2.34 (s, 3H), 2.19 (d, J = 5.8Hz, 1H), 1.85 (d, J = 5.4Hz, 1H), 1.13 (d, J = 6.4Hz, 2H), 1.01 (d, J = 6.2Hz, 2H).

[0663] Example 4-70: 4-(4-(((S)-3-aminopyrrolidin-1-yl)-6-methylquinazolin-2-yl)-1-(((tetrahydrofuran-2-yl)methyl)imino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of 1-oxide

[0664] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 507.2 [M+H] + . 1H NMR (600MHz, Methanol-d4) δ7.94(d,J=7.6Hz,1H),7.78(d,J=11.0Hz,2H),7.55(d,J=2.8Hz,1H),7.39(t,J=7.5Hz,1H),7.33(s,2H),5.38(dd,J=14.1 ,7.8Hz,1H),4.99(s,1H),4.94(d,J=15.1Hz,1H),4.10–3.99(m,3H),3.99– 3.96(m,0.5H),3.93(dt,J=12.3,6.2Hz,1H),3.87-3.82(m,1H),3.74–3.71( m,0.5H),3.68(t,J=6.7Hz,1H),3.63(t,J=8.5Hz,2H),3.60–3.49(m,2H),2 .98(dd,J=12.5,5.5Hz,0.5H),2.90(dd,J=12.4,4.8Hz,0.5H),2.69(dd,J=1 4.7,9.3Hz,1H),2.34(s,3H),2.25–2.16(m,1H),2.02–1.94(m,1H),1.92–1 .79(m,3H),1.67(td,J=15.3,7.4Hz,0.5H),1.59(td,J=14.6,7.5Hz,0.5H).

[0665] Example 4-71: 4-(4-(((S)-3-aminopyrrolidin-1-yl)-6-methylquinazolin-2-yl)-1-((3-methoxypropyl)imino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0666] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 495.25 [M+H] +; 1H NMR (600MHz, CD3OD) δ7.95(d,J=7.7Hz,1H),7.80(d,J=6.4Hz,2H),7.61–7.52(m,1H),7.42(t,J =7.5Hz,1H),7.34(s,2H),5.42(d,J=14.9Hz,1H),5.01(s,1H),4.80(d,J=14.7Hz,2H),4.16–3. 81(m,4H),3.74–3.38(m,6H),3.33(dt,J=3.1,1.6Hz,2H),2.94(d,J=6.2Hz,1H),2.84–2.71(m, 1H), 2.36 (s, 3H), 2.22 (dt, J=11.9, 5.9Hz, 1H), 1.88 (dd, J=12.1, 6.1Hz, 1H), 1.83–1.66 (m, 2H).

[0667] Example 4-72: 4-(4-(((S)-3-aminopyrrolidin-1-yl)-6-methylquinazolin-2-yl)-1-(((tetrahydrofuran-3-yl)methyl)imino)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine Synthesis of 1-oxide

[0668] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 507.17 [M+H] + ; 1H NMR(600MHz, Methanol-d4)δ7.92(d,J=7.8Hz,1H),7.79–7.73(m,2H),7.53(td,J=7.5,3.0Hz,1H),7.38(ddd,J=9.7,7.0,2.1Hz,1 H),7.31(d,J=1.9Hz,2H),5.39(d,J=15.0Hz,1H),4.98(s,1H),4.80–4.61(m,1H),4.11–3.88(m,2H),3.89–3.72(m,2H),3.71–3.4 6(m,6H),2.86(ddd,J=26.0,12.1,7.3Hz,1H),2.63(ddd,J=30.6,11.9,7.2Hz,1H),2.38(dq,J=18.0,7.1Hz,1H),2.32(s,3H),2.1 9(dq,J=13.0,6.6Hz,1H),1.97(tdd,J=13.6,7.9,5.8Hz,1H),1.86(dq,J=13.2,6.8Hz,1H),1.63–1.50(m,1H),1.37–1.25(m,2H).

[0669] Example 4-73: 4-(4-(((R)-3-aminopyrrolidin-1-yl)-6-methylquinazolin-2-yl)-1-((3-methoxypropyl)imino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0670] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 495.25 [M+H] +; 1 H NMR (600MHz, CD3OD) δ7.98(d,J=7.8Hz,1H),7.84–7.75(m,2H),7.61–7.53(m,1H),7.44(t,J=7. 5Hz,1H),7.39–7.33(m,2H),5.43(d,J=14.9Hz,1H),5.02(s,1H),4.83(d,J=15.7Hz,1H),4.19– 3.71(m,5H),3.69–3.41(m,5H),3.04–2.91(m,1H),2.86–2.72(m,1H),2.53(d,J=3.2Hz,3H),2. 38(s,3H),2.29(dd,J=11.5,5.9Hz,1H),2.01(ddd,J=19.2,12.5,6.2Hz,1H),1.80–1.68(m,2H).

[0671] Example 4-74: 4-(4-((S)-3-aminopyrrolidin-1-yl)-6-(difluoromethyl)quinazolin-2-yl)-1-((oxetan-2-ylmethyl)imino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0672] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 529.21 [M+H] + , 1 H NMR(600MHz,Methanold4)δ8.15(s,1H),7.99(dd,J=17.5,10.0Hz,1H),7.80(t,J=10.0Hz,1H),7.61(t,J=17.5Hz,2H),7.51–7.40(m,2H), 6.78(t,J=56.4Hz,1H),5.38(dd,J=29.0,10.0Hz,1H),5.07(s,1H),4.93(dd,J=22.3,13.0Hz,1H),4.83(dd,J=13.0,6.1Hz,1H),4.67–4.6 1(m,1H),4.55(dt,J=9.1,5.9Hz,1H),4.07(d,J=6.1Hz,3H),3.96(d,J=35.8Hz,1H),3.76–3.59(m,3H),3.58–3.49(m,1H),3.11(ddd,J=27 .0,13.2,4.8Hz,1H),2.89(d,J=12.7Hz,1H),2.70–2.61(m,1H),2.55(ddd,J=10.9,9.1,7.1Hz,1H),2.30–2.20(m,1H),1.96–1.89(m,1H).

[0673] Example 4-75: 4-(4-(((3-aminooxetane-3-yl)methyl)amino)-5-bromo-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0674] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 557.13 / 559.13 [M+H] +; 1H NMR (600MHz, CD3OD) δ8.04(d,J=7.7Hz,1H),7.86(d,J=7.4Hz,1H),7.61(t,J=7.3Hz,1H),7.47(t,J=7.6Hz ,1H),7.40(d,J=8.6Hz,1H),7.31(d,J=8.4Hz,1H),5.44(d,J=14.9Hz,1H),5.04(s,1H),4.82(d,J=15.1Hz, 1H),4.64(d,J=5.8Hz,1H),4.59(dd,J=14.4,6.1Hz,3H),4.14–3.90(m,3H),3.63(d,J=15.7Hz,1H),3.52( d,J=11.8Hz,1H),2.40(s,3H),2.34–2.25(m,1H),0.60–0.49(m,1H),0.49–0.40(m,1H),0.34–0.19(m,2H).

[0675] Example 4-76: 4-(4-(3-aminoazetidin-1-yl)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine Synthesis of 1-oxide

[0676] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 449.2 [M+H] + . 1 H NMR (600MHz, CD3OD) δ8.02(d,J=7.8Hz,1H),7.79(d,J=7.4Hz,1H),7.59(t,J=7.1Hz,1H),7.46(dd,J=14.2 ,5.9Hz,2H),7.35(dt,J=20.4,5.1Hz,2H),5.41(d,J=15.0Hz,1H),4.99(s,1H),4.81–4.66(m,3H),4.15(dd ,J=21.2,16.5Hz,2H),3.96(ddd,J=12.5,7.3,5.3Hz,2H),3.59(dd,J=12.6,3.2Hz,1H),3.54–3.48(m,1H) ,2.35(s,3H),2.32–2.25(m,1H),0.54(ddd,J=10.3,6.5,4.6Hz,1H),0.48–0.42(m,1H),0.31–0.21(m,2H).

[0677] Example 4-77: 1-(Cyclopropylimino)-4-(4-(((3-hydroxyazetidin-3-yl)methyl)amino)-6-methylquinazolin-2-yl)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0678] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 479.2 [M+H] + . 1 H NMR (600MHz, CD3OD) δ8.02(d,J=7.5Hz,1H),7.86(d,J=7.3Hz,1H),7.66(s,1H),7.58(dd,J=19.6,12.5Hz,1H),7.45(t,J= 7.3Hz,1H),7.39(d,J=8.2Hz,1H),7.33(d,J=8.5Hz,1H),5.43(d,J=15.0Hz,1H),5.02(s,1H),4.81(d,J=14.8Hz,1H),4.02 (d,J=59.9Hz,2H),3.83(d,J=13.9Hz,1H),3.77(d,J=8.5Hz,1H),3.71(dd,J=16.0,8.9Hz,3H),3.61(d,J=14.4Hz,1H),3.5 0(s,1H),2.41–2.35(m,3H),2.32–2.25(m,1H),0.54(d,J=4.1Hz,1H),0.44(d,J=5.0Hz,1H),0.26(dd,J=13.2,7.1Hz,2H).

[0679] Example 4-78: 4-(4-((azetidin-3-ylmethyl)amino)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of 1-oxide

[0680] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 463.2 [M+H] + . 1H NMR (600MHz, CD3OD) δ7.97(dd,J=19.5,7.7Hz,1H),7.76(d,J=7.1Hz,1H),7.63(d,J=13.1Hz,1H),7.59–7.52(m, 1H),7.41(t,J=7.4Hz,1H),7.36–7.33(m,1H),7.31–7.27(m,1H),5.41(d,J=15.0Hz,1H),5.01(s,1H),4.75(t,J =19.0Hz,1H),3.97–3.87(m,3H),3.83–3.73(m,3H),3.59(t,J=13.5Hz,1H),3.54–3.46(m,1H),3.28(dt,J=14.8 ,7.5Hz,1H),2.34(d,J=13.5Hz,3H),2.30–2.23(m,2H),0.55–0.48(m,1H),0.45–0.38(m,1H),0.28–0.17(m,2H).

[0681] Example 4-79: 4-(4-(((R)-3-aminopyrrolidin-1-yl)-6-methylquinazolin-2-yl)-1-imino-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0682] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 423.19 [M+H] + . 1 H NMR (600MHz, DMSO-d6) δ7.92(d,J=6.1Hz,1H),7.75(s,1H),7.71(s,1H),7.52(s,1H),7.40(s,1H),7.32(d,J=7.3Hz,1H),7. 25(s,1H),5.11(d,J=41.7Hz,2H),4.62(s,2H),3.95-3.80(m,3H),3.70–3.38(m,4H),2.33(s,3H),2.04(s,1H),1.75(s,1H).

[0683] Example 4-80: 4-(4-(3-(aminomethyl)-3-(hydroxymethyl)azetidin-1-yl)-6-methylquinazolin-2-yl)-1-(cyclopropylimino)-2,3,4,5-tetrahydro-benzo[f][1,4]thiazepine Synthesis of -1-oxide

[0684] The synthesis method of this compound is the same as that of Example 4-2, ESI-MS (m / z): 493.22 [M+H] + , 1 H NMR (600MHz, Methanol-d4) δ8.04(d,J=7.7Hz,1H),7.80(d,J=7.4Hz,1H),7.60(t,J=7. 3Hz,1H),7.52(s,1H),7.48(t,J=7.6Hz,1H),7.38(dd,J=23.2,8.6Hz,2H),5.43(d,J=1 4.9Hz,1H),5.10–4.90(m,2H),4.35(d,J=33.7Hz,4H),3.95(s,3H),3.61–3.49(m,2H), 3.39(s,2H),2.37(s,3H),2.29(d,J=3.4Hz,1H),0.57–0.44(m,2H),0.31–0.22(m,2H).

[0685] The following are the efficacy tests and data of the compounds of the present invention.

[0686] Test Example 1: Antiviral detection test of small molecules against RSV virus A2 strain based on ELISA method

[0687] 1. Cell Lines

[0688] Cell line source: Nanjing Kebai Biotechnology Co., Ltd.

[0689] Cell type: Human laryngeal carcinoma epithelial Hep-2 cells

[0690] 2. Reagents and Consumables

[0691] 96-well culture plate (Cat. No. 3610, Corning Costar);

[0692] Fetal bovine serum (Cat. No. 10099-141, GIBCO);

[0693] DMEM medium (Cat. No. 11995500BT, GIBCO);

[0694] Envision 2104 microplate reader.

[0695] 3. Test methods

[0696] 1. Day 1: HEp-2 cells were plated at 1×10 4 The density of cells / well was plated into 96-well plates;

[0697] 2. Day 2:

[0698] A. Compound dilution: The compound was diluted to 9 μM in the first well, and then diluted 3-fold in a series of 10 dilutions;

[0699] B. Remove the HEp-2 cell plate prepared on day 1 from the incubator and discard the supernatant. Add 100 PFU / well / 50 μL of RSV A2 virus to each well and incubate in a 37°C, 5% CO2 incubator for 2 hours. Discard the supernatant and add 100 μL of serially diluted compound or DMEM containing 2% FBS to each well.

[0700] 3. Day 5:

[0701] A. Add fixative: Discard the serially diluted compound or maintenance solution in the wells and add 100 μL / well of fixative (4% paraformaldehyde). Incubate at room temperature for 10 minutes, then rinse once with 250 μL of PBS.

[0702] B. Add 100 μL / well of blocking solution and incubate in a 37°C, 5% CO2 incubator for 30 minutes;

[0703] C. After incubation, add detection antibody (Anti RSV Fpro) at 0.3 μg / 50 μL / well (6 μg / mL) and incubate in a 37°C, 5% CO2 incubator for 1 hour.

[0704] D. After incubation, add HRP secondary antibody (10,000-fold dilution with 0.2% BSA) and incubate in a 37°C, 5% CO2 incubator for 1 hour.

[0705] E. After incubation, wash the wells four times with PBST (250 μL / well), letting them sit for 5 minutes each time. After each wash, spin dry the wells.

[0706] F. Add 100 μL / well of colorimetric solution and incubate at room temperature in the dark for 20 min. Add 50 μL / well of stop solution and gently tap to mix. Detect absorbance on a microplate reader at channel 450.

[0707] 4. Data Analysis

[0708] SC: OD450 value of the sample (cells + test compound + virus)

[0709] CC: OD450 value of normal growth cell control (cells)

[0710] VC: OD450 value of virus growth control (cells + virus)

[0711] IC was calculated using Graphpad Prism 6 software and the formula XY-analysis / Nonlinear regression (curve fit) / Dose response-Inhibition / log (inhibition) vs. response-Variable slope (four parameters). 50 Curve fitting and calculation of IC 50 value.

[0712] 5. The experimental results show that the compounds of the present invention have a good inhibitory effect on RSV virus A2 strain in vitro; the inhibitory effect of the preferred compounds is better than that of the control compound AK0529 (i.e., AK0529 IC 50 / Compound IC of the present invention 50 >1), more preferably AK0529 IC 50 / Compound IC of the present invention 50 ≥2, more preferably AK0529 IC 50 / Compound IC of the present invention 50 ≥3, preferably AK0529 IC 50 / Compound IC of the present invention 50 ≥4, more preferably AK0529IC 50 / Compound IC of the present invention 50 ≥5, preferably AK0529 IC 50 / Compound IC of the present invention 50 ≥10, preferably AK0529 IC 50 / Compound IC of the present invention 50 ≥20. If 1<AK0529 IC 50 / Compound IC of the present invention 50 <2, or 2≤AK0529 IC 50 / Compound IC of the present invention 50 <3, or 3≤AK0529 IC 50 / Compound IC of the present invention 50 <4, or 4≤AK0529 IC 50 / Compound IC of the present invention 50 <5, or 5≤AK0529 IC 50 / Compound IC of the present invention 50 <10, or 10≤AK0529 IC 50 / Compound IC of the present invention 50 <20, or AK0529 IC 50 / Compound IC of the present invention 50≥20. IC of the exemplary compound against RSV virus A2 strain in vitro 50 As shown in Table 1 below.

[0713] Table 1 In vitro inhibitory activity of the compounds of the present invention against RSV A2 strain

[0714] Note: A stands for IC 50 <10nM, B represents IC 50 >10nΜ.

[0715] AK0529 is the compound of Example 61-1 in patent WO2013020993A1, and the preparation method refers to Example 61-1 of patent WO2013020993A1.

[0716] Test Example 2: Pharmacokinetic Experiment

[0717] The compound of the present invention for oral administration is dissolved in a suitable solvent to form a clear solution or suspension.

[0718] Administration method and dosage: 10 mg / kg or 20 mg / kg of the compound of the present invention was administered by oral gavage.

[0719] Number of animals: 3 ICR mice per group were administered orally.

[0720] Sample collection: 100 μL of blood was collected from the orbital vein of mice in the gavage group at 0.25 h, 0.5 h, 1 h, 2 h, 4 h, and 6 h after the end of administration (using pre-heparinized 100 μL capillary blood collection tubes) and placed in sodium heparin anticoagulant tubes. The blood was centrifuged at 3000 g for 10 min within 2 h to separate the mouse plasma samples. At 6 h after the gavage group, clean blood was collected and lung tissue was collected.

[0721] Sample processing: After the plasma and lung tissue homogenates were precipitated with methanol at a certain ratio, the supernatant was diluted with 50% methanol water at a certain ratio and loaded on the sample.

[0722] Sample detection: Detect drug concentration in plasma by LC / MS / MS method, draw drug-time curve, and calculate pharmacokinetic parameters (such as T 1 / 2 (h) / AUC 0-t ), describing the pharmacokinetic behavior of the compound in mice after administration.

[0723] Data processing: WinNonlin calculates pharmacokinetic parameters

[0724] The test results show that the compounds of the present invention have good pharmacokinetics in vivo and have drug potential. 1 / 2The drug concentration in lung tissue at 1h and 6h was significantly better than that of the control compound AK0529.

[0725] Table 2 Pharmacokinetic parameters of mice after oral administration of 20 mg / kg

[0726] Test Example 3: In vitro inhibition experiment on human potassium ion channel (hERG)

[0727] Experimental equipment: Electrophysiological detection was performed using a fully automatic patch clamp QPatch 48X (Sophion) device.

[0728] Experimental Procedure: Prepared cells are placed in the centrifuge of the Qpatch workstation. Cells are washed using multiple centrifugation / suspension cycles, and the cell culture medium is replaced with extracellular medium. An MTP-96 plate is removed and placed in the MTP source position. A QPlate chip is removed and placed in the Qplate source position. A robotic arm scans the barcodes on the MTP-96 plate and QPlate chip and grabs them to the measurement station. Intracellular and extracellular fluids are aspirated from the liquid reservoirs and applied to the intracellular fluid reservoir and cell and test substance reservoirs of the QPlate chip, respectively. At the measurement station, all measurement sites on the QPlate undergo initial quality control. This quality control process involves aspirating the cell suspension from the cell reservoir in the centrifuge, positioning the cells onto the chip wells using a pressure controller, establishing a high-resistance seal, and establishing whole-cell recording mode. Once a stable control current baseline is achieved, the test compound is aspirated from the test compound MTP-96 plate and applied to the cells at a concentration gradient. The current measured in compound-free external solution for each cell serves as its own control, and two independent replicates are measured. All Qpatch electrophysiological experiments were performed at 24°C.

[0729] Compound treatment: compound dilution gradient is 0.3, 1, 3, 10, 30 μM gradient

[0730] Data processing: IC was calculated using GraphPad Prism software. 50 value.

[0731] The test results show that the compound of the present invention has no significant inhibitory effect on hERG channels within the test concentration range of this test, indicating that the compound of the present invention has a low risk of cardiotoxicity. 50 IC larger than AK0529 50 , indicating that the hERG activity of the compounds of the present invention is significantly better than that of the control compound AK0529. Exemplary compounds are shown in Table 3 below.

[0732] Table 3

[0733] Test Example 4: In vivo pharmacodynamics experiment

[0734] The compound of the present invention is dissolved in a suitable solvent to form a clear solution or suspension for oral administration.

[0735] Animals: BALB / c mice, 6 weeks old, female.

[0736] Preparation of RSV infection model in vivo: Mice were inoculated with virus via intranasal drops on day 0, with an inoculation dose of 3.5 × 10 6 pfu.

[0737] Animal grouping: The animals were divided into a vehicle control group and a drug-treated group, with 5 animals in each group.

[0738] Administration and dosage: Oral administration of the compound of the present invention at 100 mg / kg, 50 mg / kg or the vehicle used for oral administration of the compound of the present invention. The administration volume is 10 mL / kg.

[0739] Experimental procedure: Mice were inoculated with virus via intranasal drops on day 0, with a dose of 3.5x10 6 pfu. Mice were treated with the compound of the invention for 5 consecutive days from day 0 to day 4 at a dose of 50 mg / kg, once daily, by oral gavage, in a volume of 10 mL / kg, with the first dose administered 1 hour before virus inoculation. Alternatively, mice were treated once on day 0 at a dose of 100 mg / kg, by oral gavage, in a volume of 10 mL / kg, with the first dose administered 1 hour before virus inoculation. Mice were euthanized on day 5, and lung tissue samples were collected. Animals were observed daily from day 0 to day 5, and body weight, health, and survival were recorded.

[0740] Sample processing: After lung removal, samples were quickly frozen in a 10-fold weight-to-volume HBSS solution (w:v (g:mL) = 1:10). Store at -80°C for plaque assay to detect viral load.

[0741] Sample testing: Plaque assay was used to detect the viral load in lung tissue.

[0742] *Preparation of HBSS solution: Add 25 μM HEPES, 0.21 mM sucrose, 5 μM Sodium L-glutamate, and 2 μL of triple antibody mixture containing 20 units of penicillin, 20 μg of streptomycin, and 0.05 μg of amphotericin B per mL of Hanks Buffer stock solution.

[0743] Experimental results: The viral load in lung tissue of the compound of the present invention was lower than that of the control compound AK0529 on day 5 after the first administration, and the administration frequency was less than that of the control compound AK0529, indicating that the compound of the present invention has a good antiviral effect in vivo. Exemplary compounds are shown in Table 4 below.

[0744] Table 4 Changes in RSV viral load in the lungs of mice after administration

[0745] Note: a: BID means twice-a-day dosing, b: QD means once-a-day dosing, c: This value is the lower limit of viral load detection.

[0746] The above describes the embodiments of the present invention. However, the present invention is not limited to the above embodiments. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present invention shall be included in the scope of protection of the present invention.

Claims

1. A compound as represented by formula (I) or its tautomer, stereoisomer, isotope derivative or pharmaceutically acceptable salt, which has the following structure: in, Cy1 is independently selected from the group consisting of absence, C 4-12 Carbocyclic group, 4-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; when Cy1 is absent, R 1 Connected to the heteroaromatic ring, R 1 are independently selected from: hydrogen, deuterium, halogen, oxo, hydroxy, amino, nitro, cyano, -R a1 、-OR a1 、-SR a1 、-N(R a1 )2, -S(O)2R a1 、-S(O)2N(R a1 )2. -S(O)R a1 、-S(O)(NR a1 )R a1 、-S(O)N(R a1 )2、-P(O)(OR a1 )2、-P(O)(N(R a1 )2)2、-SC(R a1 )3. -C(R a1 )2OR a1 ,-C(R a1 )2N(R a1 )2. -C(O)R a1 、-C(O)OR a1 、-C(O)N(R a1 )2. -C(O)OR a1 -OC(O)R a1 、-C(O)N(R a1 )OR a1 、-OC(O)R a1 、-OC(O)N(R a1 )2、-N(R a1 )C(O)OR a1 、-N(R a1 )C(O)R a1 、-N(R a1 )C(O)N(R a1 )2、-N(R a1 )S(O)2R a1 、-C(S)R a1 、-C(S)OR a1 、-C(S)N(R a1 )2. -C(S)N(R a1 )OR a1 、-OC(S)R a1 、-OC(S)N(R a1 )2; R a1 Independently selected from: hydrogen, deuterium, C 1-6 Alkyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1- 6 alkyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, optionally substituted with one or more R a2 replace; or two R attached to the same atom a1 Together with the atoms to which they are attached, they form deuterated, halogen, oxo, hydroxyl, amino, nitro, cyano, thiol, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-14 Aryl, 5-12 membered heteroaryl, one or more arbitrarily substituted C 3-12 Carbocyclyl, 3-12 membered heterocyclyl or 5-12 membered heteroaryl; R a2 are independently selected from: deuterium, halogen, oxo, hydroxyl, amino, nitro, cyano, thiol, C 1-6 Alkyl, C 1-6 Alkoxy; X 1 Independently selected from CR 2 or N; X is independently selected from CR 2 or N; R 2 are independently selected from hydrogen, deuterium, halogen, hydroxyl, amino, nitro, cyano, -OR b1 、-SR b1 、-N(R b1 )2, -S(O)2R b1 、-S(O)2N(R b1 )2. -S(O)R b1 、-S(O)(NR b1 )R b1 、-S(O)N(R b1 )2、-P(O)(OR b1 )2、-P(O)(N(R b1 )2)2、-C(R b1 )2(OR b1 )、-C(R b1 )2N(R b1 )2. -C(O)R b1 、-C(O)OR b1 、-C(O)N(R b1 )2、-C(O)N(R b1 )OR b1 、-OC(O)R b1 、-OC(O)N(R b1 )2、-N(R b1 )C(O)OR b1 、-N(R b1 )C(O)R b1 、-N(R b1 )C(O)N(R b1 )2、-N(R b1 )S(O)2R b1 , C 1-6 Alkyl, C 3-7 Carbocyclic group, 3-7 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1-6 Alkyl, C 3-7 Cycloalkyl, 3-7 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl is optionally substituted with one or more R b2 replace; R b1 Independently selected from: hydrogen, deuterium, C 1-6 Alkyl, C 3-7 carbocyclic group, 4-7 membered heterocyclic group, phenyl group, 5-6 membered heteroaryl group; the C 1-6 Alkyl, C 3-7 The carbocyclic group, 4-7 membered heterocyclic group, phenyl group or 5-6 membered heteroaryl group are optionally substituted with one or more selected from deuterium, halogen, oxo, hydroxyl, amino, nitro, cyano, mercapto, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocycloalkyl, C 6-14 substituted by a substituent of an aryl group or a 5-12-membered heteroaryl group; or two R attached to the same atom b1 Together with the atoms to which they are attached, they form deuterated, halogen, oxo, hydroxyl, amino, nitro, cyano, thiol, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, 3-10 membered heterocycloalkyl, C 6-14 Aryl, 5-12 membered heteroaryl, one or more arbitrarily substituted C 3-12 Carbocyclyl, 3-12 membered heterocyclyl or 5-12 membered heteroaryl; R b2 are independently selected from: deuterium, halogen, oxo, hydroxyl, amino, nitro, cyano, thiol, C 1-6 Alkyl, C 1-6 Alkoxy; m is independently selected from: 0, 1, 2, 3, 4; Q is independently selected from: deuterium, halogen, -R 3 、-OR 3 、-SR 3 、-N(R 3 )-C 0-6 Alkylene-R 3 、-N(R 3 )-C 0-6 Alkylene-N(R 3 )2, -S(O)2R 3 、-S(O)2N(R 3 )2. -S(O)R 3 、-S(O)(NR 3 )R 3 、-S(O)N(R 3 )2、-P(O)(OR 3 )2、-P(O)(N(R 3 )2)2、-C(R 3 )2(OR 3 )、-C(R 3 )2N(R 3 )2. -C(O)R 3 、-C(O)OR 3 、-C(O)N(R 3 )2、-C(O)N(R 3 )OR 3 、-OC(O)R 3 、-OC(O)N(R 3 )2、-N(R 3 )C(O)OR 3 、-N(R 3 )C(O)R 3 、-N(R 3 )C(O)N(R 3 )2、-N(R 3 )S(O)2R 3 The alkylene group is optionally replaced by one or more R c1 replace; R 3 Each independently selected from: hydrogen, deuterium, C 1-6 Alkyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1-6 Alkyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, optionally substituted with one or more R c2 replace; or two R attached to the same nitrogen atom 3 Together with the nitrogen atom to which they are attached, they form halogen, hydroxyl, amino, -C(O)NH2, -(CH2) 1-6 NH2, oxo, C 1-6 Alkyl, C 1-6 Alkoxy, oxetanylamino, C 1-6 One or more arbitrarily substituted 3-12 membered heterocyclic groups or 5-12 membered heteroaryl groups in the alkylpiperazinyl group; R c1 are independently selected from: deuterium, halogen, hydroxyl, amino, nitro, cyano, thiol, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, phenyl, 5-6 membered heteroaryl; R c2 Independently selected from: deuterium, oxo, halogen, hydroxyl, amino, cyano, -OR c3 、-SR c3 、-N(R c3 )2, -S(O)2R c3 、-S(O)2N(R c3 )2. -S(O)R c3 、-S(O)(NR c3 )R c3 、-P(O)(OR c3 )2、-P(O)(N(R c3 )2)2、-C(R c3 )2(OR c3 )、-C(R c3 )2N(R c3 )2. -C(O)R c3 、-C(O)OR c3 、-C(O)N(R c3 )2、-C(O)N(R c3 )OR c3 、-OC(O)R c3 、-OC(O)N(R c3 )2、-N(R c3 )C(O)OR c3 、-N(R c3 )C(O)R c3 、-N(R c3 )C(O)N(R c3 )2、-N(R c3 )C(O)R c3 N(R c3 )OC(O)R c3 、-N(R c3 )S(O)2R c3 , C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl; said C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl is optionally substituted with one or more R c4 replace; R c3 , R c4 are independently selected from: hydrogen, deuterium, oxo, halogen, hydroxyl, amino, C 1-18 Alkyl, C 1-6 Alkoxy, C 1-6 haloalkyl, optionally substituted with one or more hydroxyl groups 1-6 alkyl, optionally substituted by one or more amino groups 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-6 membered heteroaryl; Het has the following structure: in, When A or B and When connected, A and B are independently selected from -C(R d1 )-、-N-、 The "#" is a connection one end of When A or B does not When connected, A and B are independently selected from a bond, -C(R d1 )2-、-NR d1 -、-C(R d1 )2N(R d1 )-、-NR d1 C(R d1 )2-; R d1 are independently selected from: absence, bond, hydrogen, deuterium, hydroxyl, amino, nitro, cyano, C 1-6 Alkyl; or two R attached to the same carbon atom d1 Together they form an oxo group; When R d1 When it does not exist, That is Y is independently selected from -O-, -N(R d2 )-、-C(R d2 )2-, -S-, -C(O)-, -C(=N-OC 0-6 alkyl)-, -S(O)-, -S(O)2-, -S(O)(=NR d2 )-; R d2 Independently selected from: hydrogen, deuterium, halogen, hydroxyl, amino, nitro, cyano, -OR d3 、-SR d3 、-N(R d3 )2. -C(O)R d3 、-(C 1- 6-alkylene)-C(O)R d3 、-(C 1-6 Alkylene)-S(O)2R d3 、-C(O)OR d3 、-(C 1-6 Alkylene)-C(O)OR d3 、-C(O)N(R d3 )2、-(C 1-6 Alkylene)-C(O)N(R d3 )2. -C(O)-(C 1-6 Alkylene)-N(R d3 )2, -S(O)2R d3 、-S(O)2N(R d3 )2. -S(O)R d3 、-C(O)N(R d3 )OR d3 、-OC(O)R d3 、-OC(O)N(R d3 )2、-N(R d3 )C(O)OR d3 、-N(R d3 )C(O)R d3 、-N(R d3 )C(O)N(R d3 )2、-N(R d3 )S(O)2R d3 , C 1- 6 alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1-6 Alkyl, C 1- 6 alkylene, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, optionally substituted with one or more selected from deuterium, halogen, oxo, hydroxyl, amino, nitro, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 substituted by a substituent of an aryl group or a 5-12-membered heteroaryl group; R d3 are independently selected from: hydrogen, deuterium, halogen, hydroxyl, amino, nitro, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Carbocyclic group, 3-12 Heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, optionally substituted with one or more selected from deuterium, halogen, oxo, hydroxyl, amino, nitro, cyano, C 1-6 Alkyl, C 1-6 substituted by an alkoxy substituent; R 13 , R 14 , R 15 , R 16 are independently selected from: hydrogen, deuterium, oxo, halogen, hydroxyl, amino, imino, sulfinamide, nitro, cyano, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, optionally substituted with one or more R d4 Replace; when R 13 , R 14 When one of them is selected from oxo and imino, the other is absent; when R 15 , R 16 When one of them is selected from an oxo group and an imino group, the other one does not exist; or R 13 and R 14 Together with the carbon atoms to which they are attached, they form groups that are substituted by halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 One or more arbitrarily substituted C 3-12 Carbocyclic group or 3-12 membered heterocyclic group; or R 15 and R 16 Together with the carbon atoms to which they are attached, they form groups that are substituted by halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 One or more arbitrarily substituted C 3-12 Carbocyclic group or 3-12 membered heterocyclic group; R d4 are independently selected from: deuterium, halogen, oxo, hydroxy, amino, cyano, sulfonyl, urea, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl; said C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl is optionally substituted with one or more halogens; Cy2 is independently selected from: phenyl, 5-6 membered heterocyclyl, 5-6 membered heteroaryl; Cy3 is independently selected from: phenyl, 5-6 membered heterocyclyl, 5-6 membered heteroaryl; R 17 and R 18 are independently selected from: deuterium, halogen, hydroxyl, amino, cyano, nitro, carboxyl, oxo, -OR d5 、-SR d5 、-N(R d5 )2, -S(O)2R d5 、-S(O)2N(R d5 )2. -S(O)R d5 、-S(O)(NR d5 )R d5 、-S(O)N(R d5 )2、-P(O)(OR d5 )2、-P(O)(N(R d5 )2)2、-C(R d5 )2(OR d5 )、-C(R d5 )2N(R d5 )2. -C(O)R d5 、-C(O)OR d5 、-C(O)N(R d5 )2、-C(O)N(R d5 )OR d5 、-OC(O)R d5 、-OC(O)N(R d5 )2、-N(R d5 )C(O)OR d5 、-N(R d5 )C(O)R d5 、-N(R d5 )C(O)N(R d5 )2、-N(R d5 )S(O)2R d5 、-N(R d5 )S(O)2N(R d5 )2、-N(R d5 )S(O)2O(R d5 ), C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, optionally substituted with one or more selected from deuterium, halogen, oxo, hydroxyl, amino, cyano, carboxyl, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 substituted by a cycloalkyl substituent; R d5 Independently selected from: hydrogen, deuterium, halogen, hydroxyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl and 5-12 membered heteroaryl are optionally substituted by one or more substituents selected from deuterium, halogen, hydroxyl, amino, cyano and carboxyl; Z is independently selected from C, N; E is independently selected from: -C(R d6 )2-、-N(R d6 )-; R d6 are independently selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, amino, cyano, nitro, sulfenamide, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl; said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl may be optionally substituted by one or more substituents selected from deuterium, halogen, oxo, hydroxyl, amino, carboxyl, cyano; or two R groups attached to the same carbon atom may be substituted by one or more substituents selected from deuterium, halogen, oxo, hydroxyl, amino, carboxyl, cyano. d6 Together they form an oxo group, a thio group, or an imino group; or two R groups connected to the same carbon atom d6 Together with the carbon atoms to which they are attached, they form a C 3-15 Carbocyclic group, 3-15 membered heterocyclic group; n and q are independently selected from 0, 1, 2, 3, and 4; When multiple R a1 , R a2 , R b1 , R b2 , R c1 , R c2 , R c3 , R c4 , R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R 1 , R 3 , R 17 , R 18 When they appear simultaneously, each R a1 , each R a2 , each R b1 , each R b2 , each R c1 , each R c2 , each R c3 , each R d1 , each R d2 , each R d3 , each R d4 , each R d5 , each R d6 , each R 1 , each R 3 , each R 17 , each R 18 Can be the same or different.

2. The compound according to claim 1 or its tautomer, stereoisomer, isotope derivative or pharmaceutically acceptable salt thereof, characterized in that: Cy1 is independently selected from 4-6 membered heterocyclic group, phenyl group, 5-6 membered heteroaryl group Preferably, Cy1 is independently selected from 4-12 membered heterocyclic groups, C 5-12 Aryl; Preferably, Cy1 is independently selected from 5-6 membered heterocyclic group, phenyl; Preferably, Cy1 is independently selected from phenyl; Preferably, Cy1 is independently selected from a 5-6 membered heterocyclic group; the heteroatom in the heterocyclic group is selected from N or S; Preferably, Cy1 is selected from the following groups: Preferably, Selected from the following groups: Preferably, Selected from the following groups:

3. The compound according to any one of claims 1 to 2, or its tautomer, stereoisomer, isotope derivative or pharmaceutically acceptable salt thereof, characterized in that: R 1 are independently selected from: hydrogen, halogen, oxo, hydroxy, amino, nitro, cyano, -R a1 、-OR a1 、-SR a1 、-N(R a1 )2, -S(O)2R a1 、-S(O)2N(R a1 )2. -C(O)R a1 、-C(O)OR a1 、-C(O)N(R a1 )2. -C(O)OR a1 -OC(O)R a1 、-N(R a1 )C(O)R a1 ; Preferably, R 1 are independently selected from: hydrogen, halogen, oxo, hydroxy, amino, cyano, -R a1 、-C(O)R a1 、-C(O)OR a1 ; Preferably, R a1 Independently selected from: hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl; said C 1-6 Alkyl, C 3-6 The cycloalkyl group is optionally substituted with one or more R a2 replace; Preferably, wherein R a2 are independently selected from: deuterium, halogen, oxo, hydroxyl, amino, nitro, cyano, thiol, C 1-4 Alkyl, C 1- 4 alkoxy; Preferably, R a2 independently selected from halogen (e.g. fluorine, chlorine, bromine), hydroxyl; Preferably, R a2 Independently selected from fluorine, hydroxyl; Preferably, R a2 independently selected from fluorine; Preferably, R 1 are independently selected from: hydrogen, fluorine, chlorine, bromine, oxo, hydroxyl, amino, -R a1 、-OR a1 、-S(O)2R a1 、-C(O)R a1 、-C(O)OR a1 、-C(O)N(R a1 )2. -C(O)OR a1 -OC(O)R a1 ; R a1 Independently selected from: hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl; said C 1-6 Alkyl, C 3-6 The cycloalkyl group is optionally substituted with one or more R a2 Replacement; R a2 Independently selected from: fluorine, chlorine, bromine, oxo, hydroxyl, amino; Preferably, R 1 Independently selected from: hydrogen, halogen, oxo, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 1-4 Haloalkyl, C 1-4 Alkyl, -S(O)2C 1-4 Alkyl, -C(O)C 1-4 Alkyl, -C(O)C 1-4 Haloalkyl, -C(O)OC 1-4 Alkyl, -C(O)NHC 1-4 Alkyl, -C(O)O-(C 1-4 Alkyl)-OC(O)C 1-4 alkyl; Preferably, R 1 Independently selected from: C 1-2 Alkyl, C 1-2 Haloalkyl; Preferably, R 1 independently selected from: hydrogen, fluorine, chlorine, oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -CH2F, -CF2H, -CF3, -C(O)CH3, -C(O)CH2CH3, -S(O)2CH3, -CH2OH, -C(O)CF3, -C(O)CF2H, -C(O)OCH3, -C(O)OCH2CH3, -C(O)NHCH3, -C(O)O-CH(CH3)-OC(O)CH(CH3)2; Preferably, R 1 independently selected from methyl, -CF2H; Preferably, R 1 Independently selected from C 1-4 alkyl; Preferably, R 1 independently selected from methyl; Preferably, m is independently selected from: 0, 1, 2, 3; Preferably, m is independently selected from: 0, 1, 2; Preferably, m is independently selected from 1.

4. The compound according to any one of claims 1 to 3, or its tautomer, stereoisomer, isotope derivative or pharmaceutically acceptable salt thereof, characterized in that: X 1 is selected from N, and X is selected from N; Preferably, X 1 Selected from N; Preferably, X is selected from N; Preferably, X is selected from CR 2 ; Preferably, R 2 independently selected from halogen (e.g. fluorine, chlorine, bromine, preferably fluorine), cyano; Preferably, X is selected from CR 2 ; R 2 Independently selected from fluoro, cyano, methyl.

5. The compound according to any one of claims 1 to 4, or its tautomer, stereoisomer, isotope derivative or pharmaceutically acceptable salt thereof, characterized in that: Q is independently selected from: -R 3 、-N(R 3 )-C 0-6 Alkylene-R 3 、-N(R 3 )-C 0-6 Alkylene-N(R 3 )2、-N(R 3 )C(O)OR 3 、-N(R 3 )C(O)R 3 、-N(R 3 )C(O)N(R 3 )2、-N(R 3 )S(O)2R 3 The alkylene group is optionally replaced by one or more R c1 replace; Preferably, Q is independently selected from: -R 3 、-N(R 3 )-C 0-6 Alkylene-R 3 、-N(R 3 )-C 0-6 Alkylene-N(R 3 )2; the alkylene group is optionally replaced by one or more R c1 replace; Preferably, Q is independently selected from: -R 3 、-NH-C 0-4 Alkylene-R 3 、-NH-C 0-4 Alkylene-NHR 3 The alkylene group is optionally replaced by one or more R c1 replace; Preferably, R 3 Independently selected from: hydrogen, C 1-6 Alkyl, C 3-7 carbocyclic group, 3-7 membered heterocyclic group, phenyl group, 5-6 membered heteroaryl group; the C 1-6 Alkyl, C 3-7 Carbocyclic group, 3-7 membered heterocyclic group, phenyl group, 5-6 membered heteroaryl group are optionally substituted with one or more R c2 replace; or two R attached to the same nitrogen atom 3 Together with the nitrogen atom to which they are attached, they form halogen, hydroxyl, amino, -C(O)NH2, -(CH2) 1-4 NH2, oxo, C 1-4 Alkyl, C 1-4 Alkoxy, oxetanylamino, C 1-4 One or more optionally substituted 3-7 membered heterocyclic groups or 5-6 membered heteroaryl groups in the alkylpiperazinyl group; Preferably, R 3 Independently selected from: hydrogen, C 1-6 Alkyl, C 3-12 Carbocyclic group, 3-12 membered heterocyclic group; 1-6 Alkyl, C 3-12 Carbocyclic group, The 3-12 membered heterocyclic group is c2 replace; Preferably, R 3 Independently selected from: hydrogen, C 1-6 Alkyl, C 3-10 Carbocyclic group, 3-10 membered heterocyclic group; said C 1-6 Alkyl, C 3-10 Carbocyclic group, 3-10 membered heterocyclic group is replaced by one or more R c2 replace; Preferably, R 3 Independently selected from: hydrogen, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, 6-9 membered heterospirocyclic group; the C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, 6-9 membered heterospirocyclic group are optionally substituted with one or more R c2 replace; Preferably, R 3 Independently selected from: hydrogen, C 1-4 Alkyl, C 4-6 Cycloalkyl, 4-6 membered heterocycloalkyl, 7 membered heterospirocyclic group; the heteroatom in the 4-6 membered heterocycloalkyl, 7 membered heterospirocyclic group is selected from N or O, and the number of heteroatoms is 1 or 2; the C 1-4 Alkyl, C 4-6 Cycloalkyl, 4-6 membered heterocycloalkyl, 7 membered heterospirocycloalkyl are optionally substituted with one or more R c2 replace; Preferably, R 3 Independently selected from: hydrogen, C 1-4 alkyl, 4-6 membered heterocycloalkyl, 7 membered heterospirocycloalkyl; the heteroatom in the 4-6 membered heterocycloalkyl and 7 membered heterospirocycloalkyl is selected from N or O, and the number of heteroatoms is 1; the C 1-4 Alkyl, 4-6 membered heterocycloalkyl, 7 membered heterospirocyclic group are optionally substituted with one or more R c2 replace; Preferably, R 3 are independently selected from: hydrogen, methyl, ethyl, n-propyl, isopropyl, The above groups are optionally replaced by one or more R c2 replace; Preferably, R c1 are independently selected from: deuterium, halogen, hydroxyl, amino, nitro, cyano, thiol, C 1-4 Alkyl, C 1-4 Alkoxy; Preferably, R c1 Independently selected from: fluorine, chlorine, bromine, hydroxy, amino, methyl, ethyl, n-propyl, isopropyl; Preferably, R c1 independently selected from: fluorine; Preferably, R c2 Independently selected from: deuterium, oxo, halogen, hydroxyl, amino, -OR c3 、-N(R c3 )2. -C(R c3 )2(OR c3 )、-C(R c3 )2N(R c3 )2. -C(O)R c3 、-C(O)OR c3 、-C(O)N(R c3 )2、-C(O)N(R c3 )OR c3 、-OC(O)R c3 、-OC(O)N(R c3 )2、-N(R c3 )C(O)OR c3 、-N(R c3 )C(O)R c3 、-N(R c3 )C(O)N(R c3 )2、-N(R c3 )S(O)2R c3 , C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, phenyl, 5-6 membered heteroaryl; the C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, phenyl, 5-6 membered heteroaryl, optionally substituted with one or more R c4 replace; Preferably, R c2 Independently selected from: halogen, hydroxy, amino, C 1-4 Alkyl; the C 1-4 The alkyl group is optionally substituted with one or more R c4 replace; Preferably, R c2 Independently selected from: halogen (e.g., fluorine, chlorine, bromine), hydroxyl, amino, methyl, ethyl, n-propyl, isopropyl; the above groups are optionally substituted by one or more substituents selected from halogen (e.g., fluorine, chlorine, bromine), hydroxyl, amino; Preferably, R c3 , R c4 are independently selected from: hydrogen, halogen, hydroxyl, amino, C 1-6 Alkyl, C 1-6 haloalkyl, optionally substituted with one or more hydroxyl groups 1-6 alkyl; Preferably, R c3 Independently selected from: hydrogen, methyl, ethyl, n-propyl, isopropyl; Preferably, R c4 Independently selected from: halogen, hydroxyl, amino; Preferably, R c4 Independently selected from: hydroxyl, amino; Preferably, Q is independently selected from: -R 3 、-N(R 3 )-C 0-6 Alkylene-R 3 、-N(R 3 )-C 0-6 Alkylene-N(R 3 )2; the alkylene group is optionally substituted by one or more selected from halogen, hydroxyl, amino, C 1-6 substituted by an alkyl substituent; R 3 Each independently selected from: hydrogen, C 1-6 Alkyl, C 3-10 Carbocyclic group, 3-10 membered heterocyclic group; said C 1-6 Alkyl, C 3-10 Carbocyclic group, 3-10 membered heterocyclic group optionally with one or more R c2 replace; R c2 Independently selected from: halogen, hydroxy, amino, C 1-6 Alkyl; the C 1-6 The alkyl group is optionally substituted with one or more substituents selected from halogen, hydroxyl, and amino; Preferably, Q is independently selected from: C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -NH-C 0-6 Alkylene-R 3 、-NH-C 0-6 Alkylene-N(R 3 )2; the alkylene group is optionally substituted by one or more substituents selected from halogen, hydroxy, amino, methyl, and ethyl; R 3 Each independently selected from: hydrogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, 6-9 membered heterospirocyclic group; the C 1-6 Alkyl, C 3- 6-membered cycloalkyl, 3-6-membered heterocyclic group, 6-9-membered heterospirocyclic group are optionally substituted with one or more R c2 replace; R c2 Independently selected from: halogen, hydroxy, amino, C 1-6 Alkyl, amino substituted C 1-6 Alkyl, hydroxy substituted C 1-6 alkyl; Preferably, Q is independently selected from: C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -NH-C 0-4 Alkylene-C 3-6 Cycloalkyl, -NH-C 0-4 Alkylene-3-6 membered heterocyclic group, -NH-C 0-4 Alkylene-7-membered heterospirocyclic group, -NH-C 0-4 Alkylene -NH2, -NH-C 0-4 Alkylene-NH(C 1-4 Alkyl), -NH-C 0-4 Alkylene-N(C 1-4 alkyl)2; the alkylene group is optionally substituted by one or more substituents selected from halogen (eg, fluorine, chlorine, bromine); the C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, 7 membered heterospirocyclic group are optionally substituted by one or more selected from halogen (e.g., fluorine, chlorine, bromine), hydroxyl, amino, C 1-4 Alkyl, amino substituted C 1-4 Alkyl, hydroxy substituted C 1-4 substituted by an alkyl substituent; Preferably, Q is independently selected from: 3-10 membered nitrogen-containing heterocyclic group (preferably 3-8 membered nitrogen-containing heterocyclic group), -NH-C 0-2 Alkylene-C 3-6 Cycloalkyl-NH2, -NH-C 0-2 Alkylene-3-6 membered heterocyclic group; Connected to the nitrogen atom in a 3-10-membered nitrogen-containing heterocyclic group, is a connection site; the heteroatom in the 3-6 membered heterocyclic group is selected from N or O, and the number of heteroatoms is 1 or 2; the 3-10 membered nitrogen-containing heterocyclic group Base, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, optionally substituted by one or more selected from halogen (e.g., fluorine, chlorine, bromine), hydroxyl, amino, -C 1-2 Alkyl-NH2, -C 1-2 Alkyl-OH, -C(O)OC 1-2 substituted by an alkyl substituent; Preferably, Q is independently selected from: 3-7 membered nitrogen-containing heterocyclic group, -NH-C 0-2 Alkylene-C 3-6 Cycloalkyl-NH2, -NH-C 0-2 Alkylene-3-6 membered heterocyclic group; Connected to the nitrogen atom in the 3-7 membered nitrogen-containing heterocyclic group, is a connection site; the heteroatom in the 3-6 membered heterocyclic group is selected from N or O, and the number of heteroatoms is 1 or 2; the 3-7 membered nitrogen-containing heterocyclic group, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, optionally substituted by one or more selected from halogen (e.g., fluorine, chlorine, bromine), hydroxyl, amino, -C 1-2 Alkyl-NH2, -C 1-2 Alkyl-OH, -C(O)OC 1-2 substituted by an alkyl substituent; Preferably, Q is independently selected from: 4-6 membered nitrogen-containing heterocyclic group, -NH-C 4-5 Cycloalkyl-NH2, -NH-C 0-2 Alkylene-4-6 membered heterocyclic group; Connected to the nitrogen atom in a 4-6-membered nitrogen-containing heterocyclic group, is a connection site; the heteroatom in the 4-6 membered heterocyclic group is selected from N or O, and the number of heteroatoms is 1 or 2; the 4-6 membered nitrogen-containing heterocyclic group and the 4-6 membered heterocyclic group are optionally substituted by one or more selected from halogen (e.g., fluorine, chlorine, bromine), hydroxyl, amino, -C 1-2 Alkyl-NH2, -C 1-2 Alkyl-OH, -C(O)OC 1-2 substituted by an alkyl substituent; Preferably, Q is independently selected from: 4-6 membered nitrogen-containing heterocyclic group, -NH-C 4-5 Cycloalkyl-NH2, -NH-C 0-2 Alkylene-4-6 membered heterocyclic group; Connected to the nitrogen atom in a 4-6-membered nitrogen-containing heterocyclic group, is a connection site; the heteroatom in the 4-6 membered heterocyclic group is selected from N or O, and the number of heteroatoms is 1; the 4-6 membered nitrogen-containing heterocyclic group and the 4-6 membered heterocyclic group are optionally substituted by one or more substituents selected from fluorine, chlorine, hydroxyl, amino, -CH2NH2, -CH2OH, -C(O)OCH3; Preferably, Q is independently selected from: Preferably, Q is selected from:

6. The compound according to any one of claims 1 to 5, or its tautomer, stereoisomer, isotope derivative or pharmaceutically acceptable salt thereof, characterized in that: Het is selected from B is -N-; A is -CH2-; Preferably, Het is selected from the following structures: Cy2 is selected from phenyl or pyridyl; Preferably, Cy2 is independently selected from: phenyl, 6-membered heteroaryl; Preferably, Cy2 is independently selected from: phenyl, pyridyl; Preferably, Cy2 is independently selected from: phenyl, Preferably, Cy2 is independently selected from phenyl; Preferably, R 13 , R 14 , R 15 , R 16 are independently selected from: hydrogen; Preferably, R 17 Independently selected from: fluorine, chlorine; Preferably, n and q are independently selected from 0 and 1; Preferably, n and q are each independently selected from 0.

7. The compound according to any one of claims 1 to 6, or its tautomer, stereoisomer, isotope derivative or pharmaceutically acceptable salt thereof, characterized in that: Y is independently selected from -O-, -N(R d2 )-, -S(O)-, -S(O)2-, -S(O)(=NR d2 )-; Preferably, Y is independently selected from -S(O)-, -S(O)2-, -S(O)(=NR d2 )-; Preferably, Y is independently selected from -S(O)2-, -S(O)(=NR d2 )-; Preferably, Y is independently selected from -S(O)2-; Preferably, R d2 Independently selected from: hydrogen, deuterium, halogen, hydroxyl, amino, nitro, cyano, -SR d3 、-N(R d3 )2. -C(O)R d3 、-(C 1- 6-alkylene)-C(O)R d3 、-C(O)OR d3 、-(C 1-6 Alkylene)-C(O)OR d3 、-C(O)N(R d3 )2、-(C 1-6 Alkylene)-C(O)N(R d3 )2. -C(O)-(C 1-6 Alkylene)-N(R d3 )2, -S(O)2R d3 、-C(O)N(R d3 )OR d3 、-OC(O)R d3 、-OC(O)N(R d3 2. C 1-6 Alkyl, C 3-10 Carbocyclic group, 3-10 membered heterocyclic group, C 6-8 Aryl, 5-10 membered heteroaryl; said C 1-6 Alkyl, C 1-6 Alkylene, C 3-10 Carbocyclic group, 3-10 membered heterocyclic group, C 6- 8-membered aryl, 5-10-membered heteroaryl, optionally substituted with one or more selected from deuterium, halogen, oxo, hydroxyl, amino, nitro, cyano, C 1-6 Alkyl, C 1- 6 is substituted by an alkoxy substituent; Preferably, R d2 Independently selected from: hydrogen, deuterium, halogen, hydroxyl, amino, nitro, cyano, -SR d3 、-N(R d3 )2. -C(O)R d3 、-(C 1- 4-alkylene)-C(O)R d3 、-C(O)OR d3 、-(C 1-4 Alkylene)-C(O)OR d3 、-C(O)N(R d3 )2、-(C 1-4 Alkylene)-C(O)N(R d3 )2. -C(O)-(C 1-4 Alkylene)-N(R d3 )2, -S(O)2R d3 , C 1-4 Alkyl, C 3-6 carbocyclic group, 3-6 membered heterocyclic group, phenyl group, 5-6 membered heteroaryl group; the C 1-4 Alkyl, C 1-4 Alkylene, C 3-6 Carbocyclic group, 3-6 membered heterocyclic group, phenyl group, 5-6 membered heteroaryl group are optionally substituted with one or more selected from deuterium, halogen, oxo group, hydroxyl, amino, nitro, cyano, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent; Preferably, R d2 Independently selected from: hydrogen, -SR d3 、-C(O)R d3 、-(C 1-4 Alkylene)-C(O)R d3 、-(C 1-4 Alkylene)-C(O)OR d3 、-C(O)N(R d3 )2、-(C 1-4 Alkylene)-C(O)N(R d3 )2. -C(O)-(C 1-4 Alkylene)-N(R d3 )2, -S(O)2R d3 , C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, phenyl, 5-6 membered heteroaryl; the heteroatom in the 3-6 membered heterocyclic group and 5-6 membered heteroaryl is selected from N or O, and the number of heteroatoms is 1 or 2; the C 1-4 Alkyl, C 1-4 Alkylene, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, phenyl, 5-6 membered heteroaryl are optionally substituted by one or more substituents selected from deuterium, halogen (e.g. fluorine, chlorine, bromine, preferably fluorine), oxo, hydroxy, amino, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, methoxy, ethoxy, n-propoxy, isopropoxy; Preferably, R d3 are independently selected from: hydrogen, deuterium, halogen, hydroxyl, amino, nitro, cyano, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, phenyl, 5-6 membered heteroaryl; the C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, phenyl, 5-6 membered heteroaryl, optionally substituted with one or more selected from deuterium, halogen, oxo, hydroxy, amino, nitro, cyano, C 1-6 Alkyl, C 1-6 substituted by an alkoxy substituent; Preferably, R d3 are independently selected from: hydrogen, halogen, hydroxy, amino, nitro, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group; the C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, optionally substituted by one or more selected from halogen, oxo, hydroxyl, amino, nitro, cyano, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent; Preferably, R d3 Independently selected from: hydrogen, fluorine, chlorine, bromine, hydroxyl, amino, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclobutyl; the above groups are optionally substituted by one or more substituents selected from fluorine, chlorine, bromine, hydroxyl, amino; Preferably, R d2 Independently selected from: hydrogen, -SR d3 、-C(O)R d3 、-(C 1-6 Alkylene)-C(O)R d3 、-C(O)OR d3 、-(C 1-6 Alkylene)-C(O)OR d3 、-C(O)N(R d3 )2、-(C 1-6 Alkylene)-C(O)N(R d3 )2. -C(O)-(C 1-6 Alkylene)-N(R d3 )2, -S(O)2R d3 , C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, phenyl, 5-6 membered heteroaryl; the C 1-6 Alkyl, C 1-6 Alkylene, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, phenyl, 5-6 membered heteroaryl, optionally substituted with one or more selected from deuterium, halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 Substituents of alkoxy groups replaced by; R d3 are independently selected from: hydrogen, halogen, hydroxy, amino, cyano, C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, phenyl, 5-6 membered heteroaryl; the C 1-6 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, phenyl, 5-6 membered heteroaryl, optionally substituted with one or more selected from deuterium, halogen, hydroxyl, amino, cyano, C 1-6 Alkyl, C 1-6 substituted by an alkoxy substituent; Preferably, R d2 Independently selected from: hydrogen, -SC 1-4 Alkyl, -C(O)NH2, -C(O)NH(C 1-4 alkyl), -C(O)N(C 1-4 Alkyl)2, -C(O)C 1- 4-alkyl, -C(O)C 3-6 Cycloalkyl, -C(O)3-6 membered heterocyclic group, -C(O)-(C 1-4 Alkylene)-NH(C 1-4 alkyl), -C(O)-(C 1-4 Alkylene)-N(C 1- 4 alkyl)2, -(C 1-4 Alkylene)-C(O)OC 1-4 Alkyl, -(C 1-4 Alkylene)-C(O)C 1-4 Alkyl, -(C 1-4 Alkylene)-C(O)NH2, -(C 1-4 Alkylene)-C(O)NH(C 1-4 Alkyl), -(C 1-4 Alkylene)-C(O)N(C 1-4 Alkyl)2, -S(O)2C 1-4 Alkyl, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, phenyl, 5-6 membered heteroaryl; the C 1-4 Alkyl, C 1-4 Alkylene, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, phenyl, 5-6 membered heteroaryl are optionally substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, hydroxyl, amino, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl; Preferably, R d2 are independently selected from: hydrogen, -C(O)NH2, -C(O)NH(C 1-3 Alkyl), -C(O)C 1-3 Alkyl, -C(O)C 3-6 Cycloalkyl, -(C 1- 3 alkylene)-S(O)2(C 1-3 Alkyl), C 1-6 Alkyl (more preferably C 1-5 Alkyl, more preferably C 1-3 Alkyl), C 3-6 Cycloalkyl (more preferably C 3-4 cycloalkyl), 3-7 membered heterocyclyl (more preferably 4-5 membered heterocyclyl), 5-6 membered heteroaryl (more preferably 5 membered heteroaryl containing 2 nitrogen atoms); the alkyl, cycloalkyl, heterocyclyl, heteroaryl are optionally substituted with one or more selected from deuterium, halogen (more preferably fluorine, chlorine, bromine, more preferably fluorine), hydroxyl, amino, cyano, C 1-3 Alkyl (more preferably methyl), C 1-3 The substituent is substituted by an alkoxy group (more preferably a methoxy group) or a 3-6-membered heterocyclic group (more preferably a 4-5-membered oxygen-containing heterocyclic group); the heteroatoms in the heterocyclic group or heteroaryl group are independently selected from O or N, and the number of heteroatoms is 1 or 2; Preferably, R d2 are independently selected from: hydrogen, -C(O)NH2, -C(O)NH(C 1-2 Alkyl), -C(O)C 1-2 Alkyl, -C(O)C 3-4 Cycloalkyl, -(C 1- 2 alkylene)-S(O)2(C 1-2 Alkyl), C 1-6 Alkyl (more preferably C 1-5 Alkyl, more preferably C 1-3 Alkyl), -C 1-3 Alkylene-C 1-2 Alkoxy, -C 1-2 Alkylene-(3-6 membered heterocyclic group) (more preferably -C 1-2 Alkylene-(4-5 membered heterocyclic group)), C 3-6 Cycloalkyl (more preferably C 3-4 The alkyl group is optionally substituted with one or more substituents selected from deuterium, halogen (more preferably fluorine, chlorine, bromine, more preferably fluorine), hydroxyl, and cyano; the cycloalkyl group is optionally substituted with one or more substituents selected from halogen (more preferably fluorine, chlorine, bromine, more preferably fluorine); the heteroaryl group is optionally substituted with one or more substituents selected from C 1-2 The heterocyclic group and the heteroaryl group are substituted by a substituent of an alkyl group (preferably a methyl group); the heteroatoms in the heterocyclic group and the heteroaryl group are independently selected from O or N, and the number of heteroatoms is 1 or 2; Preferably, R d2 Independently selected from: -(C 1-3 Alkylene)-S(O)2(C 1-3 Alkyl), C 1-6 Alkyl (more preferably C 1-5 Alkyl, more preferably C 1-3 Alkyl), C 3-6 Cycloalkyl (more preferably C 3-4 cycloalkyl), 3-6 membered heterocyclic group (more preferably 4-5 membered heterocyclic group); the alkyl, cycloalkyl, heterocyclic group are optionally substituted by one or more selected from deuterium, halogen (more preferably fluorine, chlorine, bromine, more preferably fluorine), hydroxyl, cyano, C 1-3 Alkyl (more preferably methyl), C 1-3 The substituent is substituted by an alkoxy group (more preferably a methoxy group) or a 3-6-membered heterocyclic group (more preferably a 4-5-membered heterocyclic group); the heteroatom in the heterocyclic group is O, and the number of heteroatoms is 1; Preferably, R d2 Independently selected from: -(C 1-2 Alkylene)-S(O)2(C 1-2 Alkyl), C 1-6 Alkyl (more preferably C 1-5 Alkyl, more preferably C 1-3 Alkyl), -C 1-3 Alkylene-C 1-2 Alkoxy, -C 1-2 Alkylene-(3-6 membered heterocyclic group) (more preferably -C 1-2 Alkylene-(4-5 membered heterocyclic group)), C 3-6 Cycloalkyl (more preferably C 3-4 cycloalkyl), 4-6 membered heterocyclic group (more preferably 4-5 membered heterocyclic group); the alkyl group is optionally substituted by one or more substituents selected from deuterium, halogen (more preferably fluorine, chlorine, bromine, more preferably fluorine), hydroxyl, cyano; the heteroatom in the heterocyclic group is O, and the number of heteroatoms is 1; Preferably, R d2 Independently selected from: -C 1-2 Alkylene-(3-6 membered heterocyclic group) (more preferably -C 1-2 Alkylene-(4-5 membered heterocyclic group)), C 3-6 Cycloalkyl (more preferably C 3-4 cycloalkyl), 3-6 membered heterocyclic group (more preferably 4-5 membered heterocyclic group); the heteroatom in the heterocyclic group is O, and the number of heteroatoms is 1; Preferably, R d2 independently selected from: hydrogen, -C(O)NH2, -CD3, -CF3, -SCF3, -C(O)CH3, -C(O)CH2OH, -C(O)CH2N(CH3)2, -CH2CN, -CH2CH2CH2CN, -CH2CH2C(CH3)2OH, -CH2CH2CH2OH, -CH(CH3)CH2OCH3, -CH2CH2CH2OCH3, -CH2-C(O)OCH3, -C(O)NHCH3, -CH2-C(O)NH2, -S(O)2CH3, -C(O)N(CH3)2, -CH2CF3, -CH2CH2F, -CH2CHF2, -CH2CH2SO2CH3, methyl, ethyl, n-propyl, isopropyl, n-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, 8. The compound according to any one of claims 1 to 7, or its tautomer, stereoisomer, isotope derivative or pharmaceutically acceptable salt thereof, characterized in that: The compound has the structure shown in formula (II), formula (II-1), formula (III), formula (III-1), formula (IV), formula (IV-a), formula (IV-1), formula (IV-2), formula (IV-3), formula (IV-4), formula (IV-5), formula (IV-6), and formula (IV-7): Among them, Cy1, Cy2, R 1 ,Q,X,X 1 , m, n, R d2 , R 13 , R 14 , R 15 , R 16 , R 17 As defined in any one of claims 1 to 7.

9. The compound according to claim 1 or its tautomer, stereoisomer, isotope derivative or pharmaceutically acceptable salt thereof, characterized in that: The compound is selected from:

10. An intermediate for preparing a compound according to any one of claims 1 to 9, having a structure as shown in formula (Ra), formula (R-a5) or (R-a6): in, R e is selected from a protecting group, hydrogen; R d2 As defined in any one of claims 1 to 9; provided that R e and R d2 Not at the same time as hydrogen.

11. The following intermediate for preparing the compound according to any one of claims 1 to 10:

12. A pharmaceutical composition, characterized in that: The invention comprises the compound according to any one of claims 1 to 9 or its tautomer, stereoisomer, isotopic derivative or pharmaceutically acceptable salt thereof.

13. Use of the compound according to any one of claims 1 to 9 or its tautomer, stereoisomer, isotope derivative or pharmaceutically acceptable salt or the pharmaceutical composition according to claim 12 in the preparation of a medicament for preventing and / or treating diseases caused by RSV virus infection.

14. A pharmaceutical composition, characterized in that: A compound according to any one of claims 1 to 9 or its tautomer, stereoisomer, isotope derivative or pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 12, and other compounds.